lenalidomide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
3317 191732-72-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • lenalidomide hydrate
  • lenalidomide
  • revimid
  • revlimid
Lenalidomide is an analogue of thalidomide with immunomodulatory, antiangiogenic, and antineoplastic properties. Lenalidomide inhibits proliferation and induces apoptosis of certain hematopoietic tumor cells including multiple myeloma, mantle cell lymphoma, and del (5q) myelodysplastic syndromes in vitro. Lenalidomide causes a delay in tumor growth in some in vivo nonclinical hematopoietic tumor models including multiple myeloma. Immunomodulatory properties of lenalidomide include activation of T cells and natural killer (NK) cells, increased numbers of NKT cells, and inhibition of pro-inflammatory cytokines (e.g., TNF-alpha and IL-6) by monocytes. In multiple myeloma cells, the combination of lenalidomide and dexamethasone synergizes the inhibition of cell proliferation and the induction of apoptosis.
  • Molecular weight: 259.27
  • Formula: C13H13N3O3
  • CLOGP: -0.41
  • LIPINSKI: 0
  • HAC: 6
  • HDO: 2
  • TPSA: 92.50
  • ALOGS: -2.05
  • ROTB: 1
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
10 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 4 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.00 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 66 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 1.38 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Approvals:

DateAgencyCompanyOrphan
June 14, 2007 EMA CELEGENE EUROPE BV
Dec. 27, 2005 FDA CELGENE
June 25, 2010 PMDA Celgene K.K.

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Full blood count decreased 6109.20 15.46 2788 269559 19558 50313219
Diarrhoea 6075.29 15.46 11076 261271 577400 49755377
Death 4821.77 15.46 7225 265122 318154 50014623
White blood cell count decreased 4076.49 15.46 4012 268335 112710 50220067
Neuropathy peripheral 3589.28 15.46 3439 268908 93318 50239459
Thrombosis 3281.78 15.46 2582 269765 53251 50279526
Laboratory test abnormal 2678.52 15.46 1627 270720 21581 50311196
Platelet count decreased 2631.19 15.46 2968 269379 97758 50235019
Pneumonia 2483.49 15.46 5940 266407 372461 49960316
Fatigue 1661.25 15.46 7842 264505 699759 49633018
Unevaluable event 1543.89 15.46 1551 270796 44515 50288262
Plasma cell myeloma 1516.31 15.46 1295 271052 30027 50302750
Constipation 1491.43 15.46 3165 269182 182543 50150234
Drug ineffective 1457.57 15.46 1368 270979 817965 49514812
Muscle spasms 1439.45 15.46 2490 269857 123063 50209714
Adverse drug reaction 1333.35 15.46 1564 270783 53658 50279119
Rash 1330.20 15.46 5250 267097 432221 49900556
Off label use 1314.70 15.46 459 271888 473967 49858810
Human chorionic gonadotropin increased 1051.66 15.46 353 271994 898 50331879
Condition aggravated 1051.48 15.46 170 272177 296888 50035889
COVID-19 994.70 15.46 1241 271106 45421 50287356
Neutropenia 937.89 15.46 2298 270049 145667 50187110
Plasma cell myeloma recurrent 917.04 15.46 391 271956 2267 50330510
Rheumatoid arthritis 913.34 15.46 42 272305 202508 50130269
Blood potassium decreased 887.47 15.46 1044 271303 35901 50296876
Product dose omission issue 836.34 15.46 2527 269820 181311 50151466
Maternal exposure during pregnancy 830.50 15.46 5 272342 159773 50173004
Deep vein thrombosis 822.27 15.46 1441 270906 71863 50260914
Haemoglobin decreased 758.74 15.46 1931 270416 125285 50207492
Drug interaction 745.82 15.46 97 272250 199524 50133253
Neutrophil count decreased 721.21 15.46 1054 271293 44972 50287805
Systemic lupus erythematosus 687.96 15.46 14 272333 140608 50192169
Completed suicide 666.82 15.46 8 272339 131881 50200896
Pancytopenia 657.59 15.46 1419 270928 82611 50250166
Ageusia 652.16 15.46 523 271824 11060 50321717
Synovitis 637.96 15.46 5 272342 123860 50208917
Tooth disorder 598.98 15.46 695 271652 23533 50309244
Red blood cell count decreased 583.25 15.46 811 271536 33024 50299753
Exposure during pregnancy 558.89 15.46 21 272326 120994 50211783
Skin discolouration 555.45 15.46 779 271568 31978 50300799
Drug hypersensitivity 531.39 15.46 349 271998 250661 50082116
Product use issue 520.45 15.46 89 272258 149386 50183391
Asthenia 517.06 15.46 3206 269141 315836 50016941
Injection site pain 513.61 15.46 19 272328 111005 50221772
Renal disorder 503.82 15.46 679 271668 26826 50305951
Thrombocytopenia 488.68 15.46 1655 270692 126018 50206759
Infusion related reaction 480.26 15.46 157 272190 169400 50163377
Peripheral swelling 458.93 15.46 2257 270090 203679 50129098
Pulmonary thrombosis 455.67 15.46 355 271992 7186 50325591
Rash pruritic 440.10 15.46 864 271483 46982 50285795
Treatment failure 427.45 15.46 107 272240 137530 50195247
Taste disorder 424.81 15.46 355 271992 7969 50324808
Multiple allergies 421.73 15.46 356 271991 8107 50324670
Cytopenia 412.54 15.46 357 271990 8418 50324359
Plasmacytoma 412.35 15.46 218 272129 2167 50330610
Cardiac disorder 404.87 15.46 784 271563 42195 50290582
Dehydration 402.27 15.46 1756 270591 150693 50182084
Glossodynia 401.82 15.46 69 272278 115500 50217277
Arthralgia 398.19 15.46 1134 271213 437568 49895209
Seasonal allergy 384.67 15.46 434 271913 14242 50318535
Urinary tract infection 374.76 15.46 2271 270076 221749 50111028
Pain 367.83 15.46 1736 270611 577167 49755610
Dry skin 367.38 15.46 755 271592 42436 50290341
Hip fracture 352.44 15.46 556 271791 25375 50307402
Product use in unapproved indication 346.37 15.46 97 272250 115722 50217055
Overdose 343.48 15.46 61 272286 99666 50233111
Therapeutic product effect decreased 343.42 15.46 151 272196 135899 50196878
Headache 341.25 15.46 1486 270861 505049 49827728
Full blood count abnormal 338.15 15.46 516 271831 22872 50309905
Therapeutic product effect incomplete 335.46 15.46 47 272300 91468 50241309
Discomfort 327.41 15.46 89 272258 108291 50224486
Cataract 327.40 15.46 761 271586 46539 50286238
Intentional product use issue 316.28 15.46 26 272321 76892 50255885
Monoclonal immunoglobulin present 299.51 15.46 122 272225 618 50332159
Anaemia 299.18 15.46 2352 269995 250104 50082673
Injection site erythema 293.01 15.46 31 272316 74905 50257872
Pericarditis 289.37 15.46 40 272307 78649 50254128
Blood test abnormal 283.56 15.46 327 272020 10992 50321785
Full blood count increased 283.49 15.46 124 272223 772 50332005
Renal failure 279.31 15.46 1226 271121 105407 50227370
Spinal fracture 266.37 15.46 372 271975 15201 50317576
Wound 266.03 15.46 118 272229 105676 50227101
Protein total increased 254.84 15.46 162 272185 2334 50330443
Pulmonary embolism 252.56 15.46 1151 271196 100553 50232224
Hospitalisation 248.71 15.46 35 272312 67902 50264875
Suicide attempt 242.15 15.46 8 272339 51724 50281053
Pruritus 241.26 15.46 2458 269889 281110 50051667
Wrong technique in product usage process 230.32 15.46 18 272329 55492 50277285
Mobility decreased 229.78 15.46 72 272275 79876 50252901
Fall 225.71 15.46 2773 269574 332159 50000618
Psoriasis 225.33 15.46 48 272299 68952 50263825
Light chain analysis increased 223.43 15.46 112 272235 986 50331791
Intentional product misuse 219.55 15.46 7 272340 46727 50286050
Aspartate aminotransferase increased 219.30 15.46 73 272274 77925 50254852
Body height decreased 217.53 15.46 254 272093 8654 50324123
Gastric disorder 215.05 15.46 485 271862 29063 50303714
Hepatic enzyme increased 212.27 15.46 256 272091 137124 50195653
Alanine aminotransferase increased 212.18 15.46 105 272242 88254 50244523
Tachycardia 211.72 15.46 138 272209 99625 50233152
Abortion spontaneous 208.95 15.46 3 272344 41769 50291008
Plasma cell leukaemia 207.91 15.46 104 272243 911 50331866
Hypoaesthesia 206.64 15.46 1281 271066 125976 50206801
Acute myeloid leukaemia 203.13 15.46 322 272025 14752 50318025
Helicobacter infection 201.02 15.46 18 272329 49684 50283093
Suicidal ideation 199.32 15.46 30 272317 55355 50277422
Hordeolum 197.18 15.46 135 272212 2218 50330559
Oxygen saturation decreased 194.94 15.46 75 272272 73173 50259604
Anaphylactic reaction 192.88 15.46 30 272317 54025 50278752
Lactose intolerance 191.01 15.46 137 272210 2433 50330344
Back disorder 187.81 15.46 241 272106 9064 50323713
Folliculitis 187.47 15.46 5 272342 39220 50293557
Influenza 186.75 15.46 964 271383 88574 50244203
Lower respiratory tract infection 184.57 15.46 145 272202 95056 50237721
Decreased appetite 183.95 15.46 1769 270578 199154 50133623
Injection site pruritus 183.14 15.46 8 272339 40403 50292374
Myelodysplastic syndrome 181.92 15.46 307 272040 14825 50317952
Inappropriate schedule of product administration 180.73 15.46 80 272267 71751 50261026
SARS-CoV-2 test positive 180.49 15.46 170 272177 4489 50328288
Muscle injury 180.15 15.46 4 272343 37107 50295670
Injection site reaction 177.99 15.46 28 272319 50004 50282773
Sepsis 177.19 15.46 1274 271073 131651 50201126
Injection site swelling 174.84 15.46 13 272334 41760 50291017
Injection site bruising 174.56 15.46 5 272342 36763 50296014
Depressed level of consciousness 169.92 15.46 36 272311 51917 50280860
Knee arthroplasty 169.72 15.46 5 272342 35841 50296936
Hyponatraemia 168.68 15.46 161 272186 95978 50236799
Myelodysplastic syndrome transformation 168.68 15.46 69 272278 354 50332423
Loss of personal independence in daily activities 168.54 15.46 83 272264 69967 50262810
Impaired healing 162.96 15.46 86 272261 69700 50263077
Coma 160.29 15.46 53 272294 56826 50275951
Hypertension 156.41 15.46 596 271751 210607 50122170
Migraine 154.52 15.46 108 272239 75172 50257605
Fibromyalgia 153.75 15.46 28 272319 44950 50287827
Swelling 153.21 15.46 560 271787 200312 50132465
Depression 148.47 15.46 429 271918 164994 50167783
Atrial fibrillation 144.22 15.46 990 271357 100755 50232022
Clostridium difficile infection 140.88 15.46 376 271971 25063 50307714
Hypoglycaemia 140.69 15.46 56 272291 53525 50279252
Blood pressure systolic increased 140.27 15.46 14 272333 35435 50297342
Cerebrovascular accident 137.61 15.46 927 271420 93753 50239024
Musculoskeletal stiffness 137.09 15.46 305 272042 128176 50204601
Rhabdomyolysis 136.23 15.46 23 272324 39004 50293773
Skin exfoliation 135.70 15.46 444 271903 33168 50299609
Dysgeusia 135.22 15.46 489 271858 38427 50294350
Blood magnesium decreased 134.93 15.46 227 272120 10933 50321844
Alopecia 133.95 15.46 772 271575 244275 50088502
Squamous cell carcinoma of skin 133.75 15.46 152 272195 5026 50327751
C-reactive protein increased 131.69 15.46 99 272248 66375 50266402
Hip arthroplasty 131.66 15.46 8 272339 30421 50302356
Product quality issue 130.88 15.46 9 272338 30849 50301928
Sinus disorder 129.89 15.46 299 272048 18159 50314618
Sedation 129.62 15.46 9 272338 30601 50302176
Osteoarthritis 128.59 15.46 108 272239 68498 50264279
Upper limb fracture 128.51 15.46 272 272075 15601 50317176
Illness 128.18 15.46 355 271992 24185 50308592
Bradycardia 127.56 15.46 96 272251 64330 50268447
Flatulence 126.99 15.46 398 271949 29060 50303717
Bone pain 122.75 15.46 542 271805 46687 50286090
Immune system disorder 122.59 15.46 184 272163 8033 50324744
Electrocardiogram QT prolonged 122.52 15.46 63 272284 51823 50280954
Hypersensitivity 121.82 15.46 670 271677 214491 50118286
Agitation 121.40 15.46 68 272279 53316 50279461
Type 2 diabetes mellitus 120.56 15.46 20 272327 34355 50298422
Medication error 120.17 15.46 24 272323 36080 50296697
Wheezing 119.61 15.46 95 272252 61952 50270825
Tumour flare 117.51 15.46 47 272300 225 50332552
Injury 116.13 15.46 59 272288 48866 50283911
Abdominal pain 114.69 15.46 772 271575 235456 50097321
Drug withdrawal syndrome 113.53 15.46 5 272342 25076 50307701
Gallbladder disorder 113.20 15.46 267 272080 16475 50316302
Bronchitis 111.46 15.46 949 271398 103210 50229567
Dementia 111.31 15.46 258 272089 15739 50317038
Blood pressure increased 110.34 15.46 358 271989 132774 50200003
Renal impairment 109.45 15.46 740 271607 74921 50257856
Gout 108.88 15.46 210 272137 11260 50321517
Ill-defined disorder 108.76 15.46 81 272266 54573 50278204
Blood creatine phosphokinase increased 108.11 15.46 9 272338 26358 50306419
Interstitial lung disease 106.87 15.46 78 272269 53098 50279679
Incorrect dose administered 106.77 15.46 64 272283 48350 50284427
General physical health deterioration 105.33 15.46 402 271945 142032 50190745
Disease progression 104.45 15.46 877 271470 94989 50237788
Papule 102.94 15.46 122 272225 4223 50328554
Gamma-glutamyltransferase increased 102.20 15.46 18 272329 29605 50303172
Surgery 98.62 15.46 21 272326 30184 50302593
Emotional distress 97.62 15.46 18 272329 28645 50304132
Paraesthesia 94.72 15.46 1027 271320 119216 50213561
Injection site haemorrhage 94.23 15.46 5 272342 21341 50311436
Somnolence 93.03 15.46 473 271874 154512 50178265
Anxiety 93.01 15.46 567 271780 177039 50155738
Herpes zoster 92.81 15.46 676 271671 70110 50262667
COVID-19 pneumonia 91.35 15.46 163 272184 8232 50324545
Acute lymphocytic leukaemia 91.10 15.46 84 272263 2157 50330620
Drug level increased 90.09 15.46 3 272344 19265 50313512
Respiratory arrest 89.90 15.46 25 272322 29984 50302793
Pregnancy 89.80 15.46 24 272323 29553 50303224
Bone lesion 89.15 15.46 124 272223 5046 50327731
Lactic acidosis 88.98 15.46 34 272313 33321 50299456
Seizure 88.88 15.46 330 272017 117544 50215233
Memory impairment 88.03 15.46 729 271618 78631 50254146
Drug ineffective for unapproved indication 87.99 15.46 7 272340 21274 50311503
Device dislocation 86.59 15.46 8 272339 21538 50311239
Blood alkaline phosphatase increased 86.48 15.46 47 272300 37479 50295298
Hyperkalaemia 86.12 15.46 79 272268 48010 50284767
Underdose 85.75 15.46 6 272341 20272 50312505
Monoclonal immunoglobulin increased 85.23 15.46 29 272318 78 50332699
Blood cholesterol increased 85.09 15.46 103 272244 55112 50277665
Chest discomfort 84.93 15.46 238 272109 92484 50240293
Erythema 82.21 15.46 457 271890 145957 50186820
Device issue 81.38 15.46 7 272340 19965 50312812
Pregnancy test false positive 81.06 15.46 32 272315 147 50332630
Inflammation 80.68 15.46 113 272234 56799 50275978
Back pain 80.61 15.46 1646 270701 218384 50114393
Cardio-respiratory arrest 80.47 15.46 103 272244 53789 50278988
Pulmonary arterial hypertension 80.45 15.46 8 272339 20311 50312466
Blood pressure fluctuation 79.49 15.46 47 272300 35776 50297001
Nasopharyngitis 79.38 15.46 1469 270878 191458 50141319
Metabolic acidosis 79.25 15.46 56 272291 38769 50294008
Muscle spasticity 79.21 15.46 3 272344 17181 50315596
Cardiac amyloidosis 78.52 15.46 49 272298 682 50332095
Dysarthria 77.61 15.46 53 272294 37350 50295427
Incorrect route of product administration 77.57 15.46 6 272341 18660 50314117
No adverse event 77.46 15.46 42 272305 33536 50299241
Ascites 76.86 15.46 49 272298 35812 50296965
Metastases to liver 76.83 15.46 9 272338 20095 50312682
Joint range of motion decreased 76.79 15.46 6 272341 18506 50314271
Flushing 76.54 15.46 153 272194 66862 50265915
Gait disturbance 75.36 15.46 485 271862 149520 50183257
Eye disorder 75.14 15.46 247 272100 18492 50314285
Palpitations 74.27 15.46 260 272087 94246 50238531
Tremor 72.64 15.46 941 271406 113962 50218815
Diverticulitis 72.44 15.46 362 271985 32820 50299957
Musculoskeletal pain 72.40 15.46 177 272170 72000 50260777
Multiple sclerosis 71.69 15.46 12 272335 20481 50312296
Obesity 70.83 15.46 5 272342 16770 50316007
Anaphylactic shock 70.07 15.46 12 272335 20143 50312634
Abnormal behaviour 69.91 15.46 11 272336 19647 50313130
Generalised tonic-clonic seizure 69.88 15.46 27 272320 26283 50306494
Drug-induced liver injury 69.54 15.46 32 272315 28063 50304714
Withdrawal syndrome 69.45 15.46 7 272340 17583 50315194
Eye infection 69.10 15.46 155 272192 9251 50323526
Hypogeusia 68.84 15.46 53 272294 1053 50331724
Abdominal discomfort 68.75 15.46 857 271490 230784 50101993
Cardiac failure congestive 68.41 15.46 725 271622 83657 50249120
Liver injury 68.34 15.46 24 272323 24782 50307995
Sleep apnoea syndrome 67.65 15.46 22 272325 23846 50308931
Product prescribing error 67.56 15.46 15 272332 20946 50311831
Swelling face 67.06 15.46 499 271848 52096 50280681
Spinal compression fracture 66.99 15.46 184 272163 12472 50320305
Blood iron decreased 66.66 15.46 174 272173 11441 50321336
White blood cell count abnormal 66.22 15.46 111 272236 5329 50327448
Prescribed overdose 65.79 15.46 3 272344 14597 50318180
Toxic epidermal necrolysis 65.72 15.46 16 272331 20976 50311801
Coronavirus infection 65.72 15.46 80 272267 2849 50329928
Vomiting 65.56 15.46 1934 270413 458824 49873953
Blood pressure diastolic decreased 65.42 15.46 7 272340 16774 50316003
Weight decreased 64.64 15.46 1603 270744 219642 50113135
Accidental exposure to product 64.05 15.46 22 272325 23035 50309742
Diabetic ketoacidosis 63.56 15.46 10 272337 17862 50314915
Acute leukaemia 63.42 15.46 50 272297 1030 50331747
Amyloidosis 63.15 15.46 48 272299 935 50331842
Unresponsive to stimuli 62.67 15.46 44 272303 30565 50302212
Hepatitis 62.08 15.46 47 272300 31406 50301371
Increased tendency to bruise 61.94 15.46 148 272199 9208 50323569
Pallor 61.29 15.46 24 272323 23175 50309602
Transaminases increased 61.04 15.46 37 272310 27787 50304990
Oedema peripheral 60.91 15.46 1191 271156 156770 50176007
Eye swelling 60.77 15.46 242 272105 19902 50312875
Hypoacusis 60.66 15.46 246 272101 20401 50312376
Blister 60.60 15.46 245 272102 85173 50247604
Compression fracture 60.54 15.46 111 272236 5726 50327051
Heart rate increased 60.37 15.46 213 272134 77037 50255740
Clostridium difficile colitis 59.98 15.46 221 272126 17521 50315256
Tumour lysis syndrome 59.87 15.46 127 272220 7294 50325483
Dyspnoea 59.69 15.46 2377 269970 545231 49787546
Dizziness 59.35 15.46 2352 269995 344017 49988760
Osteolysis 59.27 15.46 71 272276 2486 50330291
Pathological fracture 59.15 15.46 129 272218 7553 50325224
Hyperviscosity syndrome 58.90 15.46 25 272322 143 50332634
Right ventricular failure 58.59 15.46 8 272339 15885 50316892
Dysphonia 58.39 15.46 384 271963 38508 50294269
Insomnia 58.13 15.46 1290 271057 173575 50159202
Intraductal proliferative breast lesion 57.79 15.46 70 272277 2480 50330297
Metastases to bone 57.75 15.46 13 272334 17982 50314795
Depressed mood 57.32 15.46 59 272288 33964 50298813
Device malfunction 57.22 15.46 7 272340 15114 50317663
Hepatic steatosis 56.98 15.46 30 272317 24354 50308423
Feeling jittery 56.85 15.46 160 272187 11000 50321777
Prescribed underdose 56.55 15.46 9 272338 15940 50316837
Weight increased 56.53 15.46 756 271591 201135 50131642
Therapeutic response unexpected 56.39 15.46 9 272338 15906 50316871
Hepatotoxicity 55.93 15.46 39 272308 27187 50305590
Fracture 55.50 15.46 208 272139 16625 50316152
Impaired work ability 54.98 15.46 5 272342 13635 50319142
Irritable bowel syndrome 54.92 15.46 122 272225 51319 50281458
Dyskinesia 54.52 15.46 42 272305 27819 50304958
Skin cancer 54.19 15.46 141 272206 9253 50323524
Rib fracture 54.09 15.46 226 272121 18995 50313782
Blood electrolytes decreased 53.80 15.46 45 272302 1011 50331766
Dyspnoea exertional 53.48 15.46 123 272224 51110 50281667
Procedural pain 53.34 15.46 6 272341 13826 50318951
Hallucination, visual 53.18 15.46 12 272335 16570 50316207
Liver function test abnormal 52.56 15.46 99 272248 44240 50288537
Vitamin D decreased 52.48 15.46 130 272217 8276 50324501
Body temperature decreased 52.30 15.46 12 272335 16383 50316394
Fear 52.06 15.46 8 272339 14541 50318236
Feeling abnormal 51.37 15.46 955 271392 124537 50208240
Status epilepticus 51.24 15.46 6 272341 13400 50319377
Extrapyramidal disorder 51.20 15.46 3 272344 11767 50321010
Crying 50.92 15.46 23 272324 20393 50312384
Hypercholesterolaemia 50.86 15.46 3 272344 11700 50321077
Bone erosion 50.78 15.46 3 272344 11684 50321093
Arthropathy 50.33 15.46 575 271772 157331 50175446
Leukaemia 50.28 15.46 77 272270 3422 50329355
Joint swelling 49.87 15.46 975 271372 244311 50088466
Encephalopathy 49.73 15.46 65 272282 33646 50299131
International normalised ratio increased 49.72 15.46 98 272249 43054 50289723
Dry eye 49.46 15.46 319 272028 31776 50301001
Pancreatitis acute 49.06 15.46 34 272313 23778 50308999
Pulmonary fibrosis 48.89 15.46 36 272311 24401 50308376
Obstructive airways disorder 48.86 15.46 12 272335 15640 50317137
Neuralgia 48.77 15.46 240 272107 21623 50311154
Cyanosis 48.67 15.46 11 272336 15173 50317604
Cardiac arrest 48.63 15.46 258 272089 83393 50249384
Stress 48.56 15.46 139 272208 53654 50279123
Adenocarcinoma of colon 48.43 15.46 59 272288 2103 50330674
Disability 48.13 15.46 6 272341 12769 50320008
Myoclonus 47.36 15.46 10 272337 14460 50318317
Blood potassium abnormal 47.35 15.46 59 272288 2153 50330624
Respiratory depression 46.85 15.46 5 272342 12005 50320772
Leukocytosis 46.83 15.46 32 272315 22547 50310230
Coagulopathy 46.69 15.46 19 272328 17925 50314852
Sputum discoloured 46.51 15.46 8 272339 13387 50319390
Light chain analysis abnormal 46.47 15.46 20 272327 119 50332658
Aggression 46.43 15.46 28 272319 21088 50311689
Product administration error 46.38 15.46 24 272323 19675 50313102
Sinus tachycardia 46.01 15.46 29 272318 21325 50311452
Haematemesis 45.67 15.46 49 272298 27676 50305101
Respiratory syncytial virus infection 45.50 15.46 91 272256 5011 50327766
Rash macular 45.44 15.46 215 272132 19062 50313715
Product storage error 45.43 15.46 6 272341 12218 50320559
Therapeutic response decreased 44.91 15.46 119 272228 47112 50285665
Angioedema 44.77 15.46 84 272263 37592 50295185
Blood calcium abnormal 44.72 15.46 41 272306 1045 50331732
Delirium 44.64 15.46 86 272261 38106 50294671
Pneumonia aspiration 44.50 15.46 61 272286 30943 50301834
Hypothermia 44.41 15.46 6 272341 12010 50320767
Blood pressure abnormal 44.11 15.46 160 272187 12587 50320190
Neutrophil count increased 44.08 15.46 11 272336 14184 50318593
Poor venous access 43.89 15.46 3 272344 10337 50322440
Hepatocellular injury 43.70 15.46 45 272302 25902 50306875
Blood bilirubin increased 43.06 15.46 66 272281 31972 50300805
Epilepsy 42.85 15.46 32 272315 21535 50311242
Protein total abnormal 42.65 15.46 27 272320 386 50332391
Joint stiffness 42.13 15.46 61 272286 30247 50302530
Tachypnoea 42.09 15.46 13 272334 14564 50318213
Transfusion 42.07 15.46 9 272338 12896 50319881
Drug resistance 42.01 15.46 25 272322 18964 50313813
Iron deficiency anaemia 41.93 15.46 19 272328 16815 50315962
Human chorionic gonadotropin abnormal 41.87 15.46 13 272334 23 50332754
Hyperlipidaemia 41.64 15.46 21 272326 17469 50315308
Foot deformity 41.51 15.46 26 272321 19184 50313593
Sleep disorder 41.45 15.46 163 272184 57120 50275657
Muscle rigidity 41.29 15.46 3 272344 9826 50322951
Heavy menstrual bleeding 41.17 15.46 16 272331 15521 50317256
Vision blurred 41.16 15.46 623 271724 78024 50254753
Pulmonary hypertension 41.05 15.46 73 272274 33344 50299433
Viral infection 40.80 15.46 289 272058 29697 50303080
Complication associated with device 40.68 15.46 14 272333 14641 50318136
Myalgia 40.67 15.46 450 271897 123869 50208908
Tooth infection 40.55 15.46 167 272180 13945 50318832
Vitamin B12 decreased 40.52 15.46 62 272285 2753 50330024
Cholecystitis chronic 40.48 15.46 3 272344 9666 50323111
Lower limb fracture 40.47 15.46 168 272179 14078 50318699
Device breakage 39.86 15.46 3 272344 9544 50323233
Agranulocytosis 39.78 15.46 34 272313 21387 50311390
Anhedonia 39.75 15.46 3 272344 9521 50323256
Metastases to lung 39.57 15.46 6 272341 11014 50321763
Rhinorrhoea 39.39 15.46 438 271909 51145 50281632
Rales 39.32 15.46 4 272343 9974 50322803
Liver function test decreased 39.31 15.46 13 272334 31 50332746
Coronary artery disease 39.23 15.46 62 272285 29664 50303113
Altered state of consciousness 39.22 15.46 36 272311 21874 50310903
Respiratory distress 38.91 15.46 65 272282 30424 50302353
Psychotic disorder 38.85 15.46 36 272311 21776 50311001
Anosmia 38.57 15.46 73 272274 3858 50328919
Platelet count abnormal 38.57 15.46 61 272286 2788 50329989
Gastrointestinal motility disorder 38.52 15.46 79 272268 4430 50328347
Blood urea increased 38.49 15.46 42 272305 23543 50309234
Upper respiratory tract infection 38.44 15.46 532 271815 65366 50267411
Grip strength decreased 38.41 15.46 9 272338 12112 50320665
Melaena 38.41 15.46 53 272294 26811 50305966
Blood magnesium abnormal 38.25 15.46 27 272320 467 50332310
Drug tolerance decreased 37.90 15.46 3 272344 9157 50323620
Blood calcium increased 37.70 15.46 109 272238 7610 50325167
Acute kidney injury 37.59 15.46 937 271410 227121 50105656
Oral disorder 37.57 15.46 110 272237 7734 50325043
White blood cell disorder 37.31 15.46 51 272296 2041 50330736
Transformation to acute myeloid leukaemia 37.26 15.46 19 272328 174 50332603
Angina pectoris 37.11 15.46 52 272295 26136 50306641
Blood immunoglobulin A increased 36.98 15.46 24 272323 359 50332418
Hypokinesia 36.92 15.46 10 272337 12207 50320570
Gastrointestinal haemorrhage 36.82 15.46 237 272110 73084 50259693
Speech disorder 36.57 15.46 86 272261 35462 50297315
Middle insomnia 36.56 15.46 5 272342 9916 50322861
Infection 36.54 15.46 1203 271144 171751 50161026
Arthritis 36.44 15.46 295 272052 86426 50246351
Cholestasis 36.43 15.46 50 272297 25351 50307426
Parkinsonism 36.32 15.46 3 272344 8844 50323933
Bone marrow failure 36.29 15.46 264 272083 27360 50305417
Accidental overdose 36.28 15.46 31 272316 19502 50313275
Failure to thrive 36.23 15.46 95 272252 6263 50326514
Injection site rash 36.21 15.46 21 272326 16156 50316621
Abortion induced 36.17 15.46 4 272343 9340 50323437
Uterine disorder 36.16 15.46 57 272290 2598 50330179
Colitis ulcerative 36.16 15.46 23 272324 16831 50315946
Pneumonia influenzal 36.10 15.46 42 272305 1425 50331352
Blood immunoglobulin G increased 35.86 15.46 40 272307 1295 50331482
Circulatory collapse 35.63 15.46 33 272314 19967 50312810
Skin hyperpigmentation 35.51 15.46 84 272263 5192 50327585
Invasive ductal breast carcinoma 35.32 15.46 90 272257 5831 50326946
Torsade de pointes 35.18 15.46 10 272337 11825 50320952
Blood calcium decreased 35.16 15.46 211 272136 20495 50312282
Transplant rejection 35.04 15.46 5 272342 9604 50323173
Spinal disorder 34.96 15.46 111 272236 8159 50324618
Food poisoning 34.75 15.46 63 272284 3221 50329556
Mucosal inflammation 34.59 15.46 106 272241 40036 50292741
Skin necrosis 34.57 15.46 8 272339 10859 50321918
Affect lability 34.45 15.46 4 272343 8994 50323783
Hallucination 34.24 15.46 132 272215 46525 50286252
Urinary retention 34.20 15.46 55 272292 26135 50306642
Disease complication 34.18 15.46 57 272290 2725 50330052
Acute hepatic failure 34.17 15.46 21 272326 15656 50317121
Blood lactate dehydrogenase increased 34.01 15.46 33 272314 19529 50313248
Ear swelling 33.81 15.46 36 272311 1105 50331672
Muscle strain 33.57 15.46 99 272248 6989 50325788
Hypoxia 33.57 15.46 151 272196 50972 50281805
Nervousness 33.36 15.46 259 272088 27392 50305385
Post procedural complication 33.25 15.46 20 272327 15084 50317693
Respiratory rate increased 33.15 15.46 10 272337 11375 50321402
Ovarian cyst 33.02 15.46 17 272330 13979 50318798
Gastritis 32.98 15.46 81 272266 32902 50299875
Refractory cytopenia with multilineage dysplasia 32.80 15.46 16 272331 132 50332645
Nail discolouration 32.70 15.46 51 272296 2303 50330474
Red blood cell count abnormal 32.52 15.46 32 272315 893 50331884
Jaundice 32.22 15.46 58 272289 26371 50306406
Mitral valve incompetence 32.12 15.46 28 272319 17443 50315334
Panic attack 32.06 15.46 34 272313 19308 50313469
Hallucination, auditory 32.01 15.46 9 272338 10719 50322058
Cellulitis 31.86 15.46 547 271800 70251 50262526
Hepatic failure 31.71 15.46 80 272267 32203 50300574
Myositis 31.67 15.46 3 272344 7917 50324860
Malignant neoplasm of unknown primary site 31.49 15.46 19 272328 248 50332529
Large intestine infection 31.47 15.46 41 272306 1565 50331212
Incorrect product administration duration 31.21 15.46 6 272341 9269 50323508
Breath sounds abnormal 31.03 15.46 3 272344 7789 50324988
Diabetes mellitus inadequate control 30.97 15.46 16 272331 13129 50319648
Tuberculosis 30.95 15.46 8 272339 10075 50322702
Tricuspid valve incompetence 30.90 15.46 15 272332 12755 50320022
Pelvic fracture 30.52 15.46 133 272214 11387 50321390
Haematoma 30.44 15.46 75 272272 30435 50302342
Neurotoxicity 30.42 15.46 21 272326 14719 50318058
Shock 30.27 15.46 40 272307 20610 50312167
Platelet disorder 30.15 15.46 39 272308 1478 50331299
Aphasia 30.06 15.46 68 272279 28426 50304351
Feeding disorder 30.03 15.46 125 272222 10488 50322289
Red cell distribution width increased 29.96 15.46 5 272342 8554 50324223
Pancreatitis 29.73 15.46 123 272224 42491 50290286
Hypothyroidism 29.48 15.46 90 272257 34035 50298742
Protein total decreased 29.41 15.46 78 272269 5178 50327599
Hyperglycaemia 29.36 15.46 99 272248 36306 50296471
Uveitis 29.33 15.46 7 272340 9303 50323474
Pain in jaw 29.32 15.46 107 272240 38321 50294456
Cholecystectomy 29.30 15.46 7 272340 9296 50323481
Metastases to central nervous system 29.27 15.46 12 272335 11270 50321507
Upper gastrointestinal haemorrhage 29.11 15.46 26 272321 16009 50316768
Hysterectomy 29.02 15.46 4 272343 7886 50324891
Cardiogenic shock 28.67 15.46 25 272322 15574 50317203
Posterior reversible encephalopathy syndrome 28.58 15.46 23 272324 14905 50317872
Endometrial adenocarcinoma 28.52 15.46 32 272315 1043 50331734
Colitis 28.43 15.46 325 272022 38204 50294573
Scar 28.42 15.46 14 272333 11804 50320973
Body temperature increased 28.27 15.46 81 272266 31260 50301517
Nerve injury 28.21 15.46 104 272243 8246 50324531
Spinal osteoarthritis 27.88 15.46 21 272326 14071 50318706
Proteinuria 27.71 15.46 29 272318 16568 50316209
Therapy interrupted 27.58 15.46 41 272306 20111 50312666
Bursitis 27.50 15.46 48 272299 22087 50310690
Peripheral coldness 27.46 15.46 119 272228 10164 50322613
Metastases to lymph nodes 27.20 15.46 3 272344 7021 50325756
Transient ischaemic attack 27.15 15.46 279 272068 31931 50300846
Localised infection 27.12 15.46 232 272115 25253 50307524
White blood cell count increased 26.99 15.46 126 272221 42114 50290663
Injection site discolouration 26.96 15.46 3 272344 6971 50325806
Osteoporosis 26.87 15.46 137 272210 44742 50288035
Blood pressure diastolic increased 26.84 15.46 4 272343 7439 50325338
Shock haemorrhagic 26.83 15.46 6 272341 8338 50324439
Confusional state 26.68 15.46 779 271568 185149 50147628
Pigmentation disorder 26.51 15.46 61 272286 3703 50329074
Joint effusion 26.28 15.46 19 272328 13002 50319775
Hemiparesis 26.28 15.46 42 272305 20006 50312771
Delusion 26.21 15.46 12 272335 10557 50322220
Myocardial ischaemia 26.10 15.46 15 272332 11598 50321179
Ejection fraction decreased 26.01 15.46 37 272310 18483 50314294
Left ventricular dysfunction 25.94 15.46 12 272335 10494 50322283
Colon cancer 25.88 15.46 104 272243 8587 50324190
Hypotonia 25.85 15.46 6 272341 8128 50324649
Coordination abnormal 25.77 15.46 15 272332 11519 50321258
Hepatic encephalopathy 25.40 15.46 10 272337 9626 50323151
Performance status decreased 24.99 15.46 54 272293 3141 50329636
Eczema 24.92 15.46 53 272294 22649 50310128
Ventricular tachycardia 24.92 15.46 29 272318 15792 50316985
Blood triglycerides increased 24.87 15.46 15 272332 11297 50321480
Photophobia 24.86 15.46 26 272321 14861 50317916
Ventricular fibrillation 24.65 15.46 13 272334 10546 50322231
Chalazion 24.61 15.46 18 272329 330 50332447
Hypercalcaemia 24.54 15.46 212 272135 23140 50309637
Pseudomonas infection 24.51 15.46 10 272337 9420 50323357
Schizophrenia 24.44 15.46 5 272342 7392 50325385
Paraproteinaemia 24.43 15.46 14 272333 165 50332612
Lacrimation increased 24.43 15.46 166 272181 16826 50315951
Optic neuritis 24.18 15.46 4 272343 6886 50325891
Refractory anaemia with an excess of blasts 24.16 15.46 19 272328 390 50332387
Major depression 24.15 15.46 4 272343 6880 50325897
Pulseless electrical activity 23.94 15.46 4 272343 6837 50325940
Traumatic fracture 23.89 15.46 22 272325 564 50332213
Post procedural haemorrhage 23.84 15.46 5 272342 7265 50325512
Miosis 23.68 15.46 3 272344 6307 50326470
Productive cough 23.65 15.46 176 272171 52518 50280259
Restlessness 23.49 15.46 64 272283 25109 50307668
Spinal operation 23.44 15.46 3 272344 6257 50326520
Mouth ulceration 23.44 15.46 75 272272 27949 50304828
Amnesia 23.37 15.46 338 272009 41922 50290855
Malignant neoplasm progression 23.31 15.46 244 272103 67880 50264897
Angina unstable 23.29 15.46 4 272343 6702 50326075
Atelectasis 23.27 15.46 39 272308 18231 50314546
Anuria 23.23 15.46 16 272331 11228 50321549
Gingival pain 23.04 15.46 78 272269 5928 50326849
Infusion site extravasation 22.47 15.46 5 272342 6971 50325806
Plasma cell myeloma in remission 22.34 15.46 6 272341 4 50332773
Fluid retention 22.31 15.46 390 271957 50259 50282518
Glycosylated haemoglobin increased 22.04 15.46 15 272332 10591 50322186
Hepatic cirrhosis 21.95 15.46 38 272309 17539 50315238
Malignant melanoma 21.86 15.46 110 272237 9998 50322779
Hepatic function abnormal 21.77 15.46 96 272251 32585 50300192
Lethargy 21.76 15.46 166 272181 49266 50283511
Nightmare 21.75 15.46 33 272314 16053 50316724
Motor dysfunction 21.73 15.46 8 272339 8023 50324754
Intermenstrual bleeding 21.71 15.46 5 272342 6809 50325968
Asthma 21.66 15.46 344 272003 88993 50243784
Therapy cessation 21.48 15.46 70 272277 25941 50306836
Gingival bleeding 21.43 15.46 119 272228 11234 50321543
Blood pressure decreased 21.33 15.46 195 272152 55714 50277063
Deformity 21.33 15.46 8 272339 7932 50324845
Rectal adenocarcinoma 21.23 15.46 20 272327 528 50332249
Movement disorder 21.22 15.46 39 272308 17593 50315184
Sinus bradycardia 20.94 15.46 24 272323 13159 50319618
Cushingoid 20.93 15.46 5 272342 6640 50326137
Chondrocalcinosis pyrophosphate 20.84 15.46 27 272320 1025 50331752
Lipase increased 20.72 15.46 10 272337 8531 50324246
Epstein-Barr virus infection 20.64 15.46 6 272341 6991 50325786
Bronchospasm 20.54 15.46 30 272317 14824 50317953
Apnoea 20.50 15.46 6 272341 6960 50325817
Low density lipoprotein increased 20.44 15.46 3 272344 5643 50327134
Allergic sinusitis 20.30 15.46 20 272327 559 50332218
Chest pain 20.20 15.46 763 271584 176119 50156658
Tardive dyskinesia 20.12 15.46 7 272340 7272 50325505
Respiratory acidosis 20.07 15.46 4 272343 6024 50326753
Arteriosclerosis coronary artery 20.01 15.46 8 272339 7628 50325149
Haemodialysis 19.96 15.46 10 272337 8352 50324425
Ataxia 19.91 15.46 27 272320 13759 50319018
Parainfluenzae virus infection 19.88 15.46 36 272311 1839 50330938
Balance disorder 19.83 15.46 509 271838 70081 50262696
Tubulointerstitial nephritis 19.81 15.46 32 272315 15179 50317598
Hot flush 19.77 15.46 341 272006 43828 50288949
Hyperproteinaemia 19.76 15.46 10 272337 90 50332687
Polyarthritis 19.66 15.46 9 272338 7918 50324859
Superficial spreading melanoma stage unspecified 19.62 15.46 11 272336 124 50332653
Kidney infection 19.60 15.46 170 272177 18576 50314201
Deafness 19.50 15.46 148 272199 15543 50317234
Mood swings 19.46 15.46 35 272312 15919 50316858
Cardiomegaly 19.43 15.46 35 272312 15910 50316867
Oliguria 19.35 15.46 10 272337 8206 50324571
Malignant melanoma in situ 19.27 15.46 23 272324 802 50331975
Irritability 19.24 15.46 83 272264 28343 50304434
Pyelonephritis 19.09 15.46 32 272315 14957 50317820
Wrong product administered 19.06 15.46 3 272344 5357 50327420
Peritonitis 18.86 15.46 34 272313 15452 50317325
Palmar-plantar erythrodysaesthesia syndrome 18.83 15.46 51 272296 20047 50312730
Influenza like illness 18.77 15.46 208 272139 57251 50275526
Genital haemorrhage 18.74 15.46 6 272341 6568 50326209
Sensitive skin 18.73 15.46 24 272323 901 50331876
Throat tightness 18.71 15.46 54 272293 20793 50311984
Abdominal pain upper 18.65 15.46 1042 271305 158267 50174510
Hypoaesthesia oral 18.65 15.46 110 272237 10618 50322159
Nodule 18.41 15.46 40 272307 16963 50315814
Osteonecrosis 18.32 15.46 61 272286 22456 50310321
Bronchiectasis 18.28 15.46 17 272330 10266 50322511
Walking aid user 18.11 15.46 6 272341 6427 50326350
Hypotension 18.03 15.46 1060 271287 234409 50098368
Brain injury 18.03 15.46 5 272342 6009 50326768
Fistula 17.92 15.46 11 272336 8207 50324570
Product dispensing error 17.91 15.46 13 272334 8878 50323899
Nystagmus 17.88 15.46 4 272343 5557 50327220
Clavicle fracture 17.87 15.46 45 272302 2894 50329883
Bone density decreased 17.77 15.46 20 272327 11055 50321722
Device failure 17.73 15.46 4 272343 5524 50327253
Acute respiratory failure 17.72 15.46 87 272260 28695 50304082
Central nervous system lesion 17.69 15.46 15 272332 9474 50323303
Immunoglobulins increased 17.69 15.46 14 272333 290 50332487
Toxic encephalopathy 17.67 15.46 4 272343 5511 50327266
Myeloma cast nephropathy 17.66 15.46 10 272337 115 50332662
Orthostatic hypotension 17.64 15.46 90 272257 29391 50303386
Laryngeal oedema 17.58 15.46 3 272344 5050 50327727
Pemphigoid 17.54 15.46 5 272342 5902 50326875
Neutrophil count abnormal 17.48 15.46 40 272307 2419 50330358
POEMS syndrome 17.41 15.46 6 272341 17 50332760
Oesophageal squamous cell carcinoma 17.30 15.46 10 272337 120 50332657
Sensory disturbance 17.25 15.46 23 272324 11806 50320971
Precursor B-lymphoblastic lymphoma 17.24 15.46 5 272342 6 50332771
Haematuria 17.20 15.46 75 272272 25538 50307239
Body dysmorphic disorder 17.16 15.46 13 272334 252 50332525
Haemodynamic instability 17.14 15.46 11 272336 8013 50324764
Brain oedema 17.09 15.46 25 272322 12345 50320432
Gastrointestinal fungal infection 17.03 15.46 13 272334 255 50332522
Dysphagia 16.99 15.46 304 272043 77214 50255563
Muscle twitching 16.96 15.46 36 272311 15395 50317382
Onychoclasis 16.96 15.46 64 272283 5132 50327645
Marasmus 16.94 15.46 16 272331 424 50332353
Gastroenteritis viral 16.93 15.46 165 272182 18621 50314156
Full blood count 16.92 15.46 4 272343 0 50332777
Bradyphrenia 16.86 15.46 6 272341 6146 50326631
Osteopenia 16.85 15.46 42 272305 16976 50315801
Night sweats 16.80 15.46 264 272083 33310 50299467
Breast cancer 16.70 15.46 324 272023 42566 50290211
Adrenal insufficiency 16.70 15.46 32 272315 14211 50318566
Rhinitis allergic 16.61 15.46 9 272338 7191 50325586
Uterine leiomyoma 16.61 15.46 11 272336 7880 50324897
Hydronephrosis 16.55 15.46 13 272334 8528 50324249
Viral upper respiratory tract infection 16.47 15.46 78 272269 6918 50325859
Treatment noncompliance 16.41 15.46 95 272252 30055 50302722
Physical deconditioning 16.36 15.46 16 272331 443 50332334
Basal cell carcinoma 16.34 15.46 195 272152 23161 50309616
Amenorrhoea 16.33 15.46 13 272334 8471 50324306
Activated partial thromboplastin time prolonged 16.30 15.46 7 272340 6395 50326382
Oral herpes 16.28 15.46 57 272290 20668 50312109
Muscular weakness 16.27 15.46 388 271959 94625 50238152
Lentigo maligna 16.26 15.46 11 272336 177 50332600
Bone marrow myelogram abnormal 16.26 15.46 6 272341 22 50332755
Bipolar disorder 16.25 15.46 8 272339 6749 50326028
Nasal abscess 16.16 15.46 10 272337 137 50332640
Arteriosclerosis 16.14 15.46 15 272332 9062 50323715
Pleural effusion 16.14 15.46 325 272022 81129 50251648
Blood lactic acid increased 16.09 15.46 5 272342 5580 50327197
Toxicity to various agents 16.02 15.46 958 271389 211541 50121236
Vertigo 16.00 15.46 190 272157 51642 50281135
Skin plaque 15.98 15.46 7 272340 6321 50326456
Encephalitis 15.93 15.46 10 272337 7370 50325407
Lymphopenia 15.90 15.46 38 272309 15583 50317194
Target skin lesion 15.79 15.46 9 272338 105 50332672
Enteritis 15.77 15.46 9 272338 6986 50325791
Hepatomegaly 15.72 15.46 21 272326 10772 50322005
Disorientation 15.69 15.46 119 272228 35365 50297412
Hypertriglyceridaemia 15.67 15.46 5 272342 5486 50327291
Acute generalised exanthematous pustulosis 15.63 15.46 15 272332 8923 50323854
Bundle branch block left 15.57 15.46 7 272340 6223 50326554
Anger 15.56 15.46 23 272324 11310 50321467
Hypercapnia 15.55 15.46 3 272344 4624 50328153
Febrile infection 15.55 15.46 25 272322 1159 50331618
Crepitations 15.52 15.46 7 272340 6212 50326565
Intentional dose omission 15.52 15.46 4 272343 5046 50327731
Dry mouth 15.46 15.46 404 271943 55774 50277003

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Death 5114.67 14.68 10167 257443 331917 28975000
Full blood count decreased 4602.03 14.68 2438 265172 13554 29293363
Thrombosis 3379.99 14.68 2928 264682 40117 29266800
Neuropathy peripheral 3260.25 14.68 3599 264011 67428 29239489
White blood cell count decreased 2903.56 14.68 3668 263942 79694 29227223
Rash 2708.32 14.68 5553 262057 184266 29122651
Pneumonia 2702.29 14.68 7634 259976 312538 28994379
Fatigue 2592.03 14.68 7471 260139 309350 28997567
Laboratory test abnormal 2429.40 14.68 1696 265914 16489 29290428
Platelet count decreased 2271.66 14.68 3677 263933 100995 29205922
Adverse drug reaction 1859.12 14.68 1622 265988 22398 29284519
Diarrhoea 1804.33 14.68 6831 260779 325867 28981050
Unevaluable event 1712.25 14.68 1706 265904 28145 29278772
Drug interaction 1441.59 14.68 87 267523 197298 29109619
Off label use 1363.61 14.68 512 267098 300288 29006629
Plasma cell myeloma 1342.93 14.68 1667 265943 35448 29271469
Constipation 1302.64 14.68 3059 264551 111101 29195816
Muscle spasms 1219.84 14.68 2144 265466 62938 29243979
Deep vein thrombosis 1080.69 14.68 1895 265715 55504 29251413
COVID-19 875.35 14.68 1335 266275 34679 29272238
Plasma cell myeloma recurrent 860.87 14.68 490 267120 3193 29303724
Tooth disorder 755.90 14.68 653 266957 8876 29298041
Peripheral swelling 755.11 14.68 1735 265875 62004 29244913
Cardiac disorder 735.81 14.68 1257 266353 36006 29270911
Drug abuse 699.01 14.68 4 267606 79879 29227038
Condition aggravated 688.24 14.68 233 267377 146062 29160855
Completed suicide 663.17 14.68 38 267572 90208 29216709
Product dose omission issue 557.99 14.68 2028 265582 94355 29212562
Drug ineffective 552.44 14.68 1583 266027 361587 28945330
Neutropenia 519.03 14.68 2462 265148 129249 29177668
Overdose 511.31 14.68 61 267549 79758 29227159
Renal disorder 506.13 14.68 807 266803 21788 29285129
Rash pruritic 480.83 14.68 784 266826 21579 29285338
Pulmonary thrombosis 480.81 14.68 430 267180 6135 29300782
Ageusia 470.31 14.68 488 267122 8450 29298467
Product use in unapproved indication 437.63 14.68 122 267488 86753 29220164
Red blood cell count decreased 433.70 14.68 808 266802 24794 29282123
Pulmonary embolism 412.28 14.68 1574 266036 74960 29231957
Influenza 403.96 14.68 1054 266556 40827 29266090
Squamous cell carcinoma of skin 403.39 14.68 463 267147 9023 29297894
Full blood count abnormal 395.18 14.68 578 267032 14435 29292482
Pancytopenia 388.43 14.68 1636 265974 81532 29225385
Plasmacytoma 387.76 14.68 282 267328 2933 29303984
Drug intolerance 382.13 14.68 1132 266478 47247 29259670
Acute kidney injury 371.79 14.68 1199 266411 264068 29042849
Neutrophil count decreased 357.08 14.68 1033 266577 42534 29264383
Alanine aminotransferase increased 343.77 14.68 107 267503 70837 29236080
Asthenia 339.95 14.68 3201 264409 212049 29094868
Rhabdomyolysis 336.33 14.68 70 267540 60738 29246179
Blood test abnormal 331.82 14.68 330 267280 5419 29301498
Intentional overdose 331.58 14.68 3 267607 38525 29268392
Taste disorder 314.96 14.68 295 267315 4481 29302436
Aspartate aminotransferase increased 313.79 14.68 77 267533 59648 29247269
Cataract 295.89 14.68 637 266973 21741 29285176
Back disorder 289.15 14.68 312 267298 5661 29301256
Intentional product misuse 284.07 14.68 6 267604 34655 29272262
Hospitalisation 282.71 14.68 40 267570 45948 29260969
Tachycardia 278.69 14.68 154 267456 72256 29234661
Blood creatine phosphokinase increased 270.48 14.68 27 267583 40617 29266300
Myelodysplastic syndrome 268.70 14.68 535 267075 17259 29289658
Body height decreased 266.64 14.68 233 267377 3217 29303700
Infection 265.03 14.68 1383 266227 75368 29231549
Thrombocytopenia 263.05 14.68 2102 265508 132721 29174196
Light chain analysis increased 261.36 14.68 148 267462 953 29305964
Intentional product use issue 261.15 14.68 37 267573 42461 29264456
Seasonal allergy 260.22 14.68 274 267336 4828 29302089
Pruritus 259.43 14.68 1878 265732 114971 29191946
Hip fracture 258.97 14.68 392 267218 10100 29296817
Suicide attempt 257.85 14.68 12 267598 34098 29272819
Hyperkalaemia 255.07 14.68 118 267492 61274 29245643
Cytopenia 251.40 14.68 374 267236 9485 29297432
Gallbladder disorder 250.45 14.68 283 267327 5417 29301500
Injection site pain 246.62 14.68 11 267599 32435 29274482
Bradycardia 244.80 14.68 145 267465 65484 29241433
Inappropriate schedule of product administration 242.20 14.68 53 267557 44419 29262498
Nasopharyngitis 238.54 14.68 1121 266489 58544 29248373
Abdominal pain 236.93 14.68 548 267062 134809 29172108
Rheumatoid arthritis 234.60 14.68 14 267596 32138 29274779
Wrong technique in product usage process 234.54 14.68 12 267598 31416 29275501
Hypoglycaemia 234.01 14.68 73 267537 48273 29258644
Full blood count increased 233.56 14.68 123 267487 671 29306246
Hiccups 233.18 14.68 341 267269 8512 29298405
Vomiting 231.40 14.68 1061 266549 211199 29095718
Hyponatraemia 231.09 14.68 165 267445 67468 29239449
Dry skin 230.19 14.68 592 267018 22715 29284202
Hypoaesthesia 228.89 14.68 1025 266585 52442 29254475
Acute myeloid leukaemia 225.14 14.68 476 267134 16037 29290880
Depressed level of consciousness 220.46 14.68 35 267575 36907 29270010
Multiple allergies 219.23 14.68 169 267441 1933 29304984
Haemoglobin decreased 209.23 14.68 1686 265924 106689 29200228
Protein total increased 207.28 14.68 164 267446 1954 29304963
Herpes zoster 206.39 14.68 670 266940 29382 29277535
Headache 205.25 14.68 844 266766 173163 29133754
Coma 204.97 14.68 52 267558 39398 29267519
Hypertension 204.92 14.68 471 267139 116143 29190774
Blood potassium decreased 204.68 14.68 445 267165 15289 29291628
Plasma cell leukaemia 202.42 14.68 112 267498 685 29306232
Spinal fracture 200.84 14.68 270 267340 6216 29300701
Agitation 197.52 14.68 109 267501 51195 29255722
Monoclonal immunoglobulin present 195.36 14.68 114 267496 783 29306134
Metabolic acidosis 194.99 14.68 50 267560 37612 29269305
Aggression 194.25 14.68 42 267568 35499 29271418
Suicidal ideation 187.76 14.68 42 267568 34674 29272243
Seizure 187.35 14.68 348 267262 92775 29214142
Lactic acidosis 186.61 14.68 26 267584 30221 29276696
C-reactive protein increased 183.95 14.68 85 267525 44178 29262739
Gastric disorder 182.65 14.68 339 267271 10365 29296552
Blood pressure increased 180.51 14.68 242 267368 73561 29233356
Arthropathy 175.45 14.68 510 267100 21044 29285873
Product use issue 175.06 14.68 126 267484 51318 29255599
Interstitial lung disease 173.23 14.68 160 267450 57558 29249359
Electrocardiogram QT prolonged 168.82 14.68 58 267552 36079 29270838
Ascites 162.25 14.68 64 267546 36555 29270362
Illness 161.37 14.68 247 267363 6427 29300490
Bronchitis 159.38 14.68 709 266901 36159 29270758
Skin cancer 158.25 14.68 279 267331 8189 29298728
Renal failure 157.79 14.68 1704 265906 116895 29190022
Back pain 155.80 14.68 1511 266099 100773 29206144
Hernia 155.71 14.68 275 267335 8083 29298834
Incorrect dose administered 152.25 14.68 54 267556 32930 29273987
SARS-CoV-2 test positive 152.15 14.68 168 267442 3131 29303786
Psoriasis 150.06 14.68 52 267558 32175 29274742
Cardio-respiratory arrest 148.64 14.68 143 267467 50458 29256459
Oxygen saturation decreased 147.81 14.68 114 267496 44823 29262094
Drug level increased 147.42 14.68 5 267605 18782 29288135
Localised infection 146.94 14.68 361 267249 13455 29293462
Therapeutic product effect incomplete 146.29 14.68 87 267523 39218 29267699
Skin discolouration 144.56 14.68 384 267226 15025 29291892
Basal cell carcinoma 140.40 14.68 403 267207 16507 29290410
Lactose intolerance 138.81 14.68 102 267508 1079 29305838
International normalised ratio increased 135.52 14.68 121 267489 44251 29262666
Gamma-glutamyltransferase increased 133.67 14.68 38 267572 26699 29280218
Fall 132.74 14.68 2296 265314 174882 29132035
Melaena 130.88 14.68 59 267551 31117 29275800
Product prescribing error 130.61 14.68 8 267602 17968 29288949
Sedation 128.74 14.68 7 267603 17398 29289519
Dysarthria 127.43 14.68 60 267550 30851 29276066
Depression 127.18 14.68 373 267237 84774 29222143
Spinal disorder 127.10 14.68 162 267448 3533 29303384
Blood alkaline phosphatase increased 126.91 14.68 49 267561 28357 29278560
Medication error 124.52 14.68 21 267589 21190 29285727
Anaphylactic reaction 124.12 14.68 47 267563 27526 29279391
Haematuria 123.62 14.68 130 267480 44009 29262908
Wheezing 123.10 14.68 74 267536 33166 29273751
Respiratory arrest 121.46 14.68 41 267569 25792 29281125
Swelling face 120.63 14.68 432 267178 19918 29286999
Immune system disorder 120.58 14.68 171 267439 4146 29302771
Psoriatic arthropathy 118.59 14.68 3 267607 14688 29292229
Hepatocellular injury 118.34 14.68 24 267586 21219 29285698
Angioedema 118.26 14.68 71 267539 31844 29275073
Gastrointestinal haemorrhage 116.90 14.68 351 267259 79182 29227735
Generalised tonic-clonic seizure 116.77 14.68 17 267593 19122 29287795
Bone pain 115.66 14.68 399 267211 18053 29288864
Myelodysplastic syndrome transformation 115.50 14.68 61 267549 335 29306582
Abnormal behaviour 115.37 14.68 33 267577 23094 29283823
Cholestasis 114.27 14.68 35 267575 23427 29283490
General physical health deterioration 114.26 14.68 510 267100 102347 29204570
Product quality issue 112.75 14.68 8 267602 15887 29291030
Mucosal inflammation 111.96 14.68 74 267536 31521 29275396
Upper limb fracture 110.99 14.68 159 267451 3892 29303025
Drug hypersensitivity 110.07 14.68 289 267321 68117 29238800
Dehydration 109.82 14.68 1550 266060 113198 29193719
Gout 109.79 14.68 370 267240 16541 29290376
Drug-induced liver injury 107.84 14.68 31 267579 21624 29285293
Compression fracture 107.25 14.68 127 267483 2561 29304356
Blood urea increased 106.34 14.68 61 267549 28051 29278866
Musculoskeletal disorder 106.24 14.68 179 267431 5061 29301856
Pallor 104.88 14.68 30 267580 20994 29285923
Psychotic disorder 103.48 14.68 28 267582 20326 29286591
Drug resistance 103.35 14.68 33 267577 21507 29285410
Transaminases increased 103.06 14.68 38 267572 22624 29284293
Hepatic function abnormal 102.95 14.68 122 267488 39137 29267780
Hallucination, visual 102.47 14.68 9 267601 15006 29291911
Tumour flare 101.69 14.68 63 267547 489 29306428
Hordeolum 101.46 14.68 72 267538 718 29306199
Eye disorder 101.22 14.68 221 267389 7613 29299304
Acute leukaemia 101.15 14.68 81 267529 983 29305934
Myoclonus 99.55 14.68 5 267605 13304 29293613
Adenocarcinoma of colon 99.29 14.68 129 267481 2869 29304048
Somnolence 98.93 14.68 475 267135 93480 29213437
Rib fracture 98.78 14.68 296 267314 12422 29294495
Dysgeusia 98.68 14.68 437 267173 22237 29284680
Leukocytosis 98.62 14.68 34 267576 21108 29285809
Respiratory depression 98.30 14.68 6 267604 13517 29293400
Acute lymphocytic leukaemia 97.93 14.68 120 267490 2511 29304406
Blood pressure systolic increased 96.01 14.68 18 267592 16827 29290090
Upper gastrointestinal haemorrhage 95.92 14.68 39 267571 21875 29285042
Anxiety 95.55 14.68 422 267188 84943 29221974
Hypercalcaemia 95.39 14.68 293 267317 12466 29294451
Disease progression 95.31 14.68 1147 266463 80769 29226148
Malignant neoplasm progression 94.08 14.68 347 267263 73512 29233405
Drug ineffective for unapproved indication 93.10 14.68 10 267600 14204 29292713
Emotional distress 93.02 14.68 9 267601 13886 29293031
Hypoxia 92.62 14.68 180 267430 47199 29259718
Cardiac arrest 92.28 14.68 429 267181 85162 29221755
Diabetic ketoacidosis 91.98 14.68 17 267593 16056 29290861
Prostatic disorder 91.64 14.68 122 267488 2781 29304136
Atrial fibrillation 91.22 14.68 1402 266208 104244 29202673
Hypoacusis 90.50 14.68 312 267298 14111 29292806
Delirium 90.49 14.68 135 267475 39262 29267655
Blood bilirubin increased 90.29 14.68 104 267506 33789 29273128
Hepatic failure 90.28 14.68 91 267519 31421 29275496
Multiple organ dysfunction syndrome 89.56 14.68 283 267327 62833 29244084
Joint swelling 89.11 14.68 760 266850 48870 29258047
Dyskinesia 88.95 14.68 35 267575 20026 29286891
Erythema 88.76 14.68 367 267243 75239 29231678
Accidental overdose 87.95 14.68 25 267585 17568 29289349
Pancreatitis 87.60 14.68 110 267500 34404 29272513
Underdose 87.08 14.68 5 267605 11864 29295053
Obstructive airways disorder 86.19 14.68 3 267607 11013 29295904
Unresponsive to stimuli 86.15 14.68 61 267549 25065 29281852
Sinus tachycardia 86.10 14.68 16 267594 15053 29291864
Shock 86.01 14.68 43 267567 21361 29285556
Gastrointestinal disorder 85.34 14.68 497 267113 28209 29278708
Encephalopathy 85.16 14.68 93 267517 30950 29275967
Hallucination 84.71 14.68 173 267437 44539 29262378
Agranulocytosis 84.58 14.68 39 267571 20301 29286616
Extrapyramidal disorder 84.56 14.68 3 267607 10828 29296089
Pathological fracture 83.95 14.68 136 267474 3719 29303198
Epilepsy 83.66 14.68 31 267579 18401 29288516
Blood calcium increased 83.33 14.68 123 267487 3096 29303821
Pancreatitis acute 82.57 14.68 60 267550 24325 29282592
Pregnancy of partner 81.36 14.68 45 267565 275 29306642
Tubulointerstitial nephritis 81.21 14.68 29 267581 17614 29289303
Incorrect route of product administration 80.97 14.68 4 267606 10797 29296120
Bone disorder 80.31 14.68 168 267442 5615 29301302
Increased tendency to bruise 78.03 14.68 126 267484 3436 29303481
Jaundice 77.92 14.68 90 267520 29206 29277711
Mobility decreased 77.87 14.68 71 267539 25709 29281208
Spinal compression fracture 77.70 14.68 171 267439 5923 29300994
Asthma 76.76 14.68 117 267493 33732 29273185
Anaphylactic shock 76.54 14.68 14 267596 13322 29293595
Cardiogenic shock 76.43 14.68 39 267571 19151 29287766
Hypokalaemia 75.59 14.68 219 267391 49984 29256933
Malignant melanoma 74.96 14.68 186 267424 6975 29299942
Cytomegalovirus infection 74.92 14.68 60 267550 23155 29283762
Infusion related reaction 73.98 14.68 181 267429 43705 29263212
Loss of personal independence in daily activities 73.41 14.68 73 267537 25367 29281550
Ventricular tachycardia 73.28 14.68 58 267552 22516 29284401
Hepatotoxicity 73.15 14.68 35 267575 17832 29289085
Sinusitis 73.11 14.68 547 267063 33803 29273114
Status epilepticus 72.24 14.68 7 267603 10787 29296130
Muscle rigidity 72.13 14.68 3 267607 9408 29297509
Cerebral infarction 72.13 14.68 70 267540 24605 29282312
Brain oedema 71.94 14.68 12 267598 12208 29294709
Chest discomfort 71.14 14.68 198 267412 45785 29261132
Bone lesion 70.97 14.68 104 267506 2600 29304317
Haematemesis 70.67 14.68 71 267539 24555 29282362
Insomnia 70.58 14.68 1162 266448 87599 29219318
Transplant rejection 70.40 14.68 3 267607 9209 29297708
White blood cell count increased 70.35 14.68 146 267464 37370 29269547
Sepsis 70.09 14.68 1738 265872 140944 29165973
Coronary artery disease 70.07 14.68 188 267422 44002 29262915
White blood cell count abnormal 70.06 14.68 106 267504 2729 29304188
Treatment failure 69.90 14.68 143 267467 36796 29270121
Paraesthesia 69.78 14.68 770 266840 53075 29253842
Fear 69.74 14.68 4 267606 9500 29297417
Liver function test abnormal 69.46 14.68 96 267514 28822 29278095
Fluid retention 69.44 14.68 407 267203 23153 29283764
Hepatitis 69.25 14.68 52 267558 20731 29286186
Injection site swelling 68.99 14.68 4 267606 9413 29297504
Respiratory failure 68.96 14.68 555 267055 96576 29210341
Decreased appetite 68.61 14.68 1761 265849 143581 29163336
Altered state of consciousness 68.57 14.68 48 267562 19841 29287076
Circulatory collapse 68.53 14.68 42 267568 18631 29288286
Surgery 68.39 14.68 12 267598 11767 29295150
Hemiparesis 68.07 14.68 23 267587 14463 29292454
Sinus disorder 68.04 14.68 160 267450 5795 29301122
Synovitis 68.02 14.68 9 267601 10881 29296036
Ventricular fibrillation 67.97 14.68 29 267581 15804 29291113
Abdominal discomfort 67.66 14.68 697 266913 47206 29259711
Osteonecrosis of jaw 67.21 14.68 312 267298 16198 29290719
Paranoia 67.18 14.68 6 267604 9871 29297046
Respiratory distress 67.16 14.68 117 267493 31989 29274928
Withdrawal syndrome 66.51 14.68 10 267600 10982 29295935
Hepatic encephalopathy 66.13 14.68 18 267592 13017 29293900
Blood pressure fluctuation 66.00 14.68 50 267560 19844 29287073
Treatment noncompliance 65.99 14.68 73 267537 24154 29282763
Malignant neoplasm of unknown primary site 65.26 14.68 42 267568 351 29306566
Anaemia 64.81 14.68 2323 265287 198628 29108289
Dementia 64.46 14.68 242 267368 11416 29295501
Tachypnoea 64.38 14.68 28 267582 15087 29291830
Cyanosis 64.29 14.68 12 267598 11255 29295662
Leukaemia 64.16 14.68 120 267490 3690 29303227
Colitis ulcerative 64.09 14.68 18 267592 12751 29294166
Nerve injury 63.76 14.68 105 267505 2912 29304005
Palpitations 63.60 14.68 124 267486 32480 29274437
Arteriosclerosis coronary artery 63.36 14.68 10 267600 10595 29296322
Neutrophil count increased 63.29 14.68 27 267583 14715 29292202
Blood lactate dehydrogenase increased 62.80 14.68 49 267561 19160 29287757
Feeling abnormal 62.26 14.68 760 266850 53685 29253232
Coagulopathy 62.02 14.68 43 267567 17864 29289053
Product administration error 61.76 14.68 26 267584 14284 29292633
Pulmonary hypertension 61.43 14.68 47 267563 18561 29288356
White blood cell disorder 61.40 14.68 70 267540 1353 29305564
Sleep apnoea syndrome 61.30 14.68 42 267568 17557 29289360
Blood triglycerides increased 60.97 14.68 20 267590 12814 29294103
Stress 60.48 14.68 63 267547 21427 29285490
Accidental exposure to product 60.20 14.68 12 267598 10741 29296176
Restlessness 60.02 14.68 67 267543 22078 29284839
Prescribed overdose 59.81 14.68 5 267605 8678 29298239
Delusion 59.77 14.68 14 267596 11202 29295715
Obesity 59.61 14.68 9 267601 9854 29297063
Swelling 59.51 14.68 533 267077 34750 29272167
Injection site erythema 59.21 14.68 26 267584 13930 29292987
Light chain analysis abnormal 59.07 14.68 24 267586 62 29306855
Adverse event 58.63 14.68 284 267326 15007 29291910
Disseminated intravascular coagulation 58.03 14.68 57 267553 19923 29286994
Rectal haemorrhage 57.83 14.68 143 267467 34406 29272511
Acute respiratory distress syndrome 57.25 14.68 74 267536 22861 29284056
Toxic epidermal necrolysis 57.23 14.68 48 267562 18105 29288812
Hypomagnesaemia 56.55 14.68 45 267565 17423 29289494
Myositis 56.48 14.68 12 267598 10271 29296646
Dystonia 56.46 14.68 10 267600 9739 29297178
Confusional state 56.33 14.68 816 266794 127061 29179856
Exposure during pregnancy 56.07 14.68 6 267604 8548 29298369
Haematoma 55.80 14.68 77 267533 23135 29283782
Hyperlipidaemia 55.76 14.68 22 267588 12568 29294349
Hepatic steatosis 55.71 14.68 33 267577 14913 29292004
Platelet disorder 55.68 14.68 65 267545 1290 29305627
Blood creatinine increased 55.57 14.68 497 267113 84605 29222312
Vitamin D decreased 55.46 14.68 97 267513 2828 29304089
Dry eye 54.95 14.68 168 267442 7128 29299789
Vitamin B12 decreased 54.54 14.68 57 267553 995 29305922
Urinary tract infection 54.49 14.68 939 266671 71415 29235502
Angina pectoris 54.25 14.68 106 267504 27744 29279173
Hyperhidrosis 53.89 14.68 352 267258 64188 29242729
Neurotoxicity 53.44 14.68 33 267577 14580 29292337
Device malfunction 53.20 14.68 7 267603 8500 29298417
Monoclonal immunoglobulin increased 52.87 14.68 21 267589 50 29306867
Dysphonia 52.36 14.68 325 267285 18871 29288046
Coronavirus infection 52.21 14.68 101 267509 3187 29303730
Haemodynamic instability 52.06 14.68 6 267604 8067 29298850
Acidosis 51.94 14.68 12 267598 9693 29297224
Renal injury 51.92 14.68 14 267596 10188 29296729
Tooth infection 51.90 14.68 138 267472 5401 29301516
Hepatic cytolysis 51.89 14.68 7 267603 8340 29298577
No adverse event 51.76 14.68 49 267561 17429 29289488
Hypogeusia 51.19 14.68 51 267559 839 29306078
Acute myocardial infarction 50.87 14.68 245 267365 48193 29258724
Diabetes mellitus inadequate control 50.86 14.68 23 267587 12111 29294806
Proteinuria 50.80 14.68 41 267569 15763 29291154
Injection site bruising 50.50 14.68 5 267605 7575 29299342
Venoocclusive liver disease 50.48 14.68 3 267607 6914 29300003
Blood calcium decreased 50.27 14.68 190 267420 8992 29297925
Inappropriate antidiuretic hormone secretion 50.26 14.68 18 267592 10914 29296003
Hypotension 50.12 14.68 1357 266253 192997 29113920
Pathogen resistance 49.99 14.68 7 267603 8109 29298808
Body temperature decreased 49.99 14.68 17 267593 10647 29296270
Injection site haemorrhage 49.89 14.68 8 267602 8378 29298539
Protein total abnormal 49.64 14.68 33 267577 293 29306624
Flushing 49.31 14.68 119 267491 28873 29278044
Memory impairment 49.30 14.68 526 267084 35944 29270973
Cardiomegaly 49.16 14.68 32 267578 13744 29293173
Depressed mood 48.84 14.68 46 267564 16402 29290515
Cerebrovascular accident 48.49 14.68 971 266639 75940 29230977
Kidney transplant rejection 48.34 14.68 4 267606 7001 29299916
Lower limb fracture 48.29 14.68 104 267506 3548 29303369
Angina unstable 48.10 14.68 19 267591 10846 29296071
Acute hepatic failure 48.03 14.68 24 267586 11928 29294989
Hyperthermia 47.88 14.68 13 267597 9417 29297500
Palmar-plantar erythrodysaesthesia syndrome 47.81 14.68 38 267572 14721 29292196
Pneumonia aspiration 47.80 14.68 171 267439 36566 29270351
Blood pressure decreased 47.77 14.68 230 267380 45247 29261670
Chest pain 47.40 14.68 720 266890 111253 29195664
Hepatitis cholestatic 47.39 14.68 4 267606 6889 29300028
Metastases to liver 47.36 14.68 24 267586 11832 29295085
Lipase increased 47.31 14.68 9 267601 8328 29298589
Hallucination, auditory 47.27 14.68 14 267596 9579 29297338
Mitral valve incompetence 47.27 14.68 31 267579 13262 29293655
Skin exfoliation 47.27 14.68 359 267251 22286 29284631
Cardiac amyloidosis 46.95 14.68 49 267561 854 29306063
Drug reaction with eosinophilia and systemic symptoms 46.74 14.68 116 267494 27876 29279041
Myalgia 46.70 14.68 436 267174 73583 29233334
Metastases to lung 45.61 14.68 8 267602 7847 29299070
Therapeutic response unexpected 45.60 14.68 11 267599 8627 29298290
Torsade de pointes 45.43 14.68 4 267606 6657 29300260
Hyperbilirubinaemia 45.25 14.68 41 267569 14893 29292024
Cerebral haemorrhage 45.20 14.68 140 267470 31286 29275631
Hypercholesterolaemia 45.16 14.68 6 267604 7232 29299685
Myocardial ischaemia 45.09 14.68 47 267563 15981 29290936
Adverse reaction 44.99 14.68 86 267524 2689 29304228
Injury 44.97 14.68 64 267546 18982 29287935
Duodenal ulcer 44.58 14.68 14 267596 9224 29297693
Speech disorder 44.52 14.68 91 267519 23425 29283492
Blood pressure abnormal 44.45 14.68 149 267461 6641 29300276
Respiratory rate increased 44.22 14.68 12 267598 8696 29298221
Injection site reaction 44.16 14.68 23 267587 11165 29295752
Disturbance in attention 43.97 14.68 79 267531 21345 29285572
Inflammation 43.84 14.68 87 267523 22641 29284276
Dyspnoea exertional 43.50 14.68 176 267434 36314 29270603
Anuria 43.37 14.68 16 267594 9525 29297392
Blood albumin decreased 43.34 14.68 26 267584 11669 29295248
COVID-19 pneumonia 43.31 14.68 186 267424 9336 29297581
Clostridium difficile infection 43.22 14.68 272 267338 15869 29291048
Left ventricular hypertrophy 43.18 14.68 5 267605 6698 29300219
Dyslipidaemia 43.13 14.68 3 267607 6058 29300859
Haemodialysis 43.10 14.68 18 267592 9936 29296981
Blood loss anaemia 43.08 14.68 7 267603 7259 29299658
Metastases to bone 42.69 14.68 18 267592 9880 29297037
Balance disorder 42.69 14.68 508 267102 35662 29271255
Activated partial thromboplastin time prolonged 42.59 14.68 9 267601 7733 29299184
Anhedonia 42.54 14.68 7 267603 7193 29299724
Hepatic enzyme increased 42.22 14.68 160 267450 33639 29273278
Uveitis 42.16 14.68 3 267607 5944 29300973
Rhinorrhoea 42.06 14.68 336 267274 21183 29285734
Aphasia 41.96 14.68 68 267542 19130 29287787
Shock haemorrhagic 41.79 14.68 17 267593 9534 29297383
Type 2 diabetes mellitus 41.49 14.68 37 267573 13544 29293373
Renal tubular necrosis 41.38 14.68 41 267569 14274 29292643
Blood electrolytes decreased 41.32 14.68 30 267580 311 29306606
Product storage error 41.25 14.68 5 267605 6465 29300452
Myocarditis 41.11 14.68 24 267586 10932 29295985
Gastritis 40.93 14.68 71 267539 19446 29287471
Posterior reversible encephalopathy syndrome 40.89 14.68 15 267595 8961 29297956
Osteolysis 40.80 14.68 60 267550 1505 29305412
Liver injury 40.69 14.68 33 267577 12657 29294260
Ataxia 40.68 14.68 30 267580 12073 29294844
Respiratory tract congestion 40.60 14.68 122 267488 5127 29301790
Peritonitis bacterial 40.53 14.68 3 267607 5753 29301164
Haemorrhage intracranial 40.51 14.68 43 267567 14499 29292418
Hypertriglyceridaemia 40.49 14.68 9 267601 7466 29299451
Gynaecomastia 40.47 14.68 12 267598 8205 29298712
Basosquamous carcinoma of skin 40.44 14.68 12 267598 5 29306912
Pulmonary arterial hypertension 40.29 14.68 9 267601 7440 29299477
Neuralgia 40.28 14.68 200 267410 10674 29296243
Femur fracture 40.22 14.68 147 267463 6844 29300073
Auditory disorder 40.13 14.68 27 267583 245 29306672
Upper respiratory tract infection 40.06 14.68 401 267209 26948 29279969
Oliguria 40.00 14.68 9 267601 7403 29299514
Hepatic cirrhosis 39.91 14.68 43 267567 14401 29292516
Blood iron decreased 39.85 14.68 109 267501 4339 29302578
Nephropathy toxic 39.74 14.68 24 267586 10732 29296185
Limb injury 39.71 14.68 179 267431 9176 29297741
Hypothermia 39.53 14.68 17 267593 9222 29297695
Ejection fraction decreased 39.42 14.68 52 267558 15926 29290991
Vertebral lesion 39.29 14.68 23 267587 159 29306758
Haemoptysis 39.21 14.68 143 267467 30407 29276510
Glomerular filtration rate decreased 39.08 14.68 27 267583 11239 29295678
B precursor type acute leukaemia 38.82 14.68 21 267589 122 29306795
Contusion 38.59 14.68 441 267169 30654 29276263
Mania 38.59 14.68 15 267595 8648 29298269
Jaw disorder 38.56 14.68 67 267543 1943 29304974
Toothache 38.13 14.68 125 267485 5507 29301410
Dysphagia 37.96 14.68 316 267294 54610 29252307
Blood immunoglobulin G increased 37.84 14.68 43 267567 828 29306089
Joint range of motion decreased 37.82 14.68 5 267605 6049 29300868
Eosinophilia 37.65 14.68 91 267519 22070 29284847
Schizophrenia 37.44 14.68 7 267603 6558 29300359
Pulmonary fibrosis 37.14 14.68 52 267558 15530 29291387
Left ventricular dysfunction 37.11 14.68 17 267593 8885 29298032
Disease recurrence 37.05 14.68 54 267556 15860 29291057
Lacrimation increased 37.03 14.68 143 267467 6837 29300080
Parkinsonism 37.01 14.68 10 267600 7268 29299649
Blood pressure diastolic decreased 36.96 14.68 9 267601 7013 29299904
Rales 36.93 14.68 11 267599 7499 29299418
Impaired work ability 36.85 14.68 4 267606 5636 29301281
Dyspnoea 36.76 14.68 2505 265105 324227 28982690
Subarachnoid haemorrhage 36.69 14.68 21 267589 9671 29297246
Tricuspid valve incompetence 36.63 14.68 15 267595 8379 29298538
Cardiac valve disease 36.40 14.68 80 267530 2768 29304149
Bronchospasm 36.12 14.68 21 267589 9588 29297329
Arthralgia 35.90 14.68 975 266635 138642 29168275
Weight decreased 35.81 14.68 1689 265921 149216 29157701
Oesophagitis 35.81 14.68 33 267577 11890 29295027
Coordination abnormal 35.76 14.68 10 267600 7104 29299813
Hypokinesia 35.48 14.68 12 267598 7542 29299375
Breath sounds abnormal 35.33 14.68 4 267606 5453 29301464
Refractory anaemia with an excess of blasts 35.16 14.68 29 267581 368 29306549
Aplastic anaemia 35.15 14.68 12 267598 7498 29299419
Sinus bradycardia 34.98 14.68 32 267578 11571 29295346
Bronchopulmonary aspergillosis 34.95 14.68 36 267574 12308 29294609
Flatulence 34.88 14.68 277 267333 17432 29289485
Disorientation 34.77 14.68 143 267467 29372 29277545
Eye infection 34.62 14.68 79 267531 2804 29304113
Chills 34.58 14.68 446 267164 70854 29236063
Hepatitis acute 34.56 14.68 8 267602 6454 29300463
Hypertensive crisis 34.29 14.68 14 267596 7834 29299083
Plasma cell myeloma refractory 34.26 14.68 17 267593 80 29306837
Oral disorder 34.03 14.68 93 267517 3700 29303217
Febrile neutropenia 33.95 14.68 765 266845 111475 29195442
Epstein-Barr virus infection 33.92 14.68 9 267601 6620 29300297
Viral infection 33.88 14.68 240 267370 14570 29292347
Fracture 33.75 14.68 126 267484 5927 29300990
Lower gastrointestinal haemorrhage 33.75 14.68 16 267594 8197 29298720
Knee arthroplasty 33.55 14.68 6 267604 5803 29301114
Hypovolaemic shock 33.53 14.68 7 267603 6065 29300852
Pneumonia viral 33.28 14.68 74 267536 2581 29304336
Post transplant lymphoproliferative disorder 33.23 14.68 5 267605 5488 29301429
Muscle spasticity 33.12 14.68 3 267607 4880 29302037
Iron deficiency anaemia 32.97 14.68 20 267590 8922 29297995
Papule 32.88 14.68 83 267527 3146 29303771
Haemophagocytic lymphohistiocytosis 32.84 14.68 28 267582 10476 29296441
Enterococcal infection 32.63 14.68 17 267593 8251 29298666
Toxicity to various agents 32.42 14.68 1264 266346 172397 29134520
Hypotonia 32.36 14.68 11 267599 6891 29300026
B-cell type acute leukaemia 32.12 14.68 24 267586 261 29306656
Post procedural complication 32.10 14.68 28 267582 10361 29296556
Transfusion 31.91 14.68 13 267597 7285 29299632
Eye swelling 31.91 14.68 159 267451 8498 29298419
Injection site pruritus 31.77 14.68 7 267603 5842 29301075
Sputum discoloured 31.58 14.68 10 267600 6553 29300364
Subdural haematoma 31.47 14.68 74 267536 18119 29288798
Rash macular 31.30 14.68 181 267429 10244 29296673
Visual acuity reduced 31.30 14.68 54 267556 14822 29292095
Productive cough 31.15 14.68 161 267449 31098 29275819
Hyperviscosity syndrome 31.09 14.68 20 267590 167 29306750
Acute respiratory failure 31.05 14.68 128 267482 26274 29280643
Chondrocalcinosis pyrophosphate 31.04 14.68 40 267570 882 29306035
Multiple fractures 31.02 14.68 48 267562 1261 29305656
Granulocytopenia 30.93 14.68 8 267602 5986 29300931
Product dispensing error 30.92 14.68 6 267604 5474 29301443
Red blood cell count abnormal 30.83 14.68 32 267578 554 29306363
Weight fluctuation 30.69 14.68 94 267516 3992 29302925
Klebsiella infection 30.69 14.68 14 267596 7335 29299582
Heart rate increased 30.68 14.68 216 267394 38722 29268195
Blood magnesium decreased 30.68 14.68 113 267497 5281 29301636
Limb discomfort 30.63 14.68 169 267441 9399 29297518
Electrocardiogram abnormal 30.50 14.68 14 267596 7308 29299609
Pneumonia influenzal 30.44 14.68 48 267562 1282 29305635
Food poisoning 30.33 14.68 47 267563 1236 29305681
Osteoarthritis 30.23 14.68 75 267535 18028 29288889
Haematochezia 30.21 14.68 203 267407 36780 29270137
Cardiac failure congestive 30.18 14.68 907 266703 75674 29231243
Hepatomegaly 30.16 14.68 24 267586 9293 29297624
Aspergillus infection 29.79 14.68 31 267579 10550 29296367
Asphyxia 29.61 14.68 6 267604 5309 29301608
Clavicle fracture 29.53 14.68 59 267551 1907 29305010
Aphonia 29.44 14.68 75 267535 2859 29304058
Arthropod bite 29.40 14.68 66 267544 2317 29304600
Pneumonitis 29.34 14.68 142 267468 27902 29279015
Pseudomonas infection 29.22 14.68 33 267577 10819 29296098
Blood lactic acid increased 29.18 14.68 8 267602 5758 29301159
Tumour marker increased 29.15 14.68 30 267580 514 29306403
Tendonitis 29.08 14.68 18 267592 7943 29298974
Cardiac failure 28.87 14.68 524 267086 78763 29228154
Dialysis 28.64 14.68 30 267580 10178 29296739
Right ventricular failure 28.60 14.68 18 267592 7872 29299045
Malignant melanoma in situ 28.59 14.68 44 267566 1150 29305767
POEMS syndrome 28.50 14.68 12 267598 35 29306882
Dizziness 28.43 14.68 2037 265573 187647 29119270
Eczema 28.35 14.68 51 267559 13775 29293142
Prothrombin time prolonged 28.28 14.68 23 267587 8809 29298108
Gastritis erosive 28.21 14.68 7 267603 5386 29301531
Appendix disorder 28.18 14.68 31 267579 575 29306342
Gastroenteritis viral 28.01 14.68 115 267495 5657 29301260
Eosinophil count increased 27.85 14.68 16 267594 7353 29299564
Euphoric mood 27.83 14.68 5 267605 4820 29302097
Hydronephrosis 27.62 14.68 23 267587 8707 29298210
Cholangitis 27.59 14.68 17 267593 7520 29299397
Gingival pain 27.35 14.68 59 267551 2015 29304902
Brain injury 27.24 14.68 8 267602 5504 29301413
Pulmonary congestion 27.22 14.68 44 267566 12392 29294525
Atelectasis 27.11 14.68 62 267548 15330 29291587
Adenovirus infection 27.01 14.68 4 267606 4443 29302474
Night sweats 26.95 14.68 229 267381 14703 29292214
Motor dysfunction 26.86 14.68 10 267600 5920 29300997
Hyperthyroidism 26.84 14.68 23 267587 8585 29298332
Coronary artery bypass 26.71 14.68 5 267605 4680 29302237
Peritonitis 26.69 14.68 59 267551 14765 29292152
Viral upper respiratory tract infection 26.66 14.68 66 267544 2471 29304446
Paraproteinaemia 26.64 14.68 23 267587 312 29306605
Atrial flutter 26.64 14.68 216 267394 13678 29293239
Coronary artery stenosis 26.62 14.68 23 267587 8550 29298367
Rectal adenocarcinoma 26.51 14.68 34 267576 746 29306171
Hiatus hernia 26.47 14.68 14 267596 6738 29300179
Glycosylated haemoglobin increased 26.11 14.68 28 267582 9398 29297519
Pleural effusion 25.94 14.68 476 267134 71432 29235485
Platelet count abnormal 25.92 14.68 63 267547 2331 29304586
Post procedural haemorrhage 25.92 14.68 18 267592 7473 29299444
Refractory cytopenia with multilineage dysplasia 25.85 14.68 16 267594 124 29306793
Dermatitis allergic 25.79 14.68 111 267499 5577 29301340
Multiple sclerosis 25.78 14.68 9 267601 5545 29301372
Cerebral haematoma 25.78 14.68 4 267606 4292 29302625
Therapy non-responder 25.77 14.68 408 267202 30503 29276414
Orthopnoea 25.71 14.68 5 267605 4555 29302362
Arteriosclerosis 25.69 14.68 33 267577 10223 29296694
Adrenal insufficiency 25.59 14.68 38 267572 11076 29295841
Cytokine release syndrome 25.49 14.68 50 267560 13069 29293848
Device dislocation 25.45 14.68 5 267605 4522 29302395
Cellulitis 25.38 14.68 568 267042 45272 29261645
Nightmare 25.36 14.68 40 267570 11377 29295540
Skin sensitisation 25.32 14.68 18 267592 180 29306737
Skin necrosis 25.28 14.68 7 267603 5005 29301912
Exercise tolerance decreased 25.25 14.68 4 267606 4227 29302690
Middle insomnia 25.23 14.68 10 267600 5698 29301219
Hypernatraemia 25.23 14.68 18 267592 7368 29299549
Electrocardiogram ST segment elevation 25.17 14.68 5 267605 4487 29302430
Apnoea 24.90 14.68 12 267598 6090 29300827
Lymphocyte count decreased 24.86 14.68 90 267520 19181 29287736
Metastases to central nervous system 24.86 14.68 17 267593 7114 29299803
Skin atrophy 24.81 14.68 51 267559 1683 29305234
Monocyte count increased 24.78 14.68 3 267607 3883 29303034
Gait disturbance 24.78 14.68 491 267119 72858 29234059
Hyperglycaemia 24.72 14.68 195 267415 34092 29272825
Spinal cord compression 24.70 14.68 80 267530 3502 29303415
Drug eruption 24.48 14.68 74 267536 16667 29290250
Colon cancer 24.36 14.68 135 267475 7520 29299397
Crying 24.28 14.68 9 267601 5342 29301575
Myopathy 24.27 14.68 36 267574 10497 29296420
Pulse absent 24.23 14.68 8 267602 5105 29301812
Toxic encephalopathy 24.10 14.68 6 267604 4606 29302311
Cholecystitis infective 24.10 14.68 48 267562 1548 29305369
Renal tubular disorder 24.06 14.68 5 267605 4347 29302570
Atrioventricular block first degree 24.04 14.68 9 267601 5310 29301607
Splenomegaly 23.79 14.68 53 267557 13226 29293691
Amylase increased 23.76 14.68 9 267601 5271 29301646
Skin plaque 23.76 14.68 3 267607 3759 29303158
Stent placement 23.70 14.68 5 267605 4301 29302616
Dermatitis acneiform 23.66 14.68 10 267600 5481 29301436
Respiratory tract infection 23.66 14.68 231 267379 15420 29291497
Necrosis 23.61 14.68 8 267602 5022 29301895
Bladder disorder 23.58 14.68 67 267543 2727 29304190
Abdominal pain lower 23.55 14.68 26 267584 8612 29298305
Tenosynovitis 23.52 14.68 3 267607 3730 29303187
Hypothyroidism 23.48 14.68 70 267540 15836 29291081
Hypercapnia 23.46 14.68 3 267607 3723 29303194
Anger 23.40 14.68 39 267571 10851 29296066
Ventricular hypertrophy 23.37 14.68 5 267605 4259 29302658
Hyperammonaemia 23.32 14.68 11 267599 5652 29301265
Ischaemic cardiomyopathy 23.14 14.68 11 267599 5627 29301290
Musculoskeletal pain 23.11 14.68 160 267450 28793 29278124
Hepatitis C 23.02 14.68 28 267582 8882 29298035
Neutrophilia 22.97 14.68 3 267607 3663 29303254
Ischaemia 22.96 14.68 5 267605 4207 29302710
Red cell distribution width increased 22.95 14.68 7 267603 4700 29302217
Congestive cardiomyopathy 22.85 14.68 16 267594 6614 29300303
Panic attack 22.77 14.68 25 267585 8301 29298616
Ketoacidosis 22.74 14.68 3 267607 3636 29303281
Brain herniation 22.69 14.68 3 267607 3630 29303287
Partial seizures 22.61 14.68 4 267606 3899 29303018
Urinary incontinence 22.59 14.68 75 267535 16406 29290511
Renal impairment 22.50 14.68 925 266685 80408 29226509
Hypertransaminasaemia 22.47 14.68 3 267607 3603 29303314
Anosmia 22.21 14.68 53 267557 1938 29304979
Neutrophil count abnormal 22.20 14.68 45 267565 1470 29305447
Hepatic necrosis 21.95 14.68 3 267607 3539 29303378
Disease complication 21.91 14.68 59 267551 2327 29304590
Haemolytic anaemia 21.89 14.68 32 267578 9387 29297530
Cardiomyopathy 21.88 14.68 65 267545 14722 29292195
Muscle strain 21.79 14.68 76 267534 3457 29303460
Central nervous system lesion 21.72 14.68 12 267598 5636 29301281
Salmonellosis 21.69 14.68 30 267580 710 29306207
Salivary hypersecretion 21.67 14.68 21 267589 7388 29299529
Visceral leishmaniasis 21.62 14.68 25 267585 491 29306426
Blood chloride decreased 21.61 14.68 3 267607 3498 29303419
Hypoxic-ischaemic encephalopathy 21.57 14.68 6 267604 4278 29302639
Chronic graft versus host disease 21.53 14.68 5 267605 4024 29302893
Acute graft versus host disease 21.51 14.68 13 267597 5811 29301106
Cardiotoxicity 21.49 14.68 8 267602 4736 29302181
Intracranial pressure increased 21.48 14.68 3 267607 3482 29303435
Hemiplegia 21.33 14.68 17 267593 6577 29300340
Pelvic fracture 21.33 14.68 56 267554 2175 29304742
Hypervolaemia 21.30 14.68 84 267526 17461 29289456
Gastrointestinal motility disorder 21.26 14.68 55 267555 2117 29304800
Bradykinesia 21.17 14.68 3 267607 3444 29303473
Mental status changes 21.05 14.68 208 267402 34719 29272198
Bradyphrenia 21.04 14.68 6 267604 4208 29302709
Sternal fracture 20.93 14.68 27 267583 596 29306321
Amyloidosis 20.92 14.68 52 267558 1952 29304965
Blood immunoglobulin M increased 20.90 14.68 16 267594 181 29306736
Blood immunoglobulin A increased 20.85 14.68 19 267591 278 29306639
Lentigo maligna 20.77 14.68 20 267590 315 29306602
Cardiac tamponade 20.69 14.68 8 267602 4627 29302290
Chronic kidney disease 20.66 14.68 220 267390 36196 29270721
Bundle branch block left 20.60 14.68 11 267599 5266 29301651
Type 1 diabetes mellitus 20.54 14.68 4 267606 3640 29303277
Aspiration 20.47 14.68 38 267572 10142 29296775
Pneumothorax 20.43 14.68 74 267536 15768 29291149
Cervical vertebral fracture 20.42 14.68 47 267563 1678 29305239
Behaviour disorder 20.32 14.68 4 267606 3612 29303305
Immunoglobulins abnormal 20.29 14.68 7 267603 9 29306908
5q minus syndrome 20.28 14.68 14 267596 133 29306784
Autoimmune hepatitis 20.20 14.68 4 267606 3598 29303319
Musculoskeletal chest pain 20.20 14.68 141 267469 8519 29298398
Ventricular hypokinesia 20.18 14.68 8 267602 4557 29302360
Myeloma cast nephropathy 20.16 14.68 10 267600 47 29306870
Erectile dysfunction 20.14 14.68 89 267521 17920 29288997
Respiratory acidosis 20.11 14.68 7 267603 4321 29302596
Device occlusion 20.04 14.68 13 267597 5595 29301322
Portal vein thrombosis 20.04 14.68 3 267607 3306 29303611
Vitamin B complex deficiency 20.01 14.68 15 267595 164 29306753
Pyelonephritis 19.97 14.68 12 267598 5381 29301536
Serum ferritin increased 19.91 14.68 13 267597 5575 29301342
Oral infection 19.82 14.68 48 267562 1772 29305145
Lymphadenopathy 19.71 14.68 139 267471 24910 29282007
Duodenal ulcer haemorrhage 19.55 14.68 8 267602 4471 29302446
Procedural pain 19.49 14.68 7 267603 4237 29302680
Sudden death 19.49 14.68 64 267546 14046 29292871
Kidney infection 19.42 14.68 89 267521 4594 29302323
Bone loss 19.34 14.68 24 267586 509 29306408
Gastric haemorrhage 19.33 14.68 34 267576 9263 29297654
Portal hypertension 19.29 14.68 4 267606 3482 29303435
Occult blood positive 19.16 14.68 5 267605 3719 29303198
Haematocrit decreased 19.14 14.68 169 267441 28853 29278064
Polyarthritis 19.00 14.68 6 267604 3939 29302978
Pneumatosis intestinalis 18.90 14.68 3 267607 3166 29303751
Superficial spreading melanoma stage I 18.77 14.68 7 267603 13 29306904
Duodenitis 18.69 14.68 7 267603 4128 29302789
Intraocular pressure increased 18.67 14.68 10 267600 4779 29302138
Spinal osteoarthritis 18.61 14.68 18 267592 6338 29300579
Gastric ulcer 18.58 14.68 65 267545 13996 29292921
Nausea 18.48 14.68 2314 265296 286941 29019976
Discomfort 18.36 14.68 70 267540 14693 29292224
Lyme disease 18.32 14.68 29 267581 777 29306140
Primary amyloidosis 18.29 14.68 12 267598 104 29306813
Bladder transitional cell carcinoma stage 0 18.19 14.68 12 267598 105 29306812
Stevens-Johnson syndrome 18.16 14.68 82 267528 16415 29290502
Parosmia 18.01 14.68 41 267569 1453 29305464
Incorrect product administration duration 18.00 14.68 7 267603 4034 29302883
Aplasia pure red cell 17.96 14.68 14 267596 5477 29301440
Herpes simplex 17.94 14.68 11 267599 4879 29302038
Encephalitis 17.92 14.68 19 267591 6411 29300506
Lung adenocarcinoma 17.86 14.68 76 267534 3799 29303118
Bronchiectasis 17.76 14.68 20 267590 6565 29300352
Diverticulum intestinal 17.74 14.68 4 267606 3286 29303631
Anal abscess 17.67 14.68 13 267597 5238 29301679
Scar 17.49 14.68 14 267596 5405 29301512
Bundle branch block right 17.47 14.68 21 267589 6696 29300221
Hepatic fibrosis 17.45 14.68 4 267606 3248 29303669
Spinal cord neoplasm 17.42 14.68 13 267597 141 29306776
Hepatosplenomegaly 17.29 14.68 6 267604 3711 29303206
Ecchymosis 17.01 14.68 19 267591 6261 29300656
Syncope 17.01 14.68 584 267026 80787 29226130
Bladder transitional cell carcinoma 17.00 14.68 55 267555 2406 29304511
Colon cancer metastatic 16.97 14.68 40 267570 1451 29305466
Benign prostatic hyperplasia 16.95 14.68 52 267558 11658 29295259
Psychiatric symptom 16.91 14.68 4 267606 3180 29303737
Normochromic normocytic anaemia 16.86 14.68 6 267604 3652 29303265
Cardiac murmur 16.85 14.68 21 267589 6592 29300325
Immunoglobulins increased 16.82 14.68 14 267596 180 29306737
Cyst 16.81 14.68 76 267534 3901 29303016
Idiopathic pulmonary fibrosis 16.79 14.68 4 267606 3164 29303753
Haemorrhagic stroke 16.67 14.68 17 267593 5839 29301078
Presyncope 16.52 14.68 82 267528 16007 29290910
Hospice care 16.47 14.68 13 267597 5055 29301862
Adenocarcinoma gastric 16.45 14.68 33 267577 1070 29305847
Diverticulitis 16.42 14.68 238 267372 17466 29289451
Renal cyst 16.36 14.68 29 267581 7878 29299039
Upper-airway cough syndrome 16.32 14.68 62 267548 2941 29303976
Intestinal obstruction 16.28 14.68 255 267355 19022 29287895
Hepatitis fulminant 16.21 14.68 6 267604 3565 29303352
Sciatica 16.19 14.68 88 267522 4866 29302051
Papillary thyroid cancer 16.17 14.68 23 267587 559 29306358
Polyuria 16.16 14.68 26 267584 7336 29299581
Transitional cell cancer of the renal pelvis and ureter 16.02 14.68 7 267603 23 29306894
Leukoencephalopathy 16.01 14.68 7 267603 3760 29303157
Furuncle 16.01 14.68 61 267549 2898 29304019
Mental impairment 15.95 14.68 37 267573 9104 29297813
Hip arthroplasty 15.94 14.68 7 267603 3751 29303166
Colorectal adenocarcinoma 15.92 14.68 14 267596 195 29306722
Urticaria 15.88 14.68 625 266985 54035 29252882
Gait inability 15.87 14.68 244 267366 18131 29288786
Mucormycosis 15.82 14.68 14 267596 5144 29301773
Snoring 15.81 14.68 3 267607 2781 29304136
Feeling jittery 15.78 14.68 70 267540 3563 29303354
Neoplasm 15.74 14.68 77 267533 4084 29302833
Cerebral ischaemia 15.73 14.68 17 267593 5686 29301231
Supraventricular tachycardia 15.70 14.68 42 267568 9842 29297075
Liver function test increased 15.67 14.68 55 267555 11830 29295087
Bilirubin conjugated increased 15.62 14.68 4 267606 3013 29303904
Bone erosion 15.62 14.68 3 267607 2757 29304160
Acute coronary syndrome 15.61 14.68 58 267552 12267 29294650
Emotional disorder 15.59 14.68 13 267597 4918 29301999
Hypophosphataemia 15.57 14.68 30 267580 7894 29299023
Hepatocellular carcinoma 15.31 14.68 25 267585 7013 29299904
Prostate cancer 15.31 14.68 320 267290 25207 29281710
Chest wall mass 15.28 14.68 8 267602 43 29306874
Muscle twitching 15.24 14.68 31 267579 7995 29298922
Squamous cell carcinoma of the hypopharynx 15.19 14.68 6 267604 14 29306903
Cerebral atrophy 15.16 14.68 9 267601 4063 29302854
Alanine aminotransferase abnormal 15.16 14.68 4 267606 2953 29303964
Gingival discolouration 15.15 14.68 5 267605 5 29306912
Respiration abnormal 15.12 14.68 56 267554 2624 29304293
Gastrointestinal infection 15.10 14.68 72 267538 3779 29303138
Lung consolidation 15.09 14.68 14 267596 5029 29301888
Lethargy 15.08 14.68 244 267366 37336 29269581
Anal squamous cell carcinoma 15.05 14.68 9 267601 65 29306852
Irritability 15.05 14.68 128 267482 22024 29284893
Amnesia 14.96 14.68 288 267322 22355 29284562
Tongue disorder 14.93 14.68 12 267598 4624 29302293
Mental disorder 14.90 14.68 63 267547 12842 29294075
Oedema 14.90 14.68 267 267343 40216 29266701
Plasma cell myeloma in remission 14.86 14.68 4 267606 0 29306917
Hepatic amyloidosis 14.86 14.68 4 267606 0 29306917
Hyperaesthesia teeth 14.82 14.68 20 267590 462 29306455
Myasthenia gravis 14.81 14.68 5 267605 3146 29303771
Respiratory syncytial virus infection 14.78 14.68 69 267541 3590 29303327
Inadequate analgesia 14.78 14.68 3 267607 2651 29304266
Disability 14.77 14.68 11 267599 4405 29302512
Ventricular arrhythmia 14.73 14.68 12 267598 4592 29302325
Swollen tongue 14.71 14.68 59 267551 12207 29294710
Vitamin D deficiency 14.68 14.68 17 267593 5512 29301405
Muscle haemorrhage 14.68 14.68 6 267604 3356 29303561

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Death 6348.29 14.19 9490 297733 473215 63718294
Full blood count decreased 6337.77 14.19 2767 304456 19815 64171694
Pneumonia 5023.22 14.19 9271 297952 550305 63641204
Thrombosis 4328.04 14.19 3187 304036 67455 64124054
White blood cell count decreased 4138.95 14.19 4395 302828 153442 64038067
Platelet count decreased 3560.04 14.19 4183 303040 163528 64027981
Neuropathy peripheral 3516.90 14.19 3515 303708 114010 64077499
Diarrhoea 3259.41 14.19 9118 298105 713586 63477923
Rash 2409.87 14.19 6134 301089 452415 63739094
Deep vein thrombosis 2018.03 14.19 2495 304728 102687 64088822
Fatigue 1775.88 14.19 7642 299581 741088 63450421
Unevaluable event 1685.13 14.19 1605 305618 48884 64142625
Neutropenia 1365.40 14.19 3312 303911 236312 63955197
Laboratory test abnormal 1319.07 14.19 1017 306206 23046 64168463
Drug interaction 1305.23 14.19 114 307109 361969 63829540
Plasma cell myeloma 1221.51 14.19 1293 305930 44782 64146727
Muscle spasms 1213.12 14.19 2305 304918 138718 64052791
Constipation 1159.73 14.19 3030 304193 226307 63965202
Neutrophil count decreased 1106.77 14.19 1589 305634 75607 64115902
Off label use 1106.13 14.19 842 306381 631964 63559545
COVID-19 1079.58 14.19 1438 305785 63702 64127807
Plasma cell myeloma recurrent 1051.90 14.19 471 306752 3594 64187915
Pancytopenia 981.01 14.19 2131 305092 141178 64050331
Drug ineffective 974.72 14.19 1568 305655 838679 63352830
Condition aggravated 933.72 14.19 306 306917 372120 63819389
Completed suicide 909.23 14.19 37 307186 224377 63967132
Pulmonary embolism 896.21 14.19 2082 305141 144274 64047235
Thrombocytopenia 861.86 14.19 2681 304542 221120 63970389
Pulmonary thrombosis 721.52 14.19 509 306714 10009 64181500
Haemoglobin decreased 702.44 14.19 2284 304939 192779 63998730
Rheumatoid arthritis 672.42 14.19 25 307198 164269 64027240
Human chorionic gonadotropin increased 646.22 14.19 218 307005 668 64190841
Red blood cell count decreased 639.64 14.19 959 306264 47427 64144082
Plasmacytoma 629.09 14.19 326 306897 3544 64187965
Drug abuse 601.98 14.19 5 307218 132369 64059140
Squamous cell carcinoma of skin 586.21 14.19 472 306751 11404 64180105
Rash pruritic 565.81 14.19 996 306227 56408 64135101
Product dose omission issue 561.39 14.19 2119 305104 192628 63998881
Adverse drug reaction 559.90 14.19 872 306351 44592 64146917
Overdose 509.81 14.19 76 307147 159490 64032019
Dehydration 508.14 14.19 2212 305011 214551 63976958
Drug hypersensitivity 498.78 14.19 255 306968 237560 63953949
Blood potassium decreased 490.70 14.19 770 306453 39629 64151880
Asthenia 481.03 14.19 3585 303638 424459 63767050
Anaemia 468.37 14.19 3246 303977 375434 63816075
Cytopenia 456.35 14.19 460 306763 15011 64176498
Myelodysplastic syndrome 452.24 14.19 606 306617 26973 64164536
Injection site pain 445.52 14.19 20 307203 111388 64080121
Headache 432.83 14.19 1201 306022 528266 63663243
Cardiac disorder 416.03 14.19 860 306363 54956 64136553
Synovitis 412.64 14.19 13 307210 99077 64092432
Acute myeloid leukaemia 407.48 14.19 575 306648 26888 64164621
Ageusia 406.13 14.19 410 306813 13403 64178106
Hip fracture 395.60 14.19 563 306660 26536 64164973
Arthralgia 392.71 14.19 962 306261 441298 63750211
Sepsis 381.93 14.19 2130 305093 228211 63963298
Influenza 364.67 14.19 1227 305996 105304 64086205
Product use in unapproved indication 347.49 14.19 205 307018 176413 64015096
Fall 345.69 14.19 3262 303961 413564 63777945
Plasma cell leukaemia 339.28 14.19 160 307063 1393 64190116
Renal failure 334.94 14.19 1730 305493 179958 64011551
Systemic lupus erythematosus 327.46 14.19 9 307214 77603 64113906
Atrial fibrillation 322.97 14.19 1640 305583 169449 64022060
Peripheral swelling 308.84 14.19 1876 305347 207277 63984232
Light chain analysis increased 305.09 14.19 141 307082 1167 64190342
Exposure during pregnancy 303.94 14.19 16 307207 77659 64113850
Intentional product misuse 292.26 14.19 12 307211 72283 64119226
Intentional product use issue 289.80 14.19 52 307171 95312 64096197
Renal disorder 285.04 14.19 563 306660 34802 64156707
Suicide attempt 283.03 14.19 13 307210 70994 64120515
Pain 281.97 14.19 1519 305704 551992 63639517
Tooth disorder 280.37 14.19 433 306790 21969 64169540
Blood pressure increased 270.16 14.19 254 306969 172298 64019211
Disease progression 265.82 14.19 1356 305867 140324 64051185
Pemphigus 263.98 14.19 5 307218 60696 64130813
Product use issue 262.34 14.19 203 307020 151512 64039997
Aspartate aminotransferase increased 260.71 14.19 122 307101 119666 64071843
Alanine aminotransferase increased 260.10 14.19 171 307052 138860 64052649
Monoclonal immunoglobulin present 257.92 14.19 110 307113 735 64190774
Wrong technique in product usage process 246.23 14.19 16 307207 64958 64126551
Dry skin 245.56 14.19 664 306559 50497 64141012
Tachycardia 243.91 14.19 212 307011 149367 64042142
Treatment failure 243.58 14.19 126 307097 116690 64074819
Urinary tract infection 242.68 14.19 1910 305313 229686 63961823
Taste disorder 241.45 14.19 260 306963 9173 64182336
Coma 239.24 14.19 61 307162 87554 64103955
SARS-CoV-2 test positive 238.85 14.19 215 307008 6071 64185438
Hypertension 234.39 14.19 558 306665 258703 63932806
Rhabdomyolysis 233.51 14.19 73 307150 91653 64099856
Injection site erythema 230.03 14.19 32 307191 70768 64120741
Therapeutic product effect decreased 229.48 14.19 132 307091 115219 64076290
Spinal fracture 228.48 14.19 320 306903 14854 64176655
Psoriasis 220.25 14.19 38 307185 71665 64119844
Inappropriate schedule of product administration 220.10 14.19 82 307141 92204 64099305
Acute lymphocytic leukaemia 218.41 14.19 175 307048 4196 64187313
Depressed level of consciousness 217.97 14.19 59 307164 81377 64110132
Hospitalisation 207.97 14.19 51 307172 75156 64116353
Bronchitis 206.86 14.19 1045 306178 107698 64083811
Therapeutic product effect incomplete 206.44 14.19 118 307105 103364 64088145
Pruritus 205.80 14.19 2334 304889 310066 63881443
Mobility decreased 205.17 14.19 76 307147 85764 64105745
Adenocarcinoma of colon 204.73 14.19 177 307046 4731 64186778
Basal cell carcinoma 204.22 14.19 453 306770 30385 64161124
Tumour flare 199.82 14.19 90 307133 697 64190812
Hyponatraemia 199.26 14.19 248 306975 148091 64043418
Full blood count abnormal 199.18 14.19 439 306784 29318 64162191
Abdominal pain 198.57 14.19 790 306433 311585 63879924
Cerebrovascular accident 198.41 14.19 1227 305996 136356 64055153
Anxiety 197.08 14.19 419 306804 202230 63989279
Herpes zoster 195.07 14.19 821 306402 78366 64113143
Discomfort 194.33 14.19 71 307152 80807 64110702
Cataract 192.90 14.19 610 306613 50652 64140857
Hypoglycaemia 191.83 14.19 94 307129 89798 64101711
Oxygen saturation decreased 190.90 14.19 139 307084 107037 64084472
Blood creatine phosphokinase increased 188.98 14.19 27 307196 58531 64132978
Infection 186.60 14.19 1512 305711 183368 64008141
Skin discolouration 185.94 14.19 474 306749 34781 64156728
Infusion related reaction 184.52 14.19 312 306911 164155 64027354
Bradycardia 182.67 14.19 176 307047 118043 64073466
Suicidal ideation 182.29 14.19 46 307177 66496 64125013
Anaphylactic reaction 174.13 14.19 55 307168 68609 64122900
Agitation 168.90 14.19 106 307117 88261 64103248
Somnolence 164.26 14.19 464 306759 203181 63988328
Glossodynia 163.74 14.19 52 307171 64644 64126865
Medication error 163.69 14.19 22 307201 49944 64141565
Hypoaesthesia 163.43 14.19 1179 306044 137929 64053580
Sedation 160.76 14.19 9 307214 41453 64150056
Injection site swelling 160.26 14.19 9 307214 41344 64150165
Protein total increased 159.72 14.19 131 307092 3250 64188259
Depression 158.87 14.19 403 306820 182888 64008621
Blood pressure systolic increased 156.82 14.19 24 307199 49429 64142080
Injection site bruising 154.23 14.19 4 307219 36369 64155140
Alopecia 153.32 14.19 352 306871 165338 64026171
Hyperkalaemia 152.26 14.19 154 307069 100975 64090534
Metabolic acidosis 148.69 14.19 76 307147 70882 64120627
Injection site pruritus 147.31 14.19 8 307215 37818 64153691
C-reactive protein increased 145.79 14.19 142 307081 94767 64096742
Electrocardiogram QT prolonged 144.14 14.19 101 307122 79347 64112162
Lactic acidosis 144.03 14.19 56 307167 61354 64130155
Fibromyalgia 140.90 14.19 7 307216 35724 64155785
Injection site reaction 140.54 14.19 26 307197 46638 64144871
Wheezing 137.73 14.19 109 307114 80470 64111039
Drug level increased 137.12 14.19 6 307217 34190 64157319
Respiratory arrest 136.94 14.19 41 307182 52944 64138565
Blood cholesterol increased 136.38 14.19 35 307188 50031 64141478
Hiccups 135.67 14.19 183 307040 8193 64183316
Hepatic enzyme increased 134.52 14.19 259 306964 129684 64061825
Drug withdrawal syndrome 134.36 14.19 3 307220 31288 64160221
Full blood count increased 133.72 14.19 58 307165 406 64191103
COVID-19 pneumonia 133.27 14.19 263 306960 16241 64175268
Pericarditis 132.42 14.19 66 307157 62450 64129059
Incorrect dose administered 131.99 14.19 62 307161 60703 64130806
Gout 131.16 14.19 305 306918 21108 64170401
Helicobacter infection 127.81 14.19 16 307207 38346 64153163
Emotional distress 127.77 14.19 12 307211 36026 64155483
Blood pressure fluctuation 127.22 14.19 44 307179 51827 64139682
Dysgeusia 127.10 14.19 502 306721 46545 64144964
Wound 126.30 14.19 107 307116 76370 64115139
Aggression 120.90 14.19 35 307188 46197 64145312
Acute leukaemia 120.54 14.19 82 307141 1516 64189993
Loss of personal independence in daily activities 120.11 14.19 101 307122 72353 64119156
Vomiting 119.73 14.19 1876 305347 549241 63642268
Decreased appetite 119.61 14.19 1943 305280 279346 63912163
Blood test abnormal 114.01 14.19 214 307009 12729 64178780
Product quality issue 113.90 14.19 7 307216 29792 64161717
Bone pain 113.84 14.19 489 306734 47083 64144426
Back disorder 113.82 14.19 185 307038 9805 64181704
Musculoskeletal stiffness 113.74 14.19 262 306961 122944 64068565
Rib fracture 113.32 14.19 310 306913 23728 64167781
Stress 112.41 14.19 75 307148 60459 64131050
Cardio-respiratory arrest 111.84 14.19 185 307038 98208 64093301
Cardiac failure congestive 111.79 14.19 1030 306193 129550 64061959
Gallbladder disorder 111.43 14.19 249 306974 16781 64174728
Migraine 110.66 14.19 82 307141 62595 64128914
Upper limb fracture 110.63 14.19 229 306994 14637 64176872
Product prescribing error 109.83 14.19 18 307205 35251 64156258
Dysarthria 109.78 14.19 74 307149 59332 64132177
Ascites 109.62 14.19 81 307142 61920 64129589
Inflammation 109.51 14.19 90 307133 65210 64126299
Erythema 108.30 14.19 490 306733 186580 64004929
Gamma-glutamyltransferase increased 107.69 14.19 48 307175 48462 64143047
Hypercalcaemia 107.51 14.19 362 306861 31054 64160455
Knee arthroplasty 107.39 14.19 5 307218 26994 64164515
Injury 107.21 14.19 67 307156 55925 64135584
Interstitial lung disease 107.18 14.19 188 307035 97544 64093965
Malignant neoplasm of unknown primary site 106.46 14.19 56 307167 629 64190880
Drug ineffective for unapproved indication 106.15 14.19 12 307211 31121 64160388
Pathological fracture 105.65 14.19 169 307054 8836 64182673
Osteoarthritis 105.34 14.19 88 307135 63248 64128261
Cardiac amyloidosis 105.29 14.19 72 307151 1343 64190166
Spinal compression fracture 104.60 14.19 223 307000 14552 64176957
Multiple allergies 103.41 14.19 133 307090 5681 64185828
Malignant melanoma 102.77 14.19 205 307018 12759 64178750
Swelling face 102.39 14.19 554 306669 58612 64132897
Seizure 100.93 14.19 430 306793 166462 64025047
Clostridium difficile infection 99.40 14.19 388 306835 35775 64155734
Abortion spontaneous 98.90 14.19 5 307218 25138 64166371
Palpitations 97.41 14.19 221 307002 104267 64087242
Pallor 96.66 14.19 32 307191 38749 64152760
International normalised ratio increased 96.50 14.19 142 307081 79025 64112484
Blood alkaline phosphatase increased 96.33 14.19 76 307147 56203 64135306
Anaphylactic shock 95.51 14.19 15 307208 30313 64161196
Bone lesion 95.30 14.19 120 307103 5017 64186492
Hallucination, visual 94.22 14.19 11 307212 27823 64163686
Hordeolum 94.12 14.19 81 307142 2151 64189358
Hepatocellular injury 93.94 14.19 49 307174 45186 64146323
Muscle injury 93.20 14.19 9 307214 26428 64165081
Underdose 93.19 14.19 8 307215 25821 64165688
Flushing 93.03 14.19 144 307079 78504 64113005
Myoclonus 92.79 14.19 7 307216 25111 64166398
Drug-induced liver injury 92.62 14.19 56 307167 47587 64143922
Generalised tonic-clonic seizure 92.38 14.19 37 307186 39820 64151689
Abnormal behaviour 90.63 14.19 24 307199 33598 64157911
Cellulitis 90.10 14.19 758 306465 92899 64098610
Impaired healing 88.85 14.19 94 307129 60379 64131130
Surgery 88.75 14.19 14 307209 28199 64163310
Withdrawal syndrome 88.36 14.19 6 307217 23486 64168023
Folliculitis 87.95 14.19 18 307205 30059 64161450
Weight increased 87.18 14.19 626 306597 212722 63978787
Osteolysis 85.70 14.19 85 307138 2718 64188791
Leukaemia 85.22 14.19 113 307110 4975 64186534
Depressed mood 84.32 14.19 45 307178 40967 64150542
Injection site haemorrhage 83.68 14.19 9 307214 24269 64167240
Dyskinesia 82.79 14.19 42 307181 39346 64152163
Pyrexia 82.69 14.19 3348 303875 555296 63636213
Upper respiratory tract infection 82.60 14.19 612 306611 72173 64119336
Respiratory depression 82.59 14.19 8 307215 23435 64168074
Incorrect route of product administration 81.95 14.19 8 307215 23290 64168219
Pneumonia influenzal 81.81 14.19 79 307144 2443 64189066
Pregnancy test false positive 80.45 14.19 27 307196 81 64191428
Extrapyramidal disorder 79.84 14.19 3 307220 19549 64171960
Melaena 78.93 14.19 83 307140 53465 64138044
Chest discomfort 78.56 14.19 286 306937 115820 64075689
Gait disturbance 77.88 14.19 490 306733 171665 64019844
Diabetic ketoacidosis 77.29 14.19 23 307200 29822 64161687
Hepatitis 76.21 14.19 63 307160 45519 64145990
Hip arthroplasty 75.98 14.19 7 307216 21344 64170165
Blood magnesium decreased 75.44 14.19 189 307034 13716 64177793
Type 2 diabetes mellitus 74.98 14.19 34 307189 33986 64157523
Malignant melanoma in situ 74.63 14.19 65 307158 1755 64189754
Accidental exposure to product 74.60 14.19 17 307206 26347 64165162
Compression fracture 74.52 14.19 113 307110 5639 64185870
Obstructive airways disorder 74.08 14.19 11 307212 23174 64168335
White blood cell count increased 73.27 14.19 126 307097 65888 64125621
Body temperature decreased 72.81 14.19 17 307206 25911 64165598
Renal impairment 72.76 14.19 972 306251 134045 64057464
Myelodysplastic syndrome transformation 72.69 14.19 43 307180 616 64190893
Dementia 72.57 14.19 241 306982 20525 64170984
Localised infection 72.13 14.19 310 306913 29851 64161658
Arthritis 72.00 14.19 185 307038 83629 64107880
Transaminases increased 71.67 14.19 64 307159 44530 64146979
General physical health deterioration 71.37 14.19 626 306597 203799 63987710
Back pain 71.30 14.19 1626 305597 248545 63942964
Unresponsive to stimuli 71.08 14.19 81 307142 50312 64141197
Hepatotoxicity 70.90 14.19 52 307171 39910 64151599
Pulmonary arterial hypertension 70.51 14.19 17 307206 25350 64166159
Angioedema 70.46 14.19 116 307107 61705 64129804
Dystonia 70.43 14.19 5 307218 18860 64172649
Blood pressure diastolic decreased 70.30 14.19 11 307212 22290 64169219
Muscle rigidity 70.27 14.19 3 307220 17470 64174039
Device dislocation 70.14 14.19 9 307214 21169 64170340
Diverticulitis 69.12 14.19 365 306858 38253 64153256
Prescribed overdose 68.91 14.19 8 307215 20323 64171186
Tumour lysis syndrome 68.28 14.19 226 306997 19214 64172295
Fear 68.21 14.19 8 307215 20163 64171346
Psychotic disorder 68.12 14.19 40 307183 34538 64156971
Spinal disorder 68.03 14.19 137 307086 8585 64182924
Obesity 67.47 14.19 9 307214 20553 64170956
Hepatic steatosis 66.78 14.19 32 307191 30975 64160534
Neutrophil count increased 65.92 14.19 19 307204 25155 64166354
Hypersensitivity 65.77 14.19 608 306615 195844 63995665
Musculoskeletal pain 65.64 14.19 185 307038 81109 64110400
Status epilepticus 65.38 14.19 12 307211 21651 64169858
Intraductal proliferative breast lesion 65.34 14.19 65 307158 2086 64189423
Cholestasis 64.52 14.19 71 307152 44801 64146708
Ill-defined disorder 64.12 14.19 69 307154 43983 64147526
Immune system disorder 63.60 14.19 137 307086 9004 64182505
Product administration error 63.51 14.19 26 307197 27617 64163892
Rectal adenocarcinoma 63.36 14.19 52 307171 1291 64190218
Hyperviscosity syndrome 63.11 14.19 32 307191 331 64191178
Osteonecrosis of jaw 62.98 14.19 364 306859 39461 64152048
Refractory cytopenia with multilineage dysplasia 62.54 14.19 29 307194 242 64191267
Sinus tachycardia 62.33 14.19 38 307185 32150 64159359
Joint range of motion decreased 62.21 14.19 9 307214 19334 64172175
Leukocytosis 62.06 14.19 53 307170 37687 64153822
Hypogeusia 62.03 14.19 54 307169 1457 64190052
Blood bilirubin increased 61.93 14.19 112 307111 57441 64134068
Palmar-plantar erythrodysaesthesia syndrome 61.67 14.19 30 307193 28789 64162720
Liver injury 61.30 14.19 33 307190 29899 64161610
Amyloidosis 60.79 14.19 67 307156 2427 64189082
Refractory anaemia with an excess of blasts 60.48 14.19 42 307181 804 64190705
Asthma 60.25 14.19 241 306982 94984 64096525
Blood urea increased 60.10 14.19 73 307150 44080 64147429
B precursor type acute leukaemia 59.82 14.19 29 307194 270 64191239
Monoclonal immunoglobulin increased 59.82 14.19 19 307204 45 64191464
Accidental overdose 59.10 14.19 44 307179 33513 64157996
Oedema peripheral 58.98 14.19 1364 305859 208953 63982556
Coagulopathy 58.65 14.19 40 307183 31880 64159629
Transient ischaemic attack 58.64 14.19 386 306837 43796 64147713
Transplant rejection 58.59 14.19 7 307216 17394 64174115
Heart rate increased 58.55 14.19 256 306967 98419 64093090
Multiple sclerosis 58.23 14.19 10 307213 18931 64172578
Drug resistance 58.08 14.19 49 307174 35053 64156456
Osteoporosis 57.88 14.19 69 307154 42011 64149498
Hypercholesterolaemia 57.60 14.19 4 307219 15369 64176140
Haematemesis 57.56 14.19 84 307139 46915 64144594
Colitis ulcerative 57.39 14.19 19 307204 23009 64168500
Clostridium difficile colitis 57.00 14.19 269 306954 26954 64164555
Crying 56.75 14.19 13 307210 20077 64171432
Liver function test abnormal 56.69 14.19 124 307099 59277 64132232
Prostate cancer 56.53 14.19 215 307008 19580 64171929
Pregnancy 56.03 14.19 15 307208 20850 64170659
Viral infection 55.64 14.19 328 306895 35812 64155697
Fracture 55.47 14.19 206 307017 18549 64172960
Toxic epidermal necrolysis 55.46 14.19 57 307166 37109 64154400
Lung adenocarcinoma 55.30 14.19 109 307114 6724 64184785
Encephalopathy 55.14 14.19 124 307099 58695 64132814
Irritable bowel syndrome 54.98 14.19 58 307165 37311 64154198
Hallucination 54.89 14.19 171 307052 72617 64118892
Blood immunoglobulin G increased 54.76 14.19 55 307168 1786 64189723
Shock 54.44 14.19 61 307162 38179 64153330
Prescribed underdose 54.32 14.19 10 307213 18005 64173504
Delusion 54.32 14.19 10 307213 18004 64173505
Respiratory syncytial virus infection 54.13 14.19 112 307111 7156 64184353
Sleep apnoea syndrome 54.00 14.19 38 307185 29794 64161715
Torsade de pointes 53.75 14.19 9 307214 17354 64174155
Gastric disorder 53.65 14.19 278 306945 28919 64162590
Sleep disorder 53.46 14.19 129 307094 59580 64131929
Body height decreased 53.46 14.19 114 307109 7440 64184069
Right ventricular failure 53.01 14.19 18 307205 21453 64170056
Pulmonary hypertension 52.93 14.19 77 307146 43062 64148447
Hypokinesia 52.73 14.19 8 307215 16588 64174921
Device malfunction 52.72 14.19 10 307213 17623 64173886
Delirium 52.57 14.19 162 307061 69032 64122477
Metastases to bone 52.46 14.19 16 307207 20419 64171090
Skin exfoliation 52.40 14.19 380 306843 44505 64147004
Cyanosis 52.28 14.19 20 307203 22135 64169374
Gastrooesophageal reflux disease 52.23 14.19 211 307012 82932 64108577
Injection site warmth 51.94 14.19 3 307220 13459 64178050
Jaundice 51.66 14.19 95 307128 48417 64143092
Sputum discoloured 51.56 14.19 11 307212 17845 64173664
Impaired work ability 51.55 14.19 6 307217 15213 64176296
Hemiparesis 51.39 14.19 40 307183 29787 64161722
Lactose intolerance 50.60 14.19 55 307168 1961 64189548
Parkinsonism 50.38 14.19 5 307218 14368 64177141
Acute kidney injury 50.38 14.19 1694 305529 447546 63743963
Upper gastrointestinal haemorrhage 50.34 14.19 56 307167 35164 64156345
Invasive ductal breast carcinoma 50.30 14.19 88 307135 4954 64186555
Hypothermia 50.16 14.19 16 307207 19840 64171669
Seasonal allergy 50.15 14.19 146 307077 11580 64179929
Hepatic failure 50.13 14.19 119 307104 55275 64136234
Anhedonia 50.12 14.19 4 307219 13702 64177807
Mucosal inflammation 50.10 14.19 143 307080 62441 64129068
Pemphigoid 49.78 14.19 3 307220 12983 64178526
Myositis 49.58 14.19 9 307214 16368 64175141
Epilepsy 49.38 14.19 52 307171 33479 64158030
Blood electrolytes decreased 49.33 14.19 44 307179 1227 64190282
Atrial flutter 49.30 14.19 203 307020 19177 64172332
Respiratory tract infection 49.15 14.19 326 306897 37081 64154428
Agranulocytosis 49.14 14.19 66 307157 38163 64153346
Hyperlipidaemia 49.04 14.19 24 307199 22952 64168557
Tubulointerstitial nephritis 48.91 14.19 45 307178 30864 64160645
Speech disorder 48.85 14.19 98 307125 48343 64143166
Haematuria 48.53 14.19 138 307085 60333 64131176
Hepatic encephalopathy 48.10 14.19 20 307203 21046 64170463
Procedural pain 48.09 14.19 8 307215 15500 64176009
Therapeutic response unexpected 48.03 14.19 11 307212 16990 64174519
Blood triglycerides increased 48.02 14.19 15 307208 18851 64172658
Tachypnoea 47.89 14.19 34 307189 26537 64164972
Respiratory rate increased 47.70 14.19 14 307209 18317 64173192
Acute hepatic failure 47.61 14.19 33 307190 26079 64165430
Pelvic fracture 47.59 14.19 134 307089 10429 64181080
Pancreatitis acute 47.37 14.19 82 307141 42773 64148736
Skin cancer 47.34 14.19 145 307078 11829 64179680
Blood calcium increased 47.28 14.19 117 307106 8425 64183084
Metastases to liver 46.73 14.19 28 307195 23913 64167596
Ventricular fibrillation 46.44 14.19 28 307195 23832 64167677
Transformation to acute myeloid leukaemia 46.30 14.19 36 307187 825 64190684
Plasma cell myeloma refractory 46.19 14.19 18 307205 92 64191417
Glycosylated haemoglobin increased 45.99 14.19 10 307213 16009 64175500
Myalgia 45.99 14.19 508 306715 158109 64033400
Restlessness 45.94 14.19 74 307149 39711 64151798
Cardiogenic shock 45.86 14.19 52 307171 32375 64159134
Metastases to lung 44.91 14.19 9 307214 15255 64176254
Myocardial infarction 44.80 14.19 1070 306153 164751 64026758
Circulatory collapse 44.62 14.19 57 307166 33675 64157834
Chondrocalcinosis pyrophosphate 44.59 14.19 47 307176 1617 64189892
Post procedural complication 44.53 14.19 23 307200 21330 64170179
Poor venous access 44.38 14.19 4 307219 12413 64179096
Proteinuria 44.29 14.19 40 307183 27683 64163826
Altered state of consciousness 44.24 14.19 70 307153 37832 64153677
Eye swelling 43.64 14.19 216 307007 22065 64169444
Iron deficiency anaemia 43.57 14.19 25 307198 21864 64169645
Adenocarcinoma pancreas 43.39 14.19 49 307174 1824 64189685
Coronavirus infection 43.29 14.19 87 307136 5443 64186066
B-cell type acute leukaemia 43.22 14.19 27 307196 429 64191080
Bladder transitional cell carcinoma 42.54 14.19 54 307169 2276 64189233
Colon cancer 42.01 14.19 145 307078 12594 64178915
Tenosynovitis 41.79 14.19 4 307219 11829 64179680
Injection site urticaria 41.63 14.19 3 307220 11178 64180331
Gastrointestinal haemorrhage 41.50 14.19 416 306807 131896 64059613
Bone marrow failure 41.37 14.19 379 306844 47573 64143936
Treatment noncompliance 41.30 14.19 91 307132 43391 64148118
White blood cell count abnormal 41.19 14.19 79 307144 4775 64186734
Rash macular 41.11 14.19 222 307001 23463 64168046
Skin necrosis 41.02 14.19 9 307214 14320 64177189
Adenocarcinoma gastric 40.88 14.19 44 307179 1551 64189958
Nasopharyngitis 40.86 14.19 1223 306000 194850 63996659
Paraesthesia 40.69 14.19 882 306341 133640 64057869
Disturbance in attention 40.65 14.19 84 307139 40990 64150519
Eczema 40.59 14.19 49 307174 29671 64161838
Visceral leishmaniasis 40.59 14.19 35 307188 932 64190577
Hallucination, auditory 40.45 14.19 15 307208 16924 64174585
Spinal cord compression 40.28 14.19 86 307137 5617 64185892
Paranoia 39.87 14.19 14 307209 16338 64175171
Neurotoxicity 39.80 14.19 43 307180 27361 64164148
Dyspnoea exertional 39.76 14.19 198 307025 73532 64117977
Coordination abnormal 39.73 14.19 11 307212 14953 64176556
Transfusion 39.63 14.19 18 307205 17976 64173533
Light chain analysis abnormal 39.31 14.19 17 307206 118 64191391
Blood loss anaemia 39.22 14.19 9 307214 13883 64177626
Rales 38.96 14.19 12 307211 15217 64176292
Schizophrenia 38.85 14.19 4 307219 11164 64180345
Panic attack 38.84 14.19 26 307197 20927 64170582
Brain oedema 38.80 14.19 29 307194 22046 64169463
Diabetes mellitus inadequate control 38.80 14.19 27 307196 21294 64170215
Hypoxia 38.76 14.19 253 306970 87896 64103613
Anuria 38.70 14.19 21 307202 18943 64172566
Uveitis 38.44 14.19 7 307216 12701 64178808
Ventricular tachycardia 38.39 14.19 65 307158 34200 64157309
Disability 38.37 14.19 6 307217 12166 64179343
Arteriosclerosis coronary artery 38.37 14.19 13 307210 15516 64175993
Gastritis 38.21 14.19 92 307131 42526 64148983
Eye infection 38.21 14.19 114 307109 9167 64182342
Infusion site pain 38.12 14.19 3 307220 10394 64181115
Hepatic function abnormal 38.05 14.19 167 307056 64146 64127363
Lentigo maligna 37.86 14.19 25 307198 439 64191070
Haemodynamic instability 37.70 14.19 12 307211 14900 64176609
Hypothyroidism 37.34 14.19 86 307137 40371 64151138
Cervical vertebral fracture 37.00 14.19 59 307164 3076 64188433
Blister 36.82 14.19 230 306993 80737 64110772
Basosquamous carcinoma of skin 36.63 14.19 10 307213 10 64191499
Joint stiffness 36.59 14.19 55 307168 30349 64161160
Failure to thrive 36.58 14.19 121 307102 10283 64181226
Confusional state 36.37 14.19 956 306267 260188 63931321
Productive cough 35.90 14.19 203 307020 73000 64118509
Injection site rash 35.85 14.19 15 307208 15727 64175782
Concomitant disease aggravated 35.69 14.19 6 307217 11536 64179973
Posterior reversible encephalopathy syndrome 35.60 14.19 34 307189 22912 64168597
Lower respiratory tract infection 35.58 14.19 284 306939 94330 64097179
Haematoma 35.33 14.19 108 307115 46142 64145367
Prostatic disorder 35.26 14.19 42 307181 1657 64189852
Middle insomnia 35.07 14.19 9 307214 12868 64178641
Mitral valve incompetence 34.99 14.19 42 307181 25496 64166013
Motor dysfunction 34.97 14.19 6 307217 11367 64180142
Hernia 34.70 14.19 142 307081 13376 64178133
Primary amyloidosis 34.58 14.19 15 307208 105 64191404
Therapy non-responder 34.48 14.19 472 306751 65427 64126082
Colon cancer metastatic 34.21 14.19 44 307179 1879 64189630
Hepatic cirrhosis 34.21 14.19 45 307178 26253 64165256
Pulmonary fibrosis 34.10 14.19 56 307167 29822 64161687
Hepatitis cholestatic 34.07 14.19 8 307215 12147 64179362
Irritability 34.00 14.19 78 307145 36668 64154841
Tendonitis 33.94 14.19 28 307195 20254 64171255
Ovarian cyst 33.47 14.19 6 307217 11012 64180497
Neuralgia 33.09 14.19 226 306997 25958 64165551
Red cell distribution width increased 32.77 14.19 9 307214 12300 64179209
Blood pressure decreased 32.75 14.19 258 306965 85941 64105568
Food poisoning 32.51 14.19 59 307164 3419 64188090
Cardiac arrest 32.43 14.19 527 306696 153537 64037972
Cardiomegaly 32.40 14.19 39 307184 23645 64167864
Joint swelling 32.26 14.19 780 306443 214602 63976907
Nystagmus 32.19 14.19 3 307220 9065 64182444
Dysphagia 32.19 14.19 339 306884 106473 64085036
Pancreatitis 32.18 14.19 160 307063 59447 64132062
Pregnancy of partner 32.08 14.19 18 307205 232 64191277
Clavicle fracture 31.80 14.19 61 307162 3688 64187821
Endometrial adenocarcinoma 31.76 14.19 30 307193 902 64190607
Oliguria 31.45 14.19 15 307208 14561 64176948
Anger 31.30 14.19 18 307205 15723 64175786
Activated partial thromboplastin time prolonged 31.26 14.19 11 307212 12820 64178689
Blood calcium abnormal 31.10 14.19 34 307189 1220 64190289
Coronary artery disease 31.06 14.19 165 307058 60268 64131241
Hypomagnesaemia 30.95 14.19 84 307139 37292 64154217
Shock haemorrhagic 30.90 14.19 21 307202 16770 64174739
Lipase increased 30.80 14.19 15 307208 14387 64177122
Metastases to lymph nodes 30.64 14.19 3 307220 8714 64182795
Aplastic anaemia 30.54 14.19 14 307209 13906 64177603
Electrocardiogram abnormal 30.45 14.19 13 307210 13468 64178041
Dyslipidaemia 30.43 14.19 4 307219 9238 64182271
Hypotonia 30.22 14.19 8 307215 11204 64180305
Aphasia 30.20 14.19 97 307126 40809 64150700
Tardive dyskinesia 30.15 14.19 4 307219 9174 64182335
Blood lactate dehydrogenase increased 29.98 14.19 71 307152 33007 64158502
Respiratory distress 29.69 14.19 138 307085 52193 64139316
Heparin-induced thrombocytopenia 29.59 14.19 3 307220 8476 64183033
Autoimmune hepatitis 29.56 14.19 6 307217 10078 64181431
Squamous cell carcinoma of lung 29.55 14.19 42 307181 1976 64189533
Hepatic cytolysis 29.49 14.19 15 307208 14034 64177475
Inflammatory marker increased 29.47 14.19 3 307220 8448 64183061
Traumatic fracture 29.33 14.19 27 307196 785 64190724
Pneumonia viral 29.33 14.19 93 307130 7729 64183780
Hyperthyroidism 29.32 14.19 26 307197 18153 64173356
Flatulence 29.31 14.19 279 306944 35387 64156122
Venoocclusive liver disease 29.27 14.19 6 307217 10009 64181500
Acidosis 29.24 14.19 25 307198 17770 64173739
Performance status decreased 29.19 14.19 73 307150 5291 64186218
Injection site induration 29.09 14.19 4 307219 8928 64182581
Angina unstable 28.93 14.19 19 307204 15448 64176061
Blood lactic acid increased 28.85 14.19 7 307216 10394 64181115
Bradyphrenia 28.84 14.19 5 307218 9401 64182108
Dysphonia 28.84 14.19 343 306880 46039 64145470
Throat tightness 28.74 14.19 41 307182 23119 64168390
Foot deformity 28.60 14.19 22 307201 16482 64175027
Scar 28.58 14.19 14 307209 13384 64178125
Toxic encephalopathy 28.44 14.19 6 307217 9809 64181700
Septic shock 28.35 14.19 680 306543 104757 64086752
Heavy menstrual bleeding 28.33 14.19 11 307212 12066 64179443
Squamous cell carcinoma 28.27 14.19 136 307087 13733 64177776
Ejection fraction decreased 28.16 14.19 59 307164 28648 64162861
Squamous cell carcinoma of the hypopharynx 27.95 14.19 8 307215 11 64191498
Weight decreased 27.69 14.19 1644 305579 284095 63907414
Orthopnoea 27.69 14.19 5 307218 9129 64182380
Left ventricular dysfunction 27.64 14.19 24 307199 16930 64174579
Blood immunoglobulin A increased 27.47 14.19 22 307201 527 64190982
Renal injury 27.47 14.19 20 307203 15409 64176100
Febrile neutropenia 27.46 14.19 1124 306099 186533 64004976
Gastric ulcer 27.31 14.19 65 307158 30169 64161340
Peritonitis bacterial 27.31 14.19 5 307218 9038 64182471
Disorientation 27.28 14.19 155 307068 55673 64135836
Brain injury 27.07 14.19 7 307216 9958 64181551
Lower limb fracture 27.02 14.19 132 307091 13413 64178096
Grip strength decreased 26.98 14.19 11 307212 11713 64179796
Haemodialysis 26.85 14.19 25 307198 17052 64174457
Increased tendency to bruise 26.82 14.19 101 307122 9154 64182355
Human chorionic gonadotropin abnormal 26.79 14.19 8 307215 14 64191495
Pneumonia aspiration 26.62 14.19 169 307054 59102 64132407
Ataxia 26.52 14.19 40 307183 22044 64169465
Complication associated with device 26.26 14.19 20 307203 15060 64176449
Wrong product administered 26.26 14.19 3 307220 7717 64183792
Incorrect product administration duration 26.23 14.19 7 307216 9751 64181758
Nightmare 26.22 14.19 37 307186 20956 64170553
Myocardial ischaemia 26.14 14.19 44 307179 23207 64168302
Hiatus hernia 26.11 14.19 34 307189 19923 64171586
Tenderness 26.05 14.19 33 307190 19569 64171940
Anosmia 26.05 14.19 62 307161 4355 64187154
Dizziness 25.89 14.19 2382 304841 427781 63763728
Urinary incontinence 25.81 14.19 87 307136 36064 64155445
Hyperhidrosis 25.72 14.19 429 306794 124491 64067018
Tremor 25.53 14.19 904 306319 147326 64044183
Colorectal adenocarcinoma 25.48 14.19 17 307206 304 64191205
Pneumonia pneumococcal 25.46 14.19 51 307172 3183 64188326
Asphyxia 25.46 14.19 7 307216 9559 64181950
Gastroenteritis viral 25.35 14.19 171 307052 19558 64171951
Epstein-Barr virus infection 25.23 14.19 14 307209 12474 64179035
Kidney transplant rejection 25.23 14.19 7 307216 9504 64182005
Plasma cell myeloma in remission 25.16 14.19 7 307216 8 64191501
Eye disorder 25.12 14.19 165 307058 18704 64172805
Disseminated intravascular coagulation 25.09 14.19 75 307148 32273 64159236
Hepatomegaly 25.06 14.19 26 307197 16856 64174653
Nephropathy toxic 24.86 14.19 28 307195 17486 64174023
Nausea 24.66 14.19 3324 303899 782476 63409033
White blood cell disorder 24.62 14.19 45 307178 2622 64188887
Dyspnoea 24.50 14.19 3024 304199 715650 63475859
Movement disorder 24.40 14.19 42 307181 21958 64169551
Product dispensing error 24.37 14.19 12 307211 11438 64180071
Tricuspid valve incompetence 24.34 14.19 27 307196 16976 64174533
Salmonellosis 24.30 14.19 31 307192 1313 64190196
Mania 24.27 14.19 25 307198 16261 64175248
Therapy partial responder 24.24 14.19 105 307118 10143 64181366
Peripheral sensory neuropathy 24.23 14.19 113 307110 11265 64180244
Muscle strain 24.23 14.19 90 307133 8104 64183405
Marasmus 24.12 14.19 25 307198 843 64190666
Bladder transitional cell carcinoma stage 0 24.10 14.19 12 307211 119 64191390
Duodenal ulcer 24.06 14.19 20 307203 14415 64177094
Venous thrombosis 24.05 14.19 76 307147 6305 64185204
Venous thrombosis limb 23.87 14.19 55 307168 3782 64187727
No adverse event 23.79 14.19 64 307159 28497 64163012
Cholecystitis infective 23.77 14.19 44 307179 2589 64188920
Post transplant lymphoproliferative disorder 23.56 14.19 8 307215 9536 64181973
Bronchospasm 23.49 14.19 42 307181 21640 64169869
Catatonia 23.48 14.19 4 307219 7616 64183893
Eye movement disorder 23.46 14.19 3 307220 7076 64184433
Bone density decreased 23.45 14.19 9 307214 9943 64181566
Cytogenetic abnormality 23.44 14.19 27 307196 1027 64190482
Nasal congestion 23.39 14.19 177 307046 59481 64132028
Papule 23.36 14.19 75 307148 6275 64185234
Atrioventricular block first degree 23.23 14.19 11 307212 10723 64180786
Bile acid malabsorption 23.14 14.19 13 307210 168 64191341
Tuberculosis 23.08 14.19 17 307206 13021 64178488
Respiratory acidosis 23.08 14.19 9 307214 9846 64181663
Intracranial pressure increased 23.07 14.19 3 307220 6986 64184523
Abdominal pain lower 23.05 14.19 58 307165 26411 64165098
Glomerular filtration rate decreased 22.98 14.19 36 307187 19536 64171973
Chalazion 22.95 14.19 18 307205 418 64191091
Platelet disorder 22.92 14.19 40 307183 2247 64189262
Emotional disorder 22.89 14.19 16 307207 12591 64178918
Pseudomonas infection 22.85 14.19 31 307192 17852 64173657
Morganella infection 22.76 14.19 26 307197 980 64190529
Pathogen resistance 22.67 14.19 16 307207 12527 64178982
Paraproteinaemia 22.57 14.19 17 307206 371 64191138
Infusion site erythema 22.57 14.19 3 307220 6870 64184639
Blood calcium decreased 22.56 14.19 203 307020 25351 64166158
Cholecystitis chronic 22.56 14.19 8 307215 9279 64182230
Spinal osteoarthritis 22.54 14.19 21 307202 14320 64177189
Mouth ulceration 22.54 14.19 79 307144 32365 64159144
Ketoacidosis 22.53 14.19 3 307220 6860 64184649
Sinus bradycardia 22.50 14.19 47 307176 22846 64168663
Salivary hypersecretion 22.49 14.19 15 307208 12098 64179411
Superficial spreading melanoma stage unspecified 22.39 14.19 15 307208 270 64191239
Metastases to central nervous system 22.31 14.19 20 307203 13892 64177617
Myopathy 22.24 14.19 31 307192 17649 64173860
Blood potassium abnormal 22.23 14.19 42 307181 2510 64188999
Pain in jaw 22.23 14.19 109 307114 40646 64150863
Transitional cell carcinoma 22.11 14.19 39 307184 2210 64189299
Malaise 22.08 14.19 1607 305616 394640 63796869
Haemoptysis 21.95 14.19 140 307083 48908 64142601
Arteriosclerosis 21.87 14.19 26 307197 15851 64175658
Metabolic disorder 21.70 14.19 5 307218 7692 64183817
Device occlusion 21.70 14.19 10 307213 9903 64181606
Angina pectoris 21.57 14.19 126 307097 44955 64146554
Central nervous system lesion 21.57 14.19 15 307208 11834 64179675
Abdominal discomfort 21.44 14.19 683 306540 181639 64009870
Affect lability 21.40 14.19 8 307215 8982 64182527
Laryngeal oedema 21.34 14.19 4 307219 7109 64184400
Arthropathy 21.28 14.19 427 306796 120540 64070969
Skin plaque 21.21 14.19 8 307215 8932 64182577
Throat irritation 21.18 14.19 82 307141 32629 64158880
Nodule 21.08 14.19 33 307190 17914 64173595
Photophobia 21.08 14.19 31 307192 17262 64174247
Post procedural haemorrhage 21 14.19 17 307206 12414 64179095
Enterococcal infection 20.99 14.19 21 307202 13845 64177664
Vertigo 20.88 14.19 180 307043 58831 64132678
Viral upper respiratory tract infection 20.86 14.19 86 307137 8129 64183380
Heart rate decreased 20.83 14.19 165 307058 54902 64136607
Acute respiratory distress syndrome 20.74 14.19 105 307118 38830 64152679
Appendix disorder 20.73 14.19 31 307192 1528 64189981
Musculoskeletal chest pain 20.72 14.19 174 307049 21305 64170204
Hypertriglyceridaemia 20.64 14.19 14 307209 11191 64180318
Cardiac murmur 20.57 14.19 15 307208 11548 64179961
Muscle twitching 20.41 14.19 37 307186 18961 64172548
Injection site discolouration 20.34 14.19 4 307219 6871 64184638
Blood immunoglobulin M increased 20.28 14.19 17 307206 435 64191074
Parainfluenzae virus infection 20.23 14.19 59 307164 4684 64186825
Kidney infection 20.23 14.19 150 307073 17688 64173821
Pulmonary sepsis 20.16 14.19 45 307178 3030 64188479
Ventricular hypokinesia 20.09 14.19 6 307217 7763 64183746
Lethargy 20.04 14.19 235 306988 72359 64119150
Mental disorder 20.02 14.19 62 307161 26383 64165126
Multiple organ dysfunction syndrome 19.99 14.19 351 306872 101062 64090447
Oesophagitis 19.94 14.19 46 307177 21584 64169925
Electrocardiogram ST segment elevation 19.91 14.19 5 307218 7254 64184255
Exercise tolerance decreased 19.86 14.19 6 307217 7704 64183805
Cholangiocarcinoma 19.84 14.19 35 307188 1983 64189526
Osteopenia 19.80 14.19 27 307196 15513 64175996
Hypercapnia 19.79 14.19 6 307217 7688 64183821
Sinus disorder 19.64 14.19 143 307080 16765 64174744
Invasive lobular breast carcinoma 19.45 14.19 18 307205 527 64190982
Neuroendocrine carcinoma of the skin 19.42 14.19 24 307199 984 64190525
Myeloma cast nephropathy 19.39 14.19 11 307212 145 64191364
Acute erythroid leukaemia 19.31 14.19 13 307210 236 64191273
Inappropriate antidiuretic hormone secretion 19.29 14.19 49 307174 22240 64169269
Immunoglobulins increased 19.15 14.19 17 307206 471 64191038
Hepatitis B DNA increased 19.07 14.19 19 307204 611 64190898
Campylobacter gastroenteritis 19.02 14.19 25 307198 1091 64190418
Intestinal obstruction 19.02 14.19 260 306963 36026 64155483
Stupor 18.97 14.19 3 307220 6032 64185477
Amenorrhoea 18.94 14.19 4 307219 6535 64184974
Haemorrhage intracranial 18.80 14.19 55 307168 23829 64167680
Protein total abnormal 18.79 14.19 17 307206 483 64191026
Hyperammonaemia 18.75 14.19 12 307211 9892 64181617
Gastrointestinal stromal tumour 18.68 14.19 28 307195 1383 64190126
Feeling hot 18.61 14.19 134 307089 45529 64145980
Ear swelling 18.56 14.19 27 307196 1298 64190211
Febrile infection 18.51 14.19 42 307181 2859 64188650
Prothrombin time prolonged 18.43 14.19 29 307194 15712 64175797
Gastrointestinal infection 18.43 14.19 82 307141 8014 64183495
Abdominal tenderness 18.35 14.19 11 307212 9394 64182115
Abortion induced 18.31 14.19 4 307219 6384 64185125
Swollen tongue 18.20 14.19 95 307128 34859 64156650
Oral herpes 18.18 14.19 50 307173 22102 64169407
Pulse absent 18.12 14.19 10 307213 8936 64182573
Exfoliative rash 17.99 14.19 47 307176 3499 64188010
Retching 17.97 14.19 28 307195 15228 64176281
Apnoea 17.92 14.19 14 307209 10408 64181101
Rhinitis allergic 17.91 14.19 8 307215 8070 64183439
Cardiac valve disease 17.89 14.19 60 307163 5135 64186374
Hyperthermia 17.88 14.19 29 307194 15521 64175988
Walking aid user 17.87 14.19 4 307219 6277 64185232
Varicophlebitis 17.84 14.19 5 307218 6 64191503
Hepatitis fulminant 17.84 14.19 4 307219 6270 64185239
Hypernatraemia 17.84 14.19 19 307204 12170 64179339
Cholecystectomy 17.74 14.19 8 307215 8024 64183485
Oesophageal squamous cell carcinoma 17.74 14.19 16 307207 453 64191056
Squamous cell carcinoma of the oral cavity 17.68 14.19 16 307207 455 64191054
Gastritis erosive 17.66 14.19 12 307211 9583 64181926
5q minus syndrome 17.65 14.19 13 307210 274 64191235
Nerve injury 17.62 14.19 78 307145 7607 64183902
Normochromic normocytic anaemia 17.61 14.19 5 307218 6685 64184824
Visual acuity reduced 17.60 14.19 68 307155 27073 64164436
Type 1 diabetes mellitus 17.56 14.19 3 307220 5702 64185807
Adrenal insufficiency 17.54 14.19 52 307171 22435 64169074
Hydronephrosis 17.53 14.19 25 307198 14100 64177409
Device failure 17.51 14.19 3 307220 5689 64185820
Eosinophil count increased 17.50 14.19 25 307198 14087 64177422
Hypertensive crisis 17.48 14.19 38 307185 18210 64173299
Granuloma 17.41 14.19 5 307218 6636 64184873
Pleurisy viral 17.41 14.19 4 307219 0 64191509
Bundle branch block right 17.40 14.19 14 307209 10255 64181254
Exposure to toxic agent 17.37 14.19 4 307219 6155 64185354
Hepatitis acute 17.32 14.19 23 307200 13366 64178143
Crepitations 17.30 14.19 8 307215 7907 64183602
Spinal operation 17.26 14.19 4 307219 6129 64185380
Liver function test decreased 17.19 14.19 9 307214 100 64191409
Diverticulum intestinal 17.01 14.19 7 307216 7413 64184096
Blood chloride decreased 17.00 14.19 7 307216 7409 64184100
Pneumonia respiratory syncytial viral 16.98 14.19 27 307196 1404 64190105
Brain herniation 16.98 14.19 5 307218 6528 64184981
Polyarthritis 16.77 14.19 13 307210 9702 64181807
Granulocytopenia 16.75 14.19 15 307208 10425 64181084
Necrosis 16.74 14.19 9 307214 8162 64183347
Tongue oedema 16.67 14.19 4 307219 5986 64185523
Precursor B-lymphoblastic lymphoma 16.65 14.19 5 307218 9 64191500
Nasal abscess 16.62 14.19 10 307213 148 64191361
Alanine aminotransferase abnormal 16.62 14.19 6 307217 6882 64184627
Bronchiectasis 16.61 14.19 26 307197 14114 64177395
Bundle branch block left 16.61 14.19 14 307209 10020 64181489
Body dysmorphic disorder 16.53 14.19 12 307211 247 64191262
JC virus CSF test positive 16.51 14.19 10 307213 150 64191359
Vertebral lesion 16.50 14.19 15 307208 429 64191080
Stress cardiomyopathy 16.48 14.19 12 307211 9245 64182264
Photosensitivity reaction 16.47 14.19 39 307184 18134 64173375
Superficial spreading melanoma stage I 16.38 14.19 6 307217 25 64191484
Meningitis pneumococcal 16.35 14.19 14 307209 369 64191140
Musculoskeletal discomfort 16.35 14.19 33 307190 16244 64175265
Hyperproteinaemia 16.22 14.19 10 307213 155 64191354
Hyperglycaemia 16.20 14.19 199 307024 60769 64130740
Immunosuppression 16.20 14.19 97 307126 10649 64180860
Hypertransaminasaemia 16.14 14.19 7 307216 7184 64184325
Feeling jittery 16.03 14.19 96 307127 10539 64180970
Pulmonary congestion 16.02 14.19 59 307164 23821 64167688
Sternal fracture 16.00 14.19 34 307189 2213 64189296
Occult blood positive 16.00 14.19 5 307218 6282 64185227
Cerebral infarction 15.98 14.19 122 307101 40922 64150587
Ulcer 15.96 14.19 56 307167 22934 64168575
Neutrophilia 15.86 14.19 6 307217 6688 64184821
Immunoglobulins decreased 15.82 14.19 25 307198 1293 64190216
Red blood cell count abnormal 15.79 14.19 24 307199 1200 64190309
Pneumonia parainfluenzae viral 15.77 14.19 12 307211 266 64191243
Portal hypertension 15.73 14.19 5 307218 6214 64185295
Target skin lesion 15.71 14.19 9 307214 121 64191388
Pneumonia bacterial 15.69 14.19 124 307099 14911 64176598
Fistula 15.69 14.19 14 307209 9747 64181762
Pyelonephritis 15.69 14.19 37 307186 17229 64174280
Hypotension 15.69 14.19 1582 305641 379392 63812117
Myasthenia gravis 15.65 14.19 4 307219 5734 64185775
Prostate cancer stage II 15.62 14.19 17 307206 607 64190902
Atypical pneumonia 15.53 14.19 58 307165 5236 64186273
Platelet count abnormal 15.52 14.19 49 307174 4063 64187446
Sarcoidosis 15.44 14.19 5 307218 6141 64185368
Rash erythematous 15.38 14.19 321 306902 48312 64143197
Frustration tolerance decreased 15.36 14.19 5 307218 6120 64185389
Hyperaesthesia 15.35 14.19 15 307208 9999 64181510
Ecchymosis 15.34 14.19 27 307196 13995 64177514
Diffuse large B-cell lymphoma recurrent 15.25 14.19 41 307182 3105 64188404
Transitional cell cancer of the renal pelvis and ureter 15.24 14.19 7 307216 57 64191452
Body temperature increased 15.23 14.19 107 307116 36559 64154950
Vitamin D deficiency 15.21 14.19 20 307203 11672 64179837
Blood stem cell harvest failure 15.20 14.19 8 307215 90 64191419
Scoliosis 15.19 14.19 5 307218 6077 64185432
Hepatic amyloidosis 15.18 14.19 4 307219 3 64191506
Long QT syndrome 15.18 14.19 3 307220 5136 64186373
Full blood count 15.18 14.19 4 307219 3 64191506
Ventricular hypertrophy 15.18 14.19 6 307217 6510 64184999
Hyperbilirubinaemia 15.16 14.19 51 307172 21154 64170355
Lung squamous cell carcinoma stage III 15.15 14.19 5 307218 14 64191495
Optic neuritis 15.14 14.19 10 307213 8106 64183403
Immunoglobulins abnormal 15.04 14.19 7 307216 59 64191450
Acute biphenotypic leukaemia 14.97 14.19 9 307214 133 64191376
Night sweats 14.90 14.19 248 306975 35798 64155711
Hepatic fibrosis 14.89 14.19 4 307219 5548 64185961
Encephalitis 14.87 14.19 23 307200 12548 64178961
Blood thyroid stimulating hormone increased 14.87 14.19 9 307214 7645 64183864
Sensory disturbance 14.84 14.19 25 307198 13183 64178326
Lung squamous cell carcinoma stage IV 14.84 14.19 7 307216 61 64191448
Renal tubular disorder 14.81 14.19 5 307218 5982 64185527
Ischaemic cardiomyopathy 14.81 14.19 7 307216 6831 64184678
Cytomegalovirus infection 14.76 14.19 110 307113 37089 64154420
Blood magnesium abnormal 14.75 14.19 16 307207 569 64190940
Pneumonia streptococcal 14.70 14.19 34 307189 2344 64189165
Hydrocephalus 14.64 14.19 9 307214 7582 64183927
Areflexia 14.63 14.19 3 307220 5004 64186505
Vision blurred 14.61 14.19 547 306676 89769 64101740
Refractory cytopenia with unilineage dysplasia 14.60 14.19 19 307204 821 64190688
Large intestine infection 14.55 14.19 36 307187 2592 64188917
Rectal haemorrhage 14.52 14.19 207 307016 61610 64129899
POEMS syndrome 14.47 14.19 6 307217 37 64191472
Dyspnoea at rest 14.46 14.19 6 307217 6323 64185186
Humerus fracture 14.43 14.19 75 307148 7810 64183699
Swelling 14.39 14.19 620 306603 159598 64031911
Diverticular perforation 14.38 14.19 56 307167 5157 64186352
Wound dehiscence 14.37 14.19 5 307218 5869 64185640
Heat illness 14.35 14.19 13 307210 370 64191139
Neutrophil count abnormal 14.30 14.19 38 307185 2858 64188651
Blood iron decreased 14.28 14.19 103 307120 12039 64179470
Gastrointestinal fungal infection 14.21 14.19 13 307210 375 64191134

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L04AX04 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
IMMUNOSUPPRESSANTS
IMMUNOSUPPRESSANTS
Other immunosuppressants
MeSH PA D020533 Angiogenesis Inhibitors
MeSH PA D000970 Antineoplastic Agents
MeSH PA D006131 Growth Inhibitors
MeSH PA D006133 Growth Substances
MeSH PA D007155 Immunologic Factors
FDA EPC N0000184014 Thalidomide Analog
CHEBI has role CHEBI:35610 antineoplastic agents
CHEBI has role CHEBI:48422 angiogenesis antagonist
CHEBI has role CHEBI:50846 Immunologic factor

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Follicular lymphoma indication 55150002
Multiple myeloma indication 109989006 DOID:9538
Myelodysplastic syndrome indication 109995007
Mantle cell lymphoma indication 443487006
Marginal zone lymphoma indication 447100004
Deep venous thrombosis contraindication 128053003
Impaired renal function disorder contraindication 197663003
Pulmonary thromboembolism contraindication 233935004
Pregnancy, function contraindication 289908002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Neutropenic disorder contraindication 303011007 DOID:1227
Thromboembolic disorder contraindication 371039008
Primary malignant neoplasm contraindication 372087000
Breastfeeding (mother) contraindication 413712001
Chemotherapy-Induced Hyperuricemia contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.17 acidic
pKa2 3.13 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
10MG REVLIMID CELGENE N021880 Dec. 27, 2005 RX CAPSULE ORAL 7189740 April 11, 2023 USE OF REVLIMID (LENALIDOMIDE) FOR TREATMENT OF PATIENTS WITH TRANSFUSION-DEPENDENT ANEMIA DUE TO LOW-OR INTERMEDIATE-1-RISK MYELODYSPLASTIC SYNDROMES ASSOCIATED WITH A DELETION 5Q ABNORMALITY WITH OR WITHOUT ADDITIONAL CYTOGENETIC ABNORMALITIES
10MG REVLIMID CELGENE N021880 Dec. 27, 2005 RX CAPSULE ORAL 8404717 April 11, 2023 USE OF REVLIMID (LENALIDOMIDE) FOR TREATMENT OF PATIENTS WITH TRANSFUSION-DEPENDENT ANEMIA DUE TO LOW-OR INTERMEDIATE-1-RISK MYELODYSPLASTIC SYNDROMES ASSOCIATED WITH A DELETION 5Q ABNORMALITY WITH OR WITHOUT ADDITIONAL CYTOGENETIC ABNORMALITIES
10MG REVLIMID CELGENE N021880 Dec. 27, 2005 RX CAPSULE ORAL 9056120 April 11, 2023 USE OF REVLIMID (LENALIDOMIDE) FOR TREATMENT OF PATIENTS WITH TRANSFUSION-DEPENDENT ANEMIA DUE TO LOW-OR INTERMEDIATE-1-RISK MYELODYSPLASTIC SYNDROMES ASSOCIATED WITH A DELETION 5Q ABNORMALITY WITH OR WITHOUT ADDITIONAL CYTOGENETIC ABNORMALITIES
15MG REVLIMID CELGENE N021880 June 29, 2006 RX CAPSULE ORAL 7189740 April 11, 2023 USE OF REVLIMID (LENALIDOMIDE) FOR TREATMENT OF PATIENTS WITH TRANSFUSION-DEPENDENT ANEMIA DUE TO LOW-OR INTERMEDIATE-1-RISK MYELODYSPLASTIC SYNDROMES ASSOCIATED WITH A DELETION 5Q ABNORMALITY WITH OR WITHOUT ADDITIONAL CYTOGENETIC ABNORMALITIES
15MG REVLIMID CELGENE N021880 June 29, 2006 RX CAPSULE ORAL 8404717 April 11, 2023 USE OF REVLIMID (LENALIDOMIDE) FOR TREATMENT OF PATIENTS WITH TRANSFUSION-DEPENDENT ANEMIA DUE TO LOW-OR INTERMEDIATE-1-RISK MYELODYSPLASTIC SYNDROMES ASSOCIATED WITH A DELETION 5Q ABNORMALITY WITH OR WITHOUT ADDITIONAL CYTOGENETIC ABNORMALITIES
15MG REVLIMID CELGENE N021880 June 29, 2006 RX CAPSULE ORAL 9056120 April 11, 2023 USE OF REVLIMID (LENALIDOMIDE) FOR TREATMENT OF PATIENTS WITH TRANSFUSION-DEPENDENT ANEMIA DUE TO LOW-OR INTERMEDIATE-1-RISK MYELODYSPLASTIC SYNDROMES ASSOCIATED WITH A DELETION 5Q ABNORMALITY WITH OR WITHOUT ADDITIONAL CYTOGENETIC ABNORMALITIES
2.5MG REVLIMID CELGENE N021880 Dec. 21, 2011 RX CAPSULE ORAL 7189740 April 11, 2023 USE OF REVLIMID (LENALIDOMIDE) FOR TREATMENT OF PATIENTS WITH TRANSFUSION-DEPENDENT ANEMIA DUE TO LOW-OR INTERMEDIATE-1-RISK MYELODYSPLASTIC SYNDROMES ASSOCIATED WITH A DELETION 5Q ABNORMALITY WITH OR WITHOUT ADDITIONAL CYTOGENETIC ABNORMALITIES
2.5MG REVLIMID CELGENE N021880 Dec. 21, 2011 RX CAPSULE ORAL 8404717 April 11, 2023 USE OF REVLIMID (LENALIDOMIDE) FOR TREATMENT OF PATIENTS WITH TRANSFUSION-DEPENDENT ANEMIA DUE TO LOW-OR INTERMEDIATE-1-RISK MYELODYSPLASTIC SYNDROMES ASSOCIATED WITH A DELETION 5Q ABNORMALITY WITH OR WITHOUT ADDITIONAL CYTOGENETIC ABNORMALITIES
2.5MG REVLIMID CELGENE N021880 Dec. 21, 2011 RX CAPSULE ORAL 9056120 April 11, 2023 USE OF REVLIMID (LENALIDOMIDE) FOR TREATMENT OF PATIENTS WITH TRANSFUSION-DEPENDENT ANEMIA DUE TO LOW-OR INTERMEDIATE-1-RISK MYELODYSPLASTIC SYNDROMES ASSOCIATED WITH A DELETION 5Q ABNORMALITY WITH OR WITHOUT ADDITIONAL CYTOGENETIC ABNORMALITIES
20MG REVLIMID CELGENE N021880 June 5, 2013 RX CAPSULE ORAL 7189740 April 11, 2023 USE OF REVLIMID (LENALIDOMIDE) FOR TREATMENT OF PATIENTS WITH TRANSFUSION-DEPENDENT ANEMIA DUE TO LOW-OR INTERMEDIATE-1-RISK MYELODYSPLASTIC SYNDROMES ASSOCIATED WITH A DELETION 5Q ABNORMALITY WITH OR WITHOUT ADDITIONAL CYTOGENETIC ABNORMALITIES
20MG REVLIMID CELGENE N021880 June 5, 2013 RX CAPSULE ORAL 8404717 April 11, 2023 USE OF REVLIMID (LENALIDOMIDE) FOR TREATMENT OF PATIENTS WITH TRANSFUSION-DEPENDENT ANEMIA DUE TO LOW-OR INTERMEDIATE-1-RISK MYELODYSPLASTIC SYNDROMES ASSOCIATED WITH A DELETION 5Q ABNORMALITY WITH OR WITHOUT ADDITIONAL CYTOGENETIC ABNORMALITIES
20MG REVLIMID CELGENE N021880 June 5, 2013 RX CAPSULE ORAL 9056120 April 11, 2023 USE OF REVLIMID (LENALIDOMIDE) FOR TREATMENT OF PATIENTS WITH TRANSFUSION-DEPENDENT ANEMIA DUE TO LOW-OR INTERMEDIATE-1-RISK MYELODYSPLASTIC SYNDROMES ASSOCIATED WITH A DELETION 5Q ABNORMALITY WITH OR WITHOUT ADDITIONAL CYTOGENETIC ABNORMALITIES
25MG REVLIMID CELGENE N021880 June 29, 2006 RX CAPSULE ORAL 7189740 April 11, 2023 USE OF REVLIMID (LENALIDOMIDE) FOR TREATMENT OF PATIENTS WITH TRANSFUSION-DEPENDENT ANEMIA DUE TO LOW-OR INTERMEDIATE-1-RISK MYELODYSPLASTIC SYNDROMES ASSOCIATED WITH A DELETION 5Q ABNORMALITY WITH OR WITHOUT ADDITIONAL CYTOGENETIC ABNORMALITIES
25MG REVLIMID CELGENE N021880 June 29, 2006 RX CAPSULE ORAL 8404717 April 11, 2023 USE OF REVLIMID (LENALIDOMIDE) FOR TREATMENT OF PATIENTS WITH TRANSFUSION-DEPENDENT ANEMIA DUE TO LOW-OR INTERMEDIATE-1-RISK MYELODYSPLASTIC SYNDROMES ASSOCIATED WITH A DELETION 5Q ABNORMALITY WITH OR WITHOUT ADDITIONAL CYTOGENETIC ABNORMALITIES
25MG REVLIMID CELGENE N021880 June 29, 2006 RX CAPSULE ORAL 9056120 April 11, 2023 USE OF REVLIMID (LENALIDOMIDE) FOR TREATMENT OF PATIENTS WITH TRANSFUSION-DEPENDENT ANEMIA DUE TO LOW-OR INTERMEDIATE-1-RISK MYELODYSPLASTIC SYNDROMES ASSOCIATED WITH A DELETION 5Q ABNORMALITY WITH OR WITHOUT ADDITIONAL CYTOGENETIC ABNORMALITIES
5MG REVLIMID CELGENE N021880 Dec. 27, 2005 RX CAPSULE ORAL 7189740 April 11, 2023 USE OF REVLIMID (LENALIDOMIDE) FOR TREATMENT OF PATIENTS WITH TRANSFUSION-DEPENDENT ANEMIA DUE TO LOW-OR INTERMEDIATE-1-RISK MYELODYSPLASTIC SYNDROMES ASSOCIATED WITH A DELETION 5Q ABNORMALITY WITH OR WITHOUT ADDITIONAL CYTOGENETIC ABNORMALITIES
5MG REVLIMID CELGENE N021880 Dec. 27, 2005 RX CAPSULE ORAL 8404717 April 11, 2023 USE OF REVLIMID (LENALIDOMIDE) FOR TREATMENT OF PATIENTS WITH TRANSFUSION-DEPENDENT ANEMIA DUE TO LOW-OR INTERMEDIATE-1-RISK MYELODYSPLASTIC SYNDROMES ASSOCIATED WITH A DELETION 5Q ABNORMALITY WITH OR WITHOUT ADDITIONAL CYTOGENETIC ABNORMALITIES
5MG REVLIMID CELGENE N021880 Dec. 27, 2005 RX CAPSULE ORAL 9056120 April 11, 2023 USE OF REVLIMID (LENALIDOMIDE) FOR TREATMENT OF PATIENTS WITH TRANSFUSION-DEPENDENT ANEMIA DUE TO LOW-OR INTERMEDIATE-1-RISK MYELODYSPLASTIC SYNDROMES ASSOCIATED WITH A DELETION 5Q ABNORMALITY WITH OR WITHOUT ADDITIONAL CYTOGENETIC ABNORMALITIES
10MG REVLIMID CELGENE N021880 Dec. 27, 2005 RX CAPSULE ORAL 8530498 May 15, 2023 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA, IN COMBINATION WITH DEXAMETHASONE
10MG REVLIMID CELGENE N021880 Dec. 27, 2005 RX CAPSULE ORAL 8648095 May 15, 2023 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA, IN COMBINATION WITH DEXAMETHASONE
10MG REVLIMID CELGENE N021880 Dec. 27, 2005 RX CAPSULE ORAL 9101621 May 15, 2023 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA, AS MAINTENANCE FOLLOWING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (AUTO-HSCT)
10MG REVLIMID CELGENE N021880 Dec. 27, 2005 RX CAPSULE ORAL 9101622 May 15, 2023 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA, IN COMBINATION WITH DEXAMETHASONE, WHEREIN THOSE PATIENTS HAVE NOT RECEIVED PREVIOUS TREATMENT FOR MULTIPLE MYELOMA
10MG REVLIMID CELGENE N021880 Dec. 27, 2005 RX CAPSULE ORAL 9155730 May 15, 2023 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PREVIOUSLY TREATED FOLLICULAR LYMPHOMA IN COMBINATION WITH A RITUXIMAB PRODUCT
10MG REVLIMID CELGENE N021880 Dec. 27, 2005 RX CAPSULE ORAL 9393238 May 15, 2023 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PREVIOUSLY TREATED FOLLICULAR LYMPHOMA IN COMBINATION WITH A RITUXIMAB PRODUCT
15MG REVLIMID CELGENE N021880 June 29, 2006 RX CAPSULE ORAL 8530498 May 15, 2023 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA, IN COMBINATION WITH DEXAMETHASONE
15MG REVLIMID CELGENE N021880 June 29, 2006 RX CAPSULE ORAL 8648095 May 15, 2023 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA, IN COMBINATION WITH DEXAMETHASONE
15MG REVLIMID CELGENE N021880 June 29, 2006 RX CAPSULE ORAL 9101621 May 15, 2023 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA, AS MAINTENANCE FOLLOWING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (AUTO-HSCT)
15MG REVLIMID CELGENE N021880 June 29, 2006 RX CAPSULE ORAL 9101622 May 15, 2023 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA, IN COMBINATION WITH DEXAMETHASONE, WHEREIN THOSE PATIENTS HAVE NOT RECEIVED PREVIOUS TREATMENT FOR MULTIPLE MYELOMA
15MG REVLIMID CELGENE N021880 June 29, 2006 RX CAPSULE ORAL 9155730 May 15, 2023 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PREVIOUSLY TREATED FOLLICULAR LYMPHOMA IN COMBINATION WITH A RITUXIMAB PRODUCT
15MG REVLIMID CELGENE N021880 June 29, 2006 RX CAPSULE ORAL 9393238 May 15, 2023 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PREVIOUSLY TREATED FOLLICULAR LYMPHOMA IN COMBINATION WITH A RITUXIMAB PRODUCT
2.5MG REVLIMID CELGENE N021880 Dec. 21, 2011 RX CAPSULE ORAL 8530498 May 15, 2023 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA, IN COMBINATION WITH DEXAMETHASONE
2.5MG REVLIMID CELGENE N021880 Dec. 21, 2011 RX CAPSULE ORAL 8648095 May 15, 2023 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA, IN COMBINATION WITH DEXAMETHASONE
2.5MG REVLIMID CELGENE N021880 Dec. 21, 2011 RX CAPSULE ORAL 9101621 May 15, 2023 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA, AS MAINTENANCE FOLLOWING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (AUTO-HSCT)
2.5MG REVLIMID CELGENE N021880 Dec. 21, 2011 RX CAPSULE ORAL 9101622 May 15, 2023 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA, IN COMBINATION WITH DEXAMETHASONE, WHEREIN THOSE PATIENTS HAVE NOT RECEIVED PREVIOUS TREATMENT FOR MULTIPLE MYELOMA
2.5MG REVLIMID CELGENE N021880 Dec. 21, 2011 RX CAPSULE ORAL 9155730 May 15, 2023 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PREVIOUSLY TREATED FOLLICULAR LYMPHOMA IN COMBINATION WITH A RITUXIMAB PRODUCT
2.5MG REVLIMID CELGENE N021880 Dec. 21, 2011 RX CAPSULE ORAL 9393238 May 15, 2023 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PREVIOUSLY TREATED FOLLICULAR LYMPHOMA IN COMBINATION WITH A RITUXIMAB PRODUCT
20MG REVLIMID CELGENE N021880 June 5, 2013 RX CAPSULE ORAL 8530498 May 15, 2023 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA, IN COMBINATION WITH DEXAMETHASONE
20MG REVLIMID CELGENE N021880 June 5, 2013 RX CAPSULE ORAL 8648095 May 15, 2023 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA, IN COMBINATION WITH DEXAMETHASONE
20MG REVLIMID CELGENE N021880 June 5, 2013 RX CAPSULE ORAL 9101621 May 15, 2023 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA, AS MAINTENANCE FOLLOWING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (AUTO-HSCT)
20MG REVLIMID CELGENE N021880 June 5, 2013 RX CAPSULE ORAL 9101622 May 15, 2023 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA, IN COMBINATION WITH DEXAMETHASONE, WHEREIN THOSE PATIENTS HAVE NOT RECEIVED PREVIOUS TREATMENT FOR MULTIPLE MYELOMA
20MG REVLIMID CELGENE N021880 June 5, 2013 RX CAPSULE ORAL 9155730 May 15, 2023 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PREVIOUSLY TREATED FOLLICULAR LYMPHOMA IN COMBINATION WITH A RITUXIMAB PRODUCT
20MG REVLIMID CELGENE N021880 June 5, 2013 RX CAPSULE ORAL 9393238 May 15, 2023 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PREVIOUSLY TREATED FOLLICULAR LYMPHOMA IN COMBINATION WITH A RITUXIMAB PRODUCT
25MG REVLIMID CELGENE N021880 June 29, 2006 RX CAPSULE ORAL 8530498 May 15, 2023 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA, IN COMBINATION WITH DEXAMETHASONE
25MG REVLIMID CELGENE N021880 June 29, 2006 RX CAPSULE ORAL 8648095 May 15, 2023 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA, IN COMBINATION WITH DEXAMETHASONE
25MG REVLIMID CELGENE N021880 June 29, 2006 RX CAPSULE ORAL 9101621 May 15, 2023 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA, AS MAINTENANCE FOLLOWING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (AUTO-HSCT)
25MG REVLIMID CELGENE N021880 June 29, 2006 RX CAPSULE ORAL 9101622 May 15, 2023 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA, IN COMBINATION WITH DEXAMETHASONE, WHEREIN THOSE PATIENTS HAVE NOT RECEIVED PREVIOUS TREATMENT FOR MULTIPLE MYELOMA
25MG REVLIMID CELGENE N021880 June 29, 2006 RX CAPSULE ORAL 9155730 May 15, 2023 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PREVIOUSLY TREATED FOLLICULAR LYMPHOMA IN COMBINATION WITH A RITUXIMAB PRODUCT
25MG REVLIMID CELGENE N021880 June 29, 2006 RX CAPSULE ORAL 9393238 May 15, 2023 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PREVIOUSLY TREATED FOLLICULAR LYMPHOMA IN COMBINATION WITH A RITUXIMAB PRODUCT
5MG REVLIMID CELGENE N021880 Dec. 27, 2005 RX CAPSULE ORAL 8530498 May 15, 2023 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA, IN COMBINATION WITH DEXAMETHASONE
5MG REVLIMID CELGENE N021880 Dec. 27, 2005 RX CAPSULE ORAL 8648095 May 15, 2023 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA, IN COMBINATION WITH DEXAMETHASONE
5MG REVLIMID CELGENE N021880 Dec. 27, 2005 RX CAPSULE ORAL 9101621 May 15, 2023 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA, AS MAINTENANCE FOLLOWING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (AUTO-HSCT)
5MG REVLIMID CELGENE N021880 Dec. 27, 2005 RX CAPSULE ORAL 9101622 May 15, 2023 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA, IN COMBINATION WITH DEXAMETHASONE, WHEREIN THOSE PATIENTS HAVE NOT RECEIVED PREVIOUS TREATMENT FOR MULTIPLE MYELOMA
5MG REVLIMID CELGENE N021880 Dec. 27, 2005 RX CAPSULE ORAL 9155730 May 15, 2023 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PREVIOUSLY TREATED FOLLICULAR LYMPHOMA IN COMBINATION WITH A RITUXIMAB PRODUCT
5MG REVLIMID CELGENE N021880 Dec. 27, 2005 RX CAPSULE ORAL 9393238 May 15, 2023 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PREVIOUSLY TREATED FOLLICULAR LYMPHOMA IN COMBINATION WITH A RITUXIMAB PRODUCT
10MG REVLIMID CELGENE N021880 Dec. 27, 2005 RX CAPSULE ORAL 7468363 Oct. 7, 2023 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHOSE DISEASE HAS RELAPSED OR PROGRESSED AFTER TWO PRIOR THERAPIES, ONE OF WHICH INCLUDED BORTEZOMIB
10MG REVLIMID CELGENE N021880 Dec. 27, 2005 RX CAPSULE ORAL 7468363 Oct. 7, 2023 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PREVIOUSLY TREATED FOLLICULAR LYMPHOMA IN COMBINATION WITH A RITUXIMAB PRODUCT
10MG REVLIMID CELGENE N021880 Dec. 27, 2005 RX CAPSULE ORAL 7468363 Oct. 7, 2023 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PREVIOUSLY TREATED MARGINAL ZONE LYMPHOMA IN COMBINATION WITH A RITUXIMAB PRODUCT
10MG REVLIMID CELGENE N021880 Dec. 27, 2005 RX CAPSULE ORAL 7968569 Oct. 7, 2023 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA, IN COMBINATION WITH DEXAMETHASONE
10MG REVLIMID CELGENE N021880 Dec. 27, 2005 RX CAPSULE ORAL 8492406 Oct. 7, 2023 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PREVIOUSLY TREATED FOLLICULAR LYMPHOMA IN COMBINATION WITH A RITUXIMAB PRODUCT
15MG REVLIMID CELGENE N021880 June 29, 2006 RX CAPSULE ORAL 7468363 Oct. 7, 2023 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHOSE DISEASE HAS RELAPSED OR PROGRESSED AFTER TWO PRIOR THERAPIES, ONE OF WHICH INCLUDED BORTEZOMIB
15MG REVLIMID CELGENE N021880 June 29, 2006 RX CAPSULE ORAL 7468363 Oct. 7, 2023 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PREVIOUSLY TREATED FOLLICULAR LYMPHOMA IN COMBINATION WITH A RITUXIMAB PRODUCT
15MG REVLIMID CELGENE N021880 June 29, 2006 RX CAPSULE ORAL 7468363 Oct. 7, 2023 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PREVIOUSLY TREATED MARGINAL ZONE LYMPHOMA IN COMBINATION WITH A RITUXIMAB PRODUCT
15MG REVLIMID CELGENE N021880 June 29, 2006 RX CAPSULE ORAL 7968569 Oct. 7, 2023 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA, IN COMBINATION WITH DEXAMETHASONE
15MG REVLIMID CELGENE N021880 June 29, 2006 RX CAPSULE ORAL 8492406 Oct. 7, 2023 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PREVIOUSLY TREATED FOLLICULAR LYMPHOMA IN COMBINATION WITH A RITUXIMAB PRODUCT
2.5MG REVLIMID CELGENE N021880 Dec. 21, 2011 RX CAPSULE ORAL 7468363 Oct. 7, 2023 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHOSE DISEASE HAS RELAPSED OR PROGRESSED AFTER TWO PRIOR THERAPIES, ONE OF WHICH INCLUDED BORTEZOMIB
2.5MG REVLIMID CELGENE N021880 Dec. 21, 2011 RX CAPSULE ORAL 7468363 Oct. 7, 2023 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PREVIOUSLY TREATED FOLLICULAR LYMPHOMA IN COMBINATION WITH A RITUXIMAB PRODUCT
2.5MG REVLIMID CELGENE N021880 Dec. 21, 2011 RX CAPSULE ORAL 7468363 Oct. 7, 2023 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PREVIOUSLY TREATED MARGINAL ZONE LYMPHOMA IN COMBINATION WITH A RITUXIMAB PRODUCT
2.5MG REVLIMID CELGENE N021880 Dec. 21, 2011 RX CAPSULE ORAL 7968569 Oct. 7, 2023 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA, IN COMBINATION WITH DEXAMETHASONE
2.5MG REVLIMID CELGENE N021880 Dec. 21, 2011 RX CAPSULE ORAL 8492406 Oct. 7, 2023 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PREVIOUSLY TREATED FOLLICULAR LYMPHOMA IN COMBINATION WITH A RITUXIMAB PRODUCT
20MG REVLIMID CELGENE N021880 June 5, 2013 RX CAPSULE ORAL 7468363 Oct. 7, 2023 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHOSE DISEASE HAS RELAPSED OR PROGRESSED AFTER TWO PRIOR THERAPIES, ONE OF WHICH INCLUDED BORTEZOMIB
20MG REVLIMID CELGENE N021880 June 5, 2013 RX CAPSULE ORAL 7468363 Oct. 7, 2023 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PREVIOUSLY TREATED FOLLICULAR LYMPHOMA IN COMBINATION WITH A RITUXIMAB PRODUCT
20MG REVLIMID CELGENE N021880 June 5, 2013 RX CAPSULE ORAL 7468363 Oct. 7, 2023 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PREVIOUSLY TREATED MARGINAL ZONE LYMPHOMA IN COMBINATION WITH A RITUXIMAB PRODUCT
20MG REVLIMID CELGENE N021880 June 5, 2013 RX CAPSULE ORAL 7968569 Oct. 7, 2023 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA, IN COMBINATION WITH DEXAMETHASONE
20MG REVLIMID CELGENE N021880 June 5, 2013 RX CAPSULE ORAL 8492406 Oct. 7, 2023 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PREVIOUSLY TREATED FOLLICULAR LYMPHOMA IN COMBINATION WITH A RITUXIMAB PRODUCT
25MG REVLIMID CELGENE N021880 June 29, 2006 RX CAPSULE ORAL 7468363 Oct. 7, 2023 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHOSE DISEASE HAS RELAPSED OR PROGRESSED AFTER TWO PRIOR THERAPIES, ONE OF WHICH INCLUDED BORTEZOMIB
25MG REVLIMID CELGENE N021880 June 29, 2006 RX CAPSULE ORAL 7468363 Oct. 7, 2023 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PREVIOUSLY TREATED FOLLICULAR LYMPHOMA IN COMBINATION WITH A RITUXIMAB PRODUCT
25MG REVLIMID CELGENE N021880 June 29, 2006 RX CAPSULE ORAL 7468363 Oct. 7, 2023 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PREVIOUSLY TREATED MARGINAL ZONE LYMPHOMA IN COMBINATION WITH A RITUXIMAB PRODUCT
25MG REVLIMID CELGENE N021880 June 29, 2006 RX CAPSULE ORAL 7968569 Oct. 7, 2023 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA, IN COMBINATION WITH DEXAMETHASONE
25MG REVLIMID CELGENE N021880 June 29, 2006 RX CAPSULE ORAL 8492406 Oct. 7, 2023 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PREVIOUSLY TREATED FOLLICULAR LYMPHOMA IN COMBINATION WITH A RITUXIMAB PRODUCT
5MG REVLIMID CELGENE N021880 Dec. 27, 2005 RX CAPSULE ORAL 7468363 Oct. 7, 2023 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHOSE DISEASE HAS RELAPSED OR PROGRESSED AFTER TWO PRIOR THERAPIES, ONE OF WHICH INCLUDED BORTEZOMIB
5MG REVLIMID CELGENE N021880 Dec. 27, 2005 RX CAPSULE ORAL 7468363 Oct. 7, 2023 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PREVIOUSLY TREATED FOLLICULAR LYMPHOMA IN COMBINATION WITH A RITUXIMAB PRODUCT
5MG REVLIMID CELGENE N021880 Dec. 27, 2005 RX CAPSULE ORAL 7468363 Oct. 7, 2023 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PREVIOUSLY TREATED MARGINAL ZONE LYMPHOMA IN COMBINATION WITH A RITUXIMAB PRODUCT
5MG REVLIMID CELGENE N021880 Dec. 27, 2005 RX CAPSULE ORAL 7968569 Oct. 7, 2023 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA, IN COMBINATION WITH DEXAMETHASONE
5MG REVLIMID CELGENE N021880 Dec. 27, 2005 RX CAPSULE ORAL 8492406 Oct. 7, 2023 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PREVIOUSLY TREATED FOLLICULAR LYMPHOMA IN COMBINATION WITH A RITUXIMAB PRODUCT
10MG REVLIMID CELGENE N021880 Dec. 27, 2005 RX CAPSULE ORAL 8741929 March 8, 2028 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHOSE DISEASE HAS RELAPSED OR PROGRESSED AFTER TWO PRIOR THERAPIES, ONE OF WHICH INCLUDED BORTEZOMIB
15MG REVLIMID CELGENE N021880 June 29, 2006 RX CAPSULE ORAL 8741929 March 8, 2028 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHOSE DISEASE HAS RELAPSED OR PROGRESSED AFTER TWO PRIOR THERAPIES, ONE OF WHICH INCLUDED BORTEZOMIB
2.5MG REVLIMID CELGENE N021880 Dec. 21, 2011 RX CAPSULE ORAL 8741929 March 8, 2028 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHOSE DISEASE HAS RELAPSED OR PROGRESSED AFTER TWO PRIOR THERAPIES, ONE OF WHICH INCLUDED BORTEZOMIB
20MG REVLIMID CELGENE N021880 June 5, 2013 RX CAPSULE ORAL 8741929 March 8, 2028 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHOSE DISEASE HAS RELAPSED OR PROGRESSED AFTER TWO PRIOR THERAPIES, ONE OF WHICH INCLUDED BORTEZOMIB
25MG REVLIMID CELGENE N021880 June 29, 2006 RX CAPSULE ORAL 8741929 March 8, 2028 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHOSE DISEASE HAS RELAPSED OR PROGRESSED AFTER TWO PRIOR THERAPIES, ONE OF WHICH INCLUDED BORTEZOMIB
5MG REVLIMID CELGENE N021880 Dec. 27, 2005 RX CAPSULE ORAL 8741929 March 8, 2028 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHOSE DISEASE HAS RELAPSED OR PROGRESSED AFTER TWO PRIOR THERAPIES, ONE OF WHICH INCLUDED BORTEZOMIB

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
10MG REVLIMID CELGENE N021880 Dec. 27, 2005 RX CAPSULE ORAL Feb. 17, 2022 FOR USE IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE NOT RECEIVED AT LEAST ONE PRIOR THERAPY (FIRST LINE TREATMENT)
15MG REVLIMID CELGENE N021880 June 29, 2006 RX CAPSULE ORAL Feb. 17, 2022 FOR USE IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE NOT RECEIVED AT LEAST ONE PRIOR THERAPY (FIRST LINE TREATMENT)
2.5MG REVLIMID CELGENE N021880 Dec. 21, 2011 RX CAPSULE ORAL Feb. 17, 2022 FOR USE IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE NOT RECEIVED AT LEAST ONE PRIOR THERAPY (FIRST LINE TREATMENT)
20MG REVLIMID CELGENE N021880 June 5, 2013 RX CAPSULE ORAL Feb. 17, 2022 FOR USE IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE NOT RECEIVED AT LEAST ONE PRIOR THERAPY (FIRST LINE TREATMENT)
25MG REVLIMID CELGENE N021880 June 29, 2006 RX CAPSULE ORAL Feb. 17, 2022 FOR USE IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE NOT RECEIVED AT LEAST ONE PRIOR THERAPY (FIRST LINE TREATMENT)
5MG REVLIMID CELGENE N021880 Dec. 27, 2005 RX CAPSULE ORAL Feb. 17, 2022 FOR USE IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE NOT RECEIVED AT LEAST ONE PRIOR THERAPY (FIRST LINE TREATMENT)
10MG REVLIMID CELGENE N021880 Dec. 27, 2005 RX CAPSULE ORAL May 28, 2022 USED IN COMBINATION WITH A RITUXIMAB PRODUCT, ARE INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED FOLLICULAR LYMPHOMA (FL)
10MG REVLIMID CELGENE N021880 Dec. 27, 2005 RX CAPSULE ORAL May 28, 2022 USED IN COMBINATION WITH A RITUXIMAB PRODUCT, ARE INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED MARGINAL ZONE LYMPHOMA (MZL)
15MG REVLIMID CELGENE N021880 June 29, 2006 RX CAPSULE ORAL May 28, 2022 USED IN COMBINATION WITH A RITUXIMAB PRODUCT, ARE INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED FOLLICULAR LYMPHOMA (FL)
15MG REVLIMID CELGENE N021880 June 29, 2006 RX CAPSULE ORAL May 28, 2022 USED IN COMBINATION WITH A RITUXIMAB PRODUCT, ARE INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED MARGINAL ZONE LYMPHOMA (MZL)
2.5MG REVLIMID CELGENE N021880 Dec. 21, 2011 RX CAPSULE ORAL May 28, 2022 USED IN COMBINATION WITH A RITUXIMAB PRODUCT, ARE INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED FOLLICULAR LYMPHOMA (FL)
2.5MG REVLIMID CELGENE N021880 Dec. 21, 2011 RX CAPSULE ORAL May 28, 2022 USED IN COMBINATION WITH A RITUXIMAB PRODUCT, ARE INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED MARGINAL ZONE LYMPHOMA (MZL)
20MG REVLIMID CELGENE N021880 June 5, 2013 RX CAPSULE ORAL May 28, 2022 USED IN COMBINATION WITH A RITUXIMAB PRODUCT, ARE INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED FOLLICULAR LYMPHOMA (FL)
20MG REVLIMID CELGENE N021880 June 5, 2013 RX CAPSULE ORAL May 28, 2022 USED IN COMBINATION WITH A RITUXIMAB PRODUCT, ARE INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED MARGINAL ZONE LYMPHOMA (MZL)
25MG REVLIMID CELGENE N021880 June 29, 2006 RX CAPSULE ORAL May 28, 2022 USED IN COMBINATION WITH A RITUXIMAB PRODUCT, ARE INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED FOLLICULAR LYMPHOMA (FL)
25MG REVLIMID CELGENE N021880 June 29, 2006 RX CAPSULE ORAL May 28, 2022 USED IN COMBINATION WITH A RITUXIMAB PRODUCT, ARE INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED MARGINAL ZONE LYMPHOMA (MZL)
5MG REVLIMID CELGENE N021880 Dec. 27, 2005 RX CAPSULE ORAL May 28, 2022 USED IN COMBINATION WITH A RITUXIMAB PRODUCT, ARE INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED FOLLICULAR LYMPHOMA (FL)
5MG REVLIMID CELGENE N021880 Dec. 27, 2005 RX CAPSULE ORAL May 28, 2022 USED IN COMBINATION WITH A RITUXIMAB PRODUCT, ARE INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED MARGINAL ZONE LYMPHOMA (MZL)
10MG LENALIDOMIDE ARROW INTL A201452 May 21, 2021 RX CAPSULE ORAL Aug. 30, 2022 PATENT CHALLENGE
15MG LENALIDOMIDE ARROW INTL A201452 May 21, 2021 RX CAPSULE ORAL Aug. 30, 2022 PATENT CHALLENGE
25MG LENALIDOMIDE ARROW INTL A201452 May 21, 2021 RX CAPSULE ORAL Aug. 30, 2022 PATENT CHALLENGE
5MG LENALIDOMIDE ARROW INTL A201452 May 21, 2021 RX CAPSULE ORAL Aug. 30, 2022 PATENT CHALLENGE
10MG REVLIMID CELGENE N021880 Dec. 27, 2005 RX CAPSULE ORAL Feb. 22, 2024 TREATMENT OF MULTIPLE MYELOMA (MM), AS MAINTENANCE FOLLOWING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (AUTO-HSCT)
15MG REVLIMID CELGENE N021880 June 29, 2006 RX CAPSULE ORAL Feb. 22, 2024 TREATMENT OF MULTIPLE MYELOMA (MM), AS MAINTENANCE FOLLOWING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (AUTO-HSCT)
2.5MG REVLIMID CELGENE N021880 Dec. 21, 2011 RX CAPSULE ORAL Feb. 22, 2024 TREATMENT OF MULTIPLE MYELOMA (MM), AS MAINTENANCE FOLLOWING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (AUTO-HSCT)
20MG REVLIMID CELGENE N021880 June 5, 2013 RX CAPSULE ORAL Feb. 22, 2024 TREATMENT OF MULTIPLE MYELOMA (MM), AS MAINTENANCE FOLLOWING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (AUTO-HSCT)
25MG REVLIMID CELGENE N021880 June 29, 2006 RX CAPSULE ORAL Feb. 22, 2024 TREATMENT OF MULTIPLE MYELOMA (MM), AS MAINTENANCE FOLLOWING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (AUTO-HSCT)
5MG REVLIMID CELGENE N021880 Dec. 27, 2005 RX CAPSULE ORAL Feb. 22, 2024 TREATMENT OF MULTIPLE MYELOMA (MM), AS MAINTENANCE FOLLOWING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (AUTO-HSCT)
10MG REVLIMID CELGENE N021880 Dec. 27, 2005 RX CAPSULE ORAL May 28, 2026 INDICATED IN COMBINATION WITH A RITUXIMAB PRODUCT FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED FOLLICULAR LYMPHOMA (FL)
10MG REVLIMID CELGENE N021880 Dec. 27, 2005 RX CAPSULE ORAL May 28, 2026 INDICATED IN COMBINATION WITH A RITUXIMAB PRODUCT FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED MARGINAL ZONE LYMPHOMA (MZL)
15MG REVLIMID CELGENE N021880 June 29, 2006 RX CAPSULE ORAL May 28, 2026 INDICATED IN COMBINATION WITH A RITUXIMAB PRODUCT FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED FOLLICULAR LYMPHOMA (FL)
15MG REVLIMID CELGENE N021880 June 29, 2006 RX CAPSULE ORAL May 28, 2026 INDICATED IN COMBINATION WITH A RITUXIMAB PRODUCT FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED MARGINAL ZONE LYMPHOMA (MZL)
2.5MG REVLIMID CELGENE N021880 Dec. 21, 2011 RX CAPSULE ORAL May 28, 2026 INDICATED IN COMBINATION WITH A RITUXIMAB PRODUCT FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED FOLLICULAR LYMPHOMA (FL)
2.5MG REVLIMID CELGENE N021880 Dec. 21, 2011 RX CAPSULE ORAL May 28, 2026 INDICATED IN COMBINATION WITH A RITUXIMAB PRODUCT FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED MARGINAL ZONE LYMPHOMA (MZL)
20MG REVLIMID CELGENE N021880 June 5, 2013 RX CAPSULE ORAL May 28, 2026 INDICATED IN COMBINATION WITH A RITUXIMAB PRODUCT FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED FOLLICULAR LYMPHOMA (FL)
20MG REVLIMID CELGENE N021880 June 5, 2013 RX CAPSULE ORAL May 28, 2026 INDICATED IN COMBINATION WITH A RITUXIMAB PRODUCT FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED MARGINAL ZONE LYMPHOMA (MZL)
25MG REVLIMID CELGENE N021880 June 29, 2006 RX CAPSULE ORAL May 28, 2026 INDICATED IN COMBINATION WITH A RITUXIMAB PRODUCT FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED FOLLICULAR LYMPHOMA (FL)
25MG REVLIMID CELGENE N021880 June 29, 2006 RX CAPSULE ORAL May 28, 2026 INDICATED IN COMBINATION WITH A RITUXIMAB PRODUCT FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED MARGINAL ZONE LYMPHOMA (MZL)
5MG REVLIMID CELGENE N021880 Dec. 27, 2005 RX CAPSULE ORAL May 28, 2026 INDICATED IN COMBINATION WITH A RITUXIMAB PRODUCT FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED FOLLICULAR LYMPHOMA (FL)
5MG REVLIMID CELGENE N021880 Dec. 27, 2005 RX CAPSULE ORAL May 28, 2026 INDICATED IN COMBINATION WITH A RITUXIMAB PRODUCT FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED MARGINAL ZONE LYMPHOMA (MZL)

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Protein cereblon Cytosolic other MODULATOR EC50 6.53 SCIENTIFIC LITERATURE SCIENTIFIC LITERATURE
Tumor necrosis factor Cytokine IC50 7.89 WOMBAT-PK
Bromodomain-containing protein 4 Unclassified IC50 5.29 CHEMBL
Cereblon isoform 4 Unclassified Ki 5.51 CHEMBL

External reference:

IDSource
4025089 VUID
N0000175347 NUI
D04687 KEGG_DRUG
4025089 VANDF
C1144149 UMLSCUI
CHEBI:63791 CHEBI
CHEMBL848 ChEMBL_ID
DB00480 DRUGBANK_ID
D000077269 MESH_DESCRIPTOR_UI
216326 PUBCHEM_CID
7331 IUPHAR_LIGAND_ID
8505 INN_ID
F0P408N6V4 UNII
337535 RXNORM
20816 MMSL
355195 MMSL
73707 MMSL
d05696 MMSL
011171 NDDF
421471009 SNOMEDCT_US
421737001 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Lenalidomide HUMAN PRESCRIPTION DRUG LABEL 1 0480-1242 CAPSULE 5 mg ORAL ANDA 31 sections
Lenalidomide HUMAN PRESCRIPTION DRUG LABEL 1 0480-1243 CAPSULE 10 mg ORAL ANDA 31 sections
Lenalidomide HUMAN PRESCRIPTION DRUG LABEL 1 0480-1244 CAPSULE 15 mg ORAL ANDA 31 sections
Lenalidomide HUMAN PRESCRIPTION DRUG LABEL 1 0480-1246 CAPSULE 25 mg ORAL ANDA 31 sections
Revlimid HUMAN PRESCRIPTION DRUG LABEL 1 59572-402 CAPSULE 2.50 mg ORAL NDA 32 sections
Revlimid HUMAN PRESCRIPTION DRUG LABEL 1 59572-402 CAPSULE 2.50 mg ORAL NDA 32 sections
Revlimid HUMAN PRESCRIPTION DRUG LABEL 1 59572-405 CAPSULE 5 mg ORAL NDA 32 sections
Revlimid HUMAN PRESCRIPTION DRUG LABEL 1 59572-405 CAPSULE 5 mg ORAL NDA 32 sections
Revlimid HUMAN PRESCRIPTION DRUG LABEL 1 59572-410 CAPSULE 10 mg ORAL NDA 32 sections
Revlimid HUMAN PRESCRIPTION DRUG LABEL 1 59572-410 CAPSULE 10 mg ORAL NDA 32 sections
Revlimid HUMAN PRESCRIPTION DRUG LABEL 1 59572-415 CAPSULE 15 mg ORAL NDA 32 sections
Revlimid HUMAN PRESCRIPTION DRUG LABEL 1 59572-415 CAPSULE 15 mg ORAL NDA 32 sections
Revlimid HUMAN PRESCRIPTION DRUG LABEL 1 59572-420 CAPSULE 20 mg ORAL NDA 32 sections
Revlimid HUMAN PRESCRIPTION DRUG LABEL 1 59572-420 CAPSULE 20 mg ORAL NDA 32 sections
Revlimid HUMAN PRESCRIPTION DRUG LABEL 1 59572-425 CAPSULE 25 mg ORAL NDA 32 sections
Revlimid HUMAN PRESCRIPTION DRUG LABEL 1 59572-425 CAPSULE 25 mg ORAL NDA 32 sections